Document:

Amended Purchase Option Agreement

 Exhibit 10.47 
 EXECUTION COPY 
  
  
  
 AMENDED AND RESTATED 
 PURCHASE OPTION AGREEMENT 
 by and among 
 DYNAVAX TECHNOLOGIES CORPORATION, 
 SYMPHONY DYNAMO
HOLDINGS LLC 
 and 
 SYMPHONY DYNAMO, INC. 
  
  
 Dated as of
November 9, 2009 
  
  
  
  
  
 Amended and Restated Purchase Option
Agreement 

 TABLE OF CONTENTS 
  

					
	 	  	  	  	Page
	 Section 1.
	  	Grant of Purchase Option	  	2
			
	 Section 2.
	  	Exercise of Purchase Option	  	2
			
	 Section 2A.
	  	Purchase Option Closing Date Adjustment	  	5
			
	 Section 2B.
	  	Post-Closing Adjustment	  	5
			
	 Section 3.
	  	Dynavax Representations, Warranties and Covenants	  	6
			
	 Section 4.
	  	Holdings Representations, Warranties and Covenants	  	9
			
	 Section 5.
	  	Symphony Dynamo Representations, Warranties and Covenants	  	12
			
	 Section 6.
	  	Notice of Material Event	  	18
			
	 Section 7.
	  	Assignment Transfers; Legend	  	18
			
	 Section 8.
	  	Costs and Expenses: Payments	  	19
			
	 Section 9.
	  	Expiration: Termination of Agreement	  	19
			
	 Section 10.
	  	Survival: Indemnification	  	20
			
	 Section 11.
	  	No Petition	  	22
			
	 Section 12.
	  	Third-Party Beneficiary	  	22
			
	 Section 13.
	  	Notices	  	22
			
	 Section 14.
	  	Governing Law: Consent to Jurisdiction and Service of Process	  	23
			
	 Section 15.
	  	WAIVER OF JURY TRIAL	  	24
			
	 Section 16.
	  	Entire Agreement	  	24
			
	 Section 17.
	  	Amendment: Successors: Counterparts	  	24
			
	 Section 18.
	  	Specific Performance	  	24
			
	 Section 19.
	  	Severability	  	24
			
	 Section 20.
	  	Tax Reporting	  	24
			
	 Section 21.
	  	Original Agreement	  	25
			
	 Section 22.
	  	Amendment to Annex A	  	25
			
	 Annex A
	  	Certain Definitions	  	

  

					
		  	i	  	Amended and Restated Purchase Option Agreement

					
	Exhibit 1	  	Form of Purchase Option Exercise Notice	  	
			
	Exhibit 2	  	Form of Dynavax Promissory Note	  	
			
	Exhibit 3	  	Form of Standstill and Corporate Governance Letter Agreement	  	
			
	Exhibit 4	  	Form of Warrant Purchase Agreement	  	

  

					
		  	ii	  	Amended and Restated Purchase Option Agreement

 AMENDED AND RESTATED 
 PURCHASE OPTION AGREEMENT 
 This AMENDED AND RESTATED
PURCHASE OPTION AGREEMENT (this “Agreement”) is entered into as of November 9, 2009 (the “Closing Date”) by and among DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation
(“Dynavax”), SYMPHONY DYNAMO HOLDINGS LLC, a Delaware limited liability company (“Holdings”), and SYMPHONY DYNAMO, INC., a Delaware corporation (“Symphony Dynamo”). Capitalized
terms used herein and not defined herein shall have the meanings assigned to such terms in Annex A attached hereto. 
 PRELIMINARY STATEMENT 
 WHEREAS, Dynavax, Holdings and Symphony Dynamo, entered into that certain Purchase
Option Agreement dated as of April 18, 2006 (the “Original Agreement”), pursuant to which Holdings granted Dynavax an option to purchase all of the Common Stock of the Symphony Dynamo and any other Equity Securities
issued by Symphony Dynamo (together, the “Symphony Dynamo Equity Securities”) owned, or thereafter acquired, by Holdings on the terms described on the terms described therein; 
 WHEREAS, institutional investors have invested $50,000,000 in Holdings (the “Financing”) in exchange for membership
interests in Holdings and for a warrant to purchase up to a total of 2,000,000 shares of Dynavax Common Stock (the “Warrant”), which were issued to Holdings, and Holdings contributed the net proceeds of the Financing to
Symphony Dynamo; 
 WHEREAS, the parties to the Original Agreement desire to amend and restate the Original Agreement and accept
the rights and covenants hereof in lieu of their rights and covenants under the Original Agreement; 
 WHEREAS,
contemporaneously with the execution of this Agreement, Dynavax has exercised the Purchase Option (as defined below) by delivering the Purchase Option Exercise Notice (as defined below) to Holdings; 
 WHEREAS, on the Purchase Option Closing Date, Dynavax will issue to Holdings, subject to the satisfaction of certain conditions (including,
without limitation, the Stockholder Approval (as defined below) and cancellation of the Warrant), (i) the Dynavax Closing Shares (as defined below), (ii) warrants (the “Dynavax Closing Warrants”) to purchase
2,000,000 shares of Dynavax Common Stock, to be initially issued to Holdings (the “Dynavax Closing Warrant Shares”) and the Dynavax Promissory Note (as defined below); and 
 WHEREAS, Symphony Dynamo and Holdings have determined that it is in each of its best interest to perform and comply with certain agreements
and covenants relating to each of its ongoing operations contained in this Agreement. 
  

					
		  		  	Amended and Restated Purchase Option Agreement

 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (the “Parties”) agree as follows: 
 Section 1. Grant of Purchase Option. 
 (a) Holdings hereby grants to
Dynavax an exclusive option (the “Purchase Option”) to purchase all, but not less than all, of the outstanding Symphony Dynamo Equity Securities owned or hereafter acquired by Holdings, in accordance with the terms of this
Agreement. 
 (b) Symphony Dynamo hereby covenants and agrees that all Symphony Dynamo Equity Securities issued by Symphony
Dynamo at any time prior to the expiration of the Term (including to Holdings on, prior to, or after the date hereof or to any other Person at any time whatsoever, in all cases prior to the expiration of the Term) shall be subject to a purchase
option on the same terms as the Purchase Option (except as provided by the immediately following sentence) and all of the other terms and conditions of this Agreement without any additional action on the part of Dynavax or Holdings. Further, to the
extent Symphony Dynamo shall issue any Symphony Dynamo Equity Securities (including any issuance in respect of a transfer of Symphony Dynamo Equity Securities by any holder thereof, including Holdings) after the date hereof to any Person (including
Holdings) (any issuance of such Symphony Dynamo Equity Securities being subject to the prior written consent of Dynavax as set forth in Sections 5(c) and 7(b) hereof, as applicable), Symphony Dynamo hereby covenants and agrees
that it shall cause such Symphony Dynamo Equity Securities to be subject to the Purchase Option without the payment of, or any obligation to pay, any additional consideration in respect of such Symphony Dynamo Equity Securities by Dynavax, Symphony
Dynamo or any Symphony Dynamo Subsidiary to the Person(s) acquiring such subsequently issued Symphony Dynamo Equity Securities, the Parties acknowledging and agreeing that the sole consideration payable by Dynavax pursuant to this Agreement for all
of the outstanding Symphony Dynamo Equity Securities now or hereinafter owned by any Person shall be the Purchase Price. 
 (c) Dynavax’s right to exercise the Purchase Option granted hereby is subject to the following conditions: 
 (i) The Purchase Option may only be exercised for the purchase of all, and not less than all, of Holdings’ Symphony
Dynamo Equity Securities; 
 (ii) The Purchase Option may only be exercised a single time; and 
 (iii) The Purchase Option may be exercised only on the date hereof. 
 Section 2. Exercise of Purchase Option. 
 (a) Exercise Notice. Dynavax may exercise the Purchase Option only by delivery of a notice in the form attached hereto as Exhibit 1 (the “Purchase Option Exercise
Notice”) on the date hereof. The Purchase Option Exercise Notice shall be delivered to Holdings and Symphony Dynamo and shall be irrevocable once delivered. The date on which the Purchase Option Exercise Notice is first delivered to
Holdings and Symphony Dynamo is referred to as the “Purchase Option Exercise Date.” The Purchase Option Exercise Notice shall contain an estimated date for the settlement of the Purchase Option (the “Purchase Option
Closing”), which date shall be estimated in accordance with this Section 2(a). Such notice and election shall be irrevocable once given and made. If, during the period following delivery of the Purchase Option Exercise Notice, the
amount of cash and cash equivalents held by Symphony Dynamo is an amount less than or equal to $1,000,000 then Symphony Dynamo shall cease payment of any amounts owed to Dynavax in respect of its activities pursuant to the Amended and Restated
Research and Development Agreement, but shall continue to pay amounts owed to all other Persons. The date of the Purchase Option Closing (the “Purchase Option Closing Date”) shall be the date that is the latest of:

 (i) five (5) Business Days following the date that Dynavax receives the necessary Government Approvals
related to its HSR Filings; provided, however, that Dynavax and Holdings shall make all necessary HSR Filings within five (5) Business Days following the Purchase Option Exercise Date and shall diligently pursue the related regulatory process;
and 
  

					
		  	2	  	Amended and Restated Purchase Option Agreement

 (ii) five (5) Business Days following the date that Dynavax receives
the necessary stockholder approvals for purposes of NASDAQ Marketplace Rule 5635 in connection with the issuance of Dynavax Closing Shares (as defined below) and the Dynavax Closing Warrant Shares (the “Stockholder
Approval”); 
 (b) Purchase Price  
 (i) Subject to the post-closing adjustment pursuant to Section 2B and the following sentence, as consideration
for the sale to Dynavax by Holdings of its Symphony Dynamo Equity Securities (and for the Symphony Dynamo Equity Securities of any other Person), on the Purchase Option Closing Date, Dynavax shall issue to Holdings an aggregate of
(A) 13,000,000 shares of Dynavax Common Stock (the “Dynavax Closing Shares”) and (B) the Dynavax Closing Warrants. If, after the date hereof and prior to the Purchase Option Closing Date, (x) the number of
outstanding shares of Dynavax Common Stock has been increased, decreased, changed into or exchanged for a different number or kind of shares or securities as a result of a reorganization, recapitalization, stock dividend, stock split, reverse stock
split or other similar change in capitalization, an appropriate and proportionate adjustment shall be made to the number of Dynavax Closing Shares to be issued at the Purchase Option Closing Date, or (y) there has been a Specified Company
Issuance (as defined below), the consideration to be paid by Dynavax at the Purchase Option Closing Date may be adjusted in accordance with Section 2A. 
 (ii) As further consideration for the sale to Dynavax by Holdings of its Symphony Dynamo Equity Securities (and for the
Symphony Dynamo Equity Securities of any other Person), if Dynavax enters into any agreement or arrangement with any third party with respect to the development and/or commercialization of a Cancer Product or a Hepatitis C Product (each a
“Symphony Dynamo Product Agreement”), Dynavax shall be obligated to pay to Holdings, within 10 Business Days of Dynavax’s receipt thereof, an amount equal to 50% of the first $50,000,000 of any upfront,
pre-commercialization milestone or similar payments received by Dynavax under any such Symphony Dynamo Product Agreements. 
 For
the avoidance of doubt, payments from a third party to Dynavax for reimbursement for research and development, equity or debt issued as part of the collaboration at fair market value, commercial milestones or royalties shall not be considered
payments received by Dynavax under Symphony Dynamo Product Agreements for purposes of this Section 2(b). 
 (iii) As further consideration for the sale to Dynavax by Holdings of its Symphony Dynamo Equity Securities (and for the Symphony Dynamo Equity Securities of any other Person), on the Purchase Option Closing Date, Dynavax shall deliver a
duly executed promissory note in the principal amount of $15,000,000, substantially in the form attached hereto as Exhibit 2 (the “Dynavax Promissory Note”). 
 (iv) The Dynavax Closing Shares, the Dynavax Closing Warrants, the payments to be made to Holdings set forth in
Section 2(b)(ii) and the Dynavax Promissory Note shall constitute the “Purchase Price”. 
 (c) [Reserved.] 
 (d) Surrender of Symphony Dynamo Equity Securities. Subject to the terms and
conditions of this Agreement, on or prior to the Purchase Option Closing Date, Holdings shall surrender to Dynavax its certificates representing its Symphony Dynamo Equity Securities, and shall convey good title to such Symphony Dynamo Equity
Securities, free from any Encumbrances and from any and all restrictions that any sale, assignment or other transfer of such Symphony Dynamo Equity Securities be consented to or approved by any Person. On or prior to the Purchase Option Closing
Date, Holdings shall remove all directors serving on the Symphony Dynamo Board, other than the Dynavax Director (as defined in Section 4(b)(iv) hereof) from the Symphony Dynamo Board as of the Purchase Option Closing Date. 
  

					
		  	3	  	Amended and Restated Purchase Option Agreement

 (e) Valuation of Dynavax Stock. The value per share of the Dynavax Closing Shares as
of the date hereof has been determined by the Parties to equal $1.57. 
 (f) Standstill and Corporate Governance Letter
Agreement. Subject to the terms and conditions of this Agreement, on the Purchase Option Closing Date, Holdings and Dynavax shall enter into a standstill and corporate governance letter agreement substantially in the form attached hereto as
Exhibit 3 (the “Standstill and Corporate Governance Letter Agreement”). 
 (g) Warrant
Purchase Agreement. Subject to the terms and conditions of this Agreement, on the Purchase Option Closing Date, Holdings and Dynavax shall enter into a warrant purchase agreement substantially in the form attached hereto as Exhibit 4
(the “Warrant Purchase Agreement”). 
 (h) Share Certificates. Any stock certificate(s) issued by
Dynavax for Dynavax Common Stock pursuant to this Section 2 may contain a legend (the “33 Act Legend”) substantially as follows: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE, AND THE SAME HAVE BEEN ISSUED IN RELIANCE ON
EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. SUCH SHARES MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. 
 This legend shall be removed by Dynavax, subject to, and in accordance with, the terms of
Section 3(b)(iii) hereof. 
 (i) Government Approvals. On or prior to the Purchase Option Closing Date,
each of Dynavax, Symphony Dynamo and Holdings shall have taken all necessary action to cause all required Governmental Approvals with respect to such Party (including, if deemed necessary and without limitation, the preparing and filing of the
pre-merger notification and report forms required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Filings”)) in connection with the transactions contemplated by this Agreement to be in effect;
provided, however, that with respect to Government Approvals required by a Governmental Authority other than the United States federal government and its various branches and agencies, the Parties’ obligations under this
Section 2(i) shall be limited to causing to be in effect only those Government Approvals, the failure of which to be in effect would, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect
on any of the Parties. Each of Symphony Dynamo and Dynavax shall pay its own costs associated with taking such action. Symphony Dynamo shall pay any costs of Holdings associated with obtaining Government Approvals required in connection with the
exercise of the Purchase Option. All other costs and expenses of Holdings shall be paid by Holdings pursuant to Section 8 hereof, including any costs arising from any error in Holdings’ initial valuation of its investment in
Symphony Dynamo. 
 (j) Transfer of Title. Transfer of title to Dynavax of all of the Symphony Dynamo Equity Securities
shall be deemed to occur automatically on the Purchase Option Closing Date, subject to the issuance by Dynavax on such date of the portion of the Purchase Price comprised of the Dynavax Closing Shares and the Dynavax Closing Warrants or Alternate
Closing Securities (as defined below), as applicable, and the Dynavax Promissory Note, and its performance of its other obligations herein required to be performed, and under the Registration Rights Agreement, as applicable, on or prior to the
Purchase Option Closing Date to the reasonable satisfaction of Holdings, and thereafter Symphony Dynamo shall treat Dynavax as the sole holder of all Symphony Dynamo Equity Securities, notwithstanding the failure of Holdings to tender certificates
representing such shares to Dynavax in accordance with Section 2(d) hereof. 
  

					
		  	4	  	Amended and Restated Purchase Option Agreement

 
After the Purchase Option Closing Date, Holdings shall have no rights in connection with such Symphony Dynamo Equity Securities other than the right to receive the Purchase Price;
provided, however, that nothing in this Section 2(j) shall affect the survivability of any indemnification provision in this Agreement upon termination of this Agreement. 
 (k) Consents and Authorizations. On or prior to the Purchase Option Closing Date, Dynavax shall have obtained all consents and
authorizations necessary from stockholders and/or its board of directors for the consummation of the exercise and closing of the Purchase Option, as may be required under the organizational documents of Dynavax, any prior stockholders or board
resolution, any stock exchange or similar rules or any applicable law (including, without limitation, the Stockholder Approval); provided, however, that with respect to consents or authorizations required by a Governmental Authority
other than the United States federal government and its various branches and agencies, the Parties’ obligations under this Section 2(k) shall be limited to obtaining only those consents and authorizations, the failure of which to be
obtained would, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on any of the Parties. 
 Section 2A. Purchase Option Closing Date Adjustment. 
 (a) If at any
time or from time to time from and after the date hereof through the Purchase Option Closing Date, Dynavax has issued Additional Dynavax Securities (any such issuance of Additional Dynavax Securities, a “Specified Dynavax
Issuance”), Holdings may elect (in accordance with the procedures set forth in Section 2B) to be paid the portion of the Purchase Price comprised of the Dynavax Closing Shares and the Dynavax Closing Warrants in the form of
the Alternate Securities specified in the Specified Issuance Notice (each as defined below) (such Alternate Securities paid to Holdings at the Purchase Option Closing Date, the “Alternate Closing Securities”). 
 Section 2B. Post-Closing Adjustment. 
 (a) If at any time and from time to time from and after the Purchase Option Closing Date through the date occurring six (6) months after the Purchase Option Closing Date (or if such date is not a
Business Day, the first Business Day thereafter) (such date, the “Final Adjustment Date”), there is a Specified Dynavax Issuance, as soon as practicable, but in no event later than five (5) Business Days after the
delivery to Dynavax of a Holdings Election Notice (as defined below) (such date, the “Adjusted Securities Payment Date”), (i) Dynavax shall issue to Holdings such Alternate Securities in the form specified in the
Specified Issuance Notice, and (ii) Holdings shall deliver to Dynavax such Dynavax Closing Shares, Dynavax Closing Warrants, Alternate Closing Securities, or other securities of Dynavax issued pursuant to this Agreement, or other consideration
transferred to Holdings, other than the Dynavax Promissory Note and the amounts payable pursuant to Section 2(b)(b)(ii), as applicable, such that on the Adjusted Securities Payment Date Holdings shall own Alternate Securities, together
with all other securities of Dynavax issued, or other consideration transferred (including the Dynavax Promissory Note and the amounts payable pursuant to Section 2(b)(b)(ii)), to Holdings pursuant to this Agreement, to which Holdings is
entitled in consideration of the transfer to Dynavax of the Symphony Collaboration Equity Securities. The foregoing described transactions between Dynavax and Holdings shall be settled on a net basis. For the avoidance of doubt, the parties hereby
acknowledge and agree that Holdings may exercise its rights under this Section 2B(a) following each Specified Dynavax Issuance that occurs after the date of this Agreement and on or prior to the Final Adjustment Date. 
 (b) Not later than five (5) Business Days prior to the consummation of a Specified Dynavax Issuance, Dynavax shall, in accordance with
Section 13, deliver to Holdings a notice (a “Specified Issuance Notice”) setting forth in reasonable detail: (i) a description of the form and terms of the Additional Dynavax Securities to be issued pursuant to the
Specified Dynavax Issuance (such Additional Dynavax Securities, the “Alternate Securities”); (ii) the price at which the Alternate Securities will be issued pursuant to the Specified Dynavax Issuance; (iii) the
estimated date of issuance of such Alternate Securities; and (iv) the amount and form of Alternate Securities that would be issued to an investor participating in the Specified Dynavax Issuance upon payment to Dynavax of an amount equal to

  

					
		  	5	  	Amended and Restated Purchase Option Agreement

 
$20,446,000. If Holdings elects to exercise its rights under Section 2B(a) with respect to a Specified Dynavax Issuance, Holdings, in accordance with Section 13, shall
deliver to Dynavax a notice of such election not later than one (1) Business Day prior to the consummation of such Specified Dynavax Issuance (the “Holdings Election Notice”). The failure of Holdings to notify Dynavax pursuant
to this Section 2B(b) shall be deemed to constitute the waiver by Holdings of its rights under Section 2B(a) with respect to such Specified Dynavax Issuance. 
 (c) “Additional Dynavax Securities” shall mean all shares of Dynavax Common Stock, Options, Convertible Securities,
notes, bonds, or any other securities issued by Dynavax, or cash or other consideration paid or delivered by or on behalf of Dynavax, other than the following (collectively, “Exempted Securities”): 
 (i) rights, options or warrants to subscribe for, purchase or otherwise acquire Dynavax Common Stock
(“Options”), or shares of restricted stock or stock appreciation rights, issued to employees or directors of, or consultants or advisors to, Dynavax or any of its subsidiaries pursuant to a plan, agreement or arrangement
approved by the board of directors of Dynavax; 
 (ii)(1) shares of Dynavax Common Stock actually issued
upon the exercise of Options or (2) shares of Dynavax Common Stock actually issued upon the conversion or exchange of any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Dynavax
Common Stock, but excluding Options (“Convertible Securities”), in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; 
 (iii) shares of Dynavax Common Stock, Options or Convertible Securities issued by reason of a dividend on the outstanding
Dynavax Common Stock, stock split of the outstanding Dynavax Common Stock, split-up of the outstanding Dynavax Common Stock or other distribution on shares of Dynavax Common Stock; or 
 (iv) shares of Dynavax Common Stock sold and issued pursuant to that certain Equity Distribution Agreement dated
August 17, 2009, by and between Dynavax and Wedbush Morgan Securities, Inc. (the “ATM Securities”). 
 Section 3. Dynavax Representations, Warranties and Covenants. As of the date hereof, Dynavax hereby represents and warrants, and, except to the extent that any of the following representations and warranties is limited to the
date of this Agreement or otherwise limited, on the Purchase Option Closing Date and each Adjusted Securities Payment Date, shall be deemed to have represented and warranted, to Holdings and Symphony Dynamo that: 
 (i) Organization. Dynavax is a corporation, duly organized, validly existing and in good standing under the laws of
the State of Delaware. 
 (ii) Authority and Validity. Dynavax has all requisite corporate power and
authority to execute, deliver and perform its obligations under this Agreement, the Dynavax Promissory Note, the Warrant Purchase Agreement, and the Standstill and Corporate Governance Letter Agreement (the “Ancillary
Agreements”), and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by Dynavax of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated
hereby and thereby have been duly and validly authorized by all necessary action required on the part of Dynavax, and no other proceedings on the part of Dynavax, other than the Stockholder Approval, which will be obtained prior to the Purchase
Option Closing Date, are necessary to authorize this Agreement or the Ancillary Agreements or for Dynavax to perform its obligations hereunder or thereunder. This Agreement and the Ancillary Agreements constitute the lawful, valid and legally
binding obligations of Dynavax, enforceable in accordance with their terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights
generally and general equitable principles regardless of whether such enforceability is considered in a proceeding at law or in equity. 
  

					
		  	6	  	Amended and Restated Purchase Option Agreement

 (iii) No Violation or Conflict. The execution, delivery and
performance of this Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby do not (A) violate, conflict with or result in the breach of any provision of the Organizational Documents of Dynavax,
(B) conflict with or violate any law or Governmental Order applicable to Dynavax or any of its assets, properties or businesses, or (C) conflict with, result in any breach of, constitute a default (or event that with the giving of notice
or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the creation of any Encumbrance on any
of the assets or properties of Dynavax, pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or other instrument or arrangement to which Dynavax is a party except, in the case of
clauses (B) and (C), to the extent that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Dynavax. 
 (iv) Governmental Consents and Approvals. Other than any HSR Filings which, if such HSR Filings are required pursuant
to Section 2(a)(ii) hereof, will be obtained on or prior to the Purchase Option Closing Date, the execution, delivery and performance of this Agreement and the Ancillary Agreements by Dynavax do not, and the consummation of the
transactions contemplated hereby and thereby do not and will not, require any Governmental Approval which has not already been obtained, effected or provided, except with respect to which the failure to so obtain, effect or provide would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Dynavax. 
 (v)
Litigation. There are no actions by or against Dynavax pending before any Governmental Authority or, to the knowledge of Dynavax, threatened to be brought by or before any Governmental Authority, that would, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Dynavax. There are no pending or, to the knowledge of Dynavax, threatened actions, to which Dynavax is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or
prevent the execution, delivery or performance of this Agreement, the Ancillary Agreements or the Operative Documents or the consummation of the transactions contemplated hereby or thereby by any party hereto or thereto. Dynavax is not subject to
any Governmental Order (nor, to the knowledge of Dynavax, is there any such Governmental Order threatened to be imposed by any Governmental Authority) that would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect on Dynavax. 
 (b) Dynavax hereby covenants and agrees with Holdings as follows: 
 (i) Immediately prior to the Purchase Option Closing Date, Dynavax shall have sufficient authorized but unissued, freely
transferable and nonassessable shares of Dynavax Common Stock or Alternate Closing Securities, as applicable, available to satisfy its obligation to deliver the Dynavax Closing Shares or Alternate Closing Securities, as applicable, the Dynavax
Closing Warrant Shares and the shares of Dynavax Common Stock issuable pursuant to the Dynavax Promissory Note (the “Dynavax Promissory Note Shares”). Immediately prior to each Adjusted Securities Payment Date, Dynavax shall
have sufficient authorized but unissued, freely transferable and nonassessable Alternate Securities available to satisfy its obligation to deliver such Alternate Securities as required pursuant to Section 2B(a). Dynavax shall deliver to
Holdings on or prior to the Purchase Option Closing Date a legal opinion of Cooley Godward Kronish LLP (or such other counsel as Dynavax and Holdings shall mutually agree), which opinion shall be, in form and substance, reasonably
acceptable to Holdings. If Alternate Securities are to be issued pursuant to Section 2B(a), Dynavax shall deliver to Holdings on or before each Adjusted Securities Payment date a legal opinion of Cooley Godward Kronish LLP
(or such other counsel as Dynavax and Holdings shall mutually agree), which opinion shall be, in form and substance, reasonably acceptable to Holdings. 
  

					
		  	7	  	Amended and Restated Purchase Option Agreement

 (ii) Dynavax, on the Purchase Option Closing Date, shall convey good and
marketable title to the Dynavax Closing Shares or Alternate Closing Securities, as applicable, free from any Encumbrances and any and all other restrictions that any issuance, sale, assignment or other transfer of Dynavax Closing Shares or Alternate
Closing Securities, as applicable, be consented to or approved by any Person. Dynavax, on each Adjusted Securities Payment Date, shall convey good and marketable title to the Alternate Securities issued pursuant to Section 2B(a), free
from any Encumbrances and any and all other restrictions requiring that any issuance, sale, assignment or other transfer of such Alternate Securities be consented to or approved by any Person. 
 (iii) If the share certificates representing the Dynavax Closing Shares or Alternate Closing Securities, as applicable, and
any Alternate Securities issued pursuant to Section 2B(a), include the 33 Act Legend (as set forth in Section 2(f) hereof), Dynavax shall, within two (2) Business Days of receiving a request from Holdings or any
“Investor” (as defined in the Registration Rights Agreement), remove or cause to be removed the 33 Act Legend from such share certificates as Holdings or such Investor shall designate, so long as (x) the Dynavax Closing
Shares or Alternate Closing Securities or such Alternate Securities, as applicable, represented by such share certificates has been transferred to a third party in compliance with the registration requirements of the Securities Act or an available
exemption therefrom, and (y) Dynavax receives a certification from Holdings, such Investor or a securities broker designated by Holdings or such Investor to the effect that the sale of such Dynavax Closing Shares or Alternate Closing Securities
or such Alternate Securities, as applicable, was made under a Registration Statement and accompanied by the delivery of a current prospectus. 
 (iv) Upon the termination of this Agreement pursuant to Section 9 hereof, or as soon thereafter as is practical, Dynavax shall (A) in accordance with Sections 2.7 and 2.8 of the
Novated and Restated Technology License Agreement, deliver to Symphony Dynamo all regulatory submissions, clinical master files, development plans, consultant inputs, manufacturing reports and, to the extent requested by Symphony, other materials,
documents, files and other information relating to the Programs and necessary to enable Symphony Dynamo to continue the development of the Programs (or, where necessary, copies thereof), and (B) in accordance with and pursuant to
Section 2.12 of the Novated and Restated Technology License Agreement, negotiate in good faith, and on commercially reasonable terms and conditions, a supply agreement relating to materials, including compounds and Products, required by
Symphony Dynamo or its partners or transferees for the continued development (including clinical development), manufacture and commercialization of Products. 
 (v) [Reserved]. 
 (vi) Prior to each Adjusted Securities Payment Date, Dynavax shall take all such actions (at Dynavax’s sole cost and expense) as are necessary to permit Dynavax to issue the Alternate Securities to
Holdings in accordance with Section 2B(a). 
 (vii) Dynavax shall take all such actions (at
Dynavax’s sole cost and expense) as are necessary or advisable to cause (A) the issuance of any Alternate Securities by Dynavax to Holdings or (B) the transfer of any securities of Dynavax by Holdings to Dynavax, in each case pursuant
to Section 2B(a), to be exempted from Section 16(b) of the Exchange Act, provided that Holdings shall notify Dynavax promptly of any transactions by it involving Dynavax Common Stock that could implicate Section 16(b) of the
Exchange Act. 
 (viii) Dynavax agrees to use its commercially reasonable efforts to obtain the Stockholder
Approval. In connection with the foregoing, Dynavax shall call and hold a meeting of its stockholders to seek Stockholder Approval prior to the date that is six (6) months from the date hereof, and file with the SEC a proxy statement and shall
use its commercially reasonable efforts to solicit proxies in favor of the Stockholder Approval, and shall use its commercially reasonable efforts to respond to any comments of the SEC or its staff and to cause a definitive proxy

  

					
		  	8	  	Amended and Restated Purchase Option Agreement

 
statement related to such stockholders’ meeting to be mailed to Dynavax’s stockholders. The Dynavax Board shall recommend Stockholder Approval and such recommendation shall be included
in each proxy statement filed with the SEC and disseminated to the Dynavax stockholders in connection with such stockholder meeting (such recommendations, the “Dynavax Board Recommendation”). Dynavax shall notify Holdings
promptly of the receipt of any comments from the SEC or its staff and of any request by the SEC or its staff for amendments or supplements to such proxy statement or for additional information and will supply Holdings with copies of all
correspondence between Dynavax or any of its representatives, on the one hand, and the SEC or its staff, on the other hand, with respect to such proxy statement. If at any time prior to such stockholders’ meeting there shall occur any event
that is required to be set forth in an amendment or supplement to the proxy statement, Dynavax shall as promptly as practicable prepare and mail to its stockholders such an amendment or supplement. Each of Holdings and Dynavax agrees promptly to
correct any information provided by it or on its behalf for use in the proxy statement if and to the extent that such information shall have become false or misleading in any material respect, and Dynavax shall as promptly as practicable prepare and
mail to its stockholders an amendment or supplement to correct such information to the extent required by applicable laws and regulations. Dynavax shall provide Holdings with drafts of each such proxy statement, or amendment or supplement thereto,
and consult with Holdings regarding the same, in each case, prior to filing or mailing the same. Without limiting the generality of the foregoing, Dynavax’s obligations pursuant to the first two sentences of this
Section 3(b)(viii) shall not be affected by the withdrawal or modification by the Dynavax Board or any committee thereof of the Dynavax Board Recommendation. In the event that Stockholder Approval is not obtained at the first
meeting of stockholders at which Stockholder Approval is sought, at the written request of Holdings, Dynavax shall call and convene no more than one subsequent meeting of stockholders for the purpose of obtaining Stockholder Approval (and the
Dynavax Board will unanimously recommend Stockholder Approval), which meeting may not be unreasonably delayed by Dynavax, and all covenants between the parties set forth in this Section 2(b)(viii) shall apply equally with respect to such
subsequent meeting of stockholders. Unless otherwise required by applicable law, Dynavax shall not call or convene a meeting of its stockholders prior to the meeting of stockholders at which Stockholder Approval is sought. 
 (ix) Prior to the Purchase Option Closing Date, the Dynavax Board shall have adopted resolutions, reasonably satisfactory to
Holdings, approving the issuance of the Dynavax Closing Shares, the Dynavax Closing Warrants and the Dynavax Closing Warrant Shares or the Alternate Closing Securities, as applicable, and the Dynavax Promissory Note Shares to Holdings for purposes
of Section 203(a)(1) of the Delaware General Corporation Law (the “DGCL”), such that the restrictions on “business combinations” set forth in Section 203 of the DGCL shall not apply to Dynavax and Holdings
as a result of such issuances. 
 (x) Prior to the Purchase Option Closing, Dynavax shall take all such actions
as are necessary or advisable to cause Symphony Dynamo to declare and pay the Pre-Closing Holdings Dividend (as defined below). 
 Section 4. Holdings Representations, Warranties and Covenants. 
 (a) As of the date hereof, Holdings hereby
represents and warrants, and, except to the extent that any of the following representations and warranties is limited to the date of this Agreement or otherwise limited, on the Purchase Option Closing Date and each Adjusted Securities Payment Date,
shall be deemed to have represented and warranted, to Dynavax and Symphony Dynamo that: 
 (i)
Organization. Holdings is a limited liability company, duly formed, validly existing and in good standing under the laws of the State of Delaware. 
 (ii) Authority and Validity. Holdings has all requisite limited liability company power and authority to execute, deliver and perform its obligations under this Agreement and the

  

					
		  	9	  	Amended and Restated Purchase Option Agreement

 
Ancillary Agreements to which it is a party and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by Holdings of this Agreement and the
Ancillary Agreements to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary action required on the part of Holdings, and no other proceedings on the part
of Holdings are necessary to authorize this Agreement or the Ancillary Agreements to which it is a party or for Holdings to perform its obligations hereunder or thereunder. This Agreement and the Ancillary Agreements to which it is a party
constitute the lawful, valid and legally binding obligations of Holdings, enforceable in accordance with their terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the
enforcement of creditors’ rights generally and general equitable principles regardless of whether such enforceability is considered in a proceeding at law or in equity. 
 (iii) No Violation or Conflict. The execution, delivery and performance of this Agreement and the Ancillary Agreements
to which it is a party and the transactions contemplated hereby and thereby do not (A) violate, conflict with or result in the breach of any provision of the Organizational Documents of Holdings, (B) as of the date of this Agreement,
conflict with or violate any law or Governmental Order applicable to Holdings or any of its assets, properties or businesses, or (C) as of the date of this Agreement, conflict with, result in any breach of, constitute a default (or event that
with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the creation
of any Encumbrance on any of the assets or properties of Holdings, pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or other instrument or arrangement to which Holdings is a party
except, in the case of clauses (B) and (C), to the extent that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings.

 (iv) Governmental Consents and Approvals. The execution, delivery and performance of this Agreement and
the Ancillary Agreements to which it is a party by Holdings do not, and the consummation of the transactions contemplated hereby and thereby do not and will not, require any Governmental Approval which has not already been obtained, effected or
provided, except with respect to which the failure to so obtain, effect or provide would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings. 
 (v) Litigation. As of the date of this Agreement, there are no actions by or against Holdings pending before any
Governmental Authority or, to the knowledge of Holdings, threatened to be brought by or before any Governmental Authority, that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings. There are
no pending or, to the knowledge of Holdings, threatened actions to which Holdings is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or prevent the execution, delivery or performance of this Agreement and the
Ancillary Agreements to which it is a party or the Operative Documents or the consummation of the transactions contemplated hereby or thereby by any party hereto or thereto. As of the date of this Agreement, Holdings is not subject to any
Governmental Order (nor, to the knowledge of Holdings, is there any such Governmental Order threatened to be imposed by any Governmental Authority) that would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect on Holdings. 
 (vi) Stock Ownership. All of Symphony Dynamo’s issued and outstanding Symphony
Dynamo Equity Securities are owned beneficially and of record by Holdings, free and clear of any and all encumbrances. 
 (vii) Interim Operations. Holdings was formed solely for the purpose of engaging in the transactions contemplated by the Operative Documents, has engaged in no other business activities and has conducted its operations only as
contemplated by the Operative Documents. 
  

					
		  	10	  	Amended and Restated Purchase Option Agreement

 (viii) Accredited Investor. 
 (A) Holdings is and will remain at all relevant times an Accredited Investor. 
 (B) Holdings has relied completely on the advice of, or has consulted with or has had the opportunity to consult with, its
own personal tax, investment, legal or other advisors and has not relied on Dynavax or any of its Affiliates for advice related to any offer and sale of the Dynavax Closing Shares, and, if issued, the Alternate Securities, in connection with the
Purchase Option. Holdings has reviewed the Investment Overview and is aware of the risks disclosed therein. Holdings acknowledges that it has had a reasonable opportunity to conduct its own due diligence with respect to the Products, the Programs,
Symphony Dynamo, Dynavax and the transactions contemplated by the Operative Documents. 
 (C) Holdings is able to
bear the economic risk of such investment for an indefinite period and to afford a complete loss thereof. 
 (D)
Holdings agrees that the Dynavax Closing Shares and, if issued, the Alternate Securities may not be resold (1) without registration thereof under the Securities Act (unless an exemption from such registration is available), or (2) in
violation of any law. 
 (E) No person or entity acting on behalf of, or under the authority of, Holdings is or
will be entitled to any broker’s, finder’s, or similar fees or commission payable by Dynavax or any of its Affiliates. 
 (b) Holdings hereby covenants and agrees with Dynavax as follows: 
 (i) [Reserved.] 
 (ii) Encumbrance. Holdings will not, and will not permit any of its
Subsidiaries to, create, assume or suffer to exist any Encumbrance on any of its Symphony Dynamo Equity Securities except with the prior written consent of Dynavax. 
 (iii) Transfer and Amendment. Commencing upon the date hereof and ending upon the earlier to occur of (x) the
Purchase Option Closing Date, and the termination of this Agreement pursuant to Section 9 (such period, the “Term”), the manager of Holdings shall not (A) transfer, or permit the transfer of, any Membership
Interest without the prior written consent of Dynavax or (B) amend, or permit the amendment of, any provisions relating to the transfer of Membership Interests, as set forth in Section 7.02 of the Holdings LLC Agreement, to the extent such
amendment would adversely affect Dynavax’s right of consent set forth in Sections 7.02(b)(i) and 7.02(c) of the Holdings LLC Agreement. 
 (iv) Symphony Dynamo Directors. During the Term, Holdings agrees to vote all of its Symphony Dynamo Equity Securities (or to exercise its right with respect to such Symphony Dynamo Equity
Securities to consent to action in writing without a meeting) in favor of, as applicable, the election, removal and replacement of one director of the Symphony Dynamo Board, and any successor thereto, designated by Dynavax (the “Dynavax
Director”) as directed by Dynavax. In furtherance and not in limitation of the foregoing, Holdings hereby grants to Dynavax an irrevocable proxy, with respect to all Symphony Dynamo Equity Securities now owned or hereafter acquired by
Holdings, to vote such Symphony Dynamo Equity Securities or to exercise the right to consent to action in writing without a meeting with respect to such Symphony Dynamo Equity Securities, such irrevocable proxy to be exercised solely for the limited
purpose of electing, removing and replacing the Dynavax Director in the event of the failure or refusal of

  

					
		  	11	  	Amended and Restated Purchase Option Agreement

 
Holdings to elect, remove or replace such Dynavax Director, as directed by Dynavax. Additionally, Holdings agrees, during the Term, to the selection of two (2) independent directors (of the
four (4) directors of Symphony Dynamo not chosen by Holdings at the direction of Dynavax), and any successors thereto. Such independent directors shall be selected by mutual agreement of Dynavax and Holdings. 
 (v) Symphony Dynamo Board. During the Term, Holdings shall not vote any of its Symphony Dynamo Equity Securities (or
exercise its rights with respect to such Symphony Dynamo Equity Securities by written consent without a meeting) to increase the size of the Symphony Dynamo Board to more than five (5) members without the prior written consent of Dynavax.

 (vi) Symphony Dynamo Charter. During the Term, Holdings shall not approve or permit any amendment to
Article IV, Paragraphs (1) and (3); Article VI; Article VII; Article X; Article XI or Article XIII of the Symphony Dynamo Charter without the prior written consent of Dynavax. 
 Section 5. Symphony Dynamo Representations, Warranties and Covenants. 
 (a) As of the date hereof, Symphony Dynamo hereby represents and warrants, and, except to the extent that any of the following
representations and warranties is limited to the date of this Agreement or otherwise limited, on the Purchase Option Closing Date, shall be deemed to have represented and warranted, to Dynavax and Holdings that: 
 (i) Organization. Symphony Dynamo is a corporation, duly organized, validly existing and in good standing under the
laws of the State of Delaware. 
 (ii) Authority and Validity. Symphony Dynamo has all requisite corporate
power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance by Symphony Dynamo of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by all necessary action required on the part of Symphony Dynamo, and no other proceedings on the part of Symphony Dynamo are necessary to authorize this Agreement or for Symphony
Dynamo to perform its obligations under this Agreement. This Agreement constitutes the lawful, valid and legally binding obligation of Symphony Dynamo, enforceable in accordance with its terms, except as the same may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and general equitable principles regardless of whether such enforceability is considered in a proceeding at law or in
equity. 
 (iii) No Violation or Conflict. The execution, delivery and performance of this Agreement and
the transactions contemplated hereby do not (A) violate, conflict with or result in the breach of any provision of the Organizational Documents of Symphony Dynamo, (B) conflict with or violate any law or Governmental Order applicable to
Symphony Dynamo or any of its assets, properties or businesses, or (C) conflict with, result in any breach of, constitute a default (or event that with the giving of notice or lapse of time, or both, would become a default) under, require any
consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the creation of any Encumbrance on any of the assets or properties of Symphony Dynamo, pursuant to, any
note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or other instrument or arrangement to which Symphony Dynamo is a party except, in the case of clauses (B) and (C), to the extent
that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. 
  

					
		  	12	  	Amended and Restated Purchase Option Agreement

 (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Symphony Dynamo do not, and the consummation of the transactions contemplated hereby do not and will not, require any Governmental Approval which has not already been obtained, effected or provided, except with
respect to which the failure to so obtain, effect or provide would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. 
 (v) Litigation. There are no actions by or against Symphony Dynamo pending before any Governmental Authority or, to
the knowledge of Symphony Dynamo, threatened to be brought by or before any Governmental Authority that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. There are no pending or, to
the knowledge of Symphony Dynamo, threatened actions to which Symphony Dynamo is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or prevent the execution, delivery or performance of this Agreement or the Operative
Documents or the consummation of the transactions contemplated hereby or thereby by any party hereto or thereto. Symphony Dynamo is not subject to any Governmental Order (nor, to the knowledge of Symphony Dynamo, is there any such Governmental Order
threatened to be imposed by any Governmental Authority) that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. 
 (vi) Capitalization. Holdings is the beneficial and record owner of all issued and outstanding Symphony Dynamo Equity
Securities. No shares of Symphony Dynamo capital stock are held in treasury by Symphony Dynamo or any Symphony Dynamo Subsidiary. All of the issued and outstanding Symphony Dynamo Equity Securities (A) have been duly authorized and validly
issued and are fully paid and nonassessable, (B) were issued in compliance with all applicable state and federal securities laws, and (C) were not issued in violation of any preemptive rights or rights of first refusal. No preemptive
rights or rights of first refusal exist with respect to any Symphony Dynamo Equity Securities and no such rights will arise by virtue of or in connection with the transactions contemplated hereby (other than for the Purchase Option). Other than the
Purchase Option, there are no outstanding options, warrants, call rights, commitments or agreements of any character to acquire any Symphony Dynamo Equity Securities. There are no outstanding stock appreciation, phantom stock, profit participation
or other similar rights with respect to Symphony Dynamo. Symphony Dynamo is not obligated to redeem or otherwise acquire any of its outstanding Symphony Dynamo Equity Securities. 
 (vii) Interim Operations. Symphony Dynamo was formed solely for the purpose of engaging in the transactions
contemplated by the Operative Documents, has engaged in no other business activities and has conducted its operations only as contemplated by the Operative Documents. 
 (viii) Investment Company. Symphony Dynamo is not, and after giving effect to the transactions contemplated by the
Operative Documents will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 
 (b) Symphony Dynamo covenants and agrees that: 
 (i) Symphony Dynamo will comply with all laws, ordinances or governmental rules or regulations to which it is subject and
will obtain and maintain in effect all licenses, certificates, permits, franchises and other Governmental Approvals necessary to the ownership of its properties or to the conduct of its business, in each case to the extent necessary to ensure that
non-compliance with such laws, ordinances or governmental rules or regulations or failures to obtain or maintain in effect such licenses, certificates, permits, franchises and other Governmental Approvals would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. 
  

					
		  	13	  	Amended and Restated Purchase Option Agreement

 (ii) Symphony Dynamo will file (or cause to be filed) all material tax
returns required to be filed by it and pay all taxes shown to be due and payable on such returns and all other taxes imposed on it or its assets to the extent such taxes have become due and payable and before they have become delinquent and shall
pay all claims for which sums have become due and payable that have or might become attached to the assets of Symphony Dynamo; provided, that Symphony Dynamo need not file any such tax returns or pay any such tax or claims if (A) the
amount, applicability or validity thereof is contested by Symphony Dynamo on a timely basis in good faith and in appropriate proceedings, and Symphony Dynamo has established adequate reserves therefor in accordance with GAAP on the books of Symphony
Dynamo or (B) the failure to file such tax returns or the nonpayment of such taxes and assessments, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect on Symphony Dynamo. 
 (iii) Symphony Dynamo will at all times preserve and keep in full force and effect its corporate existence. 
 (iv) Symphony Dynamo will keep complete, proper and separate books of record and account, including a record of all costs and
expenses incurred, all charges made, all credits made and received, and all income derived in connection with the operation of the business of Symphony Dynamo, all in accordance with GAAP, in each case to the extent necessary to enable Symphony
Dynamo to comply with the periodic reporting requirements of this Agreement. 
 (v) Symphony Dynamo will perform
and observe in all material respects all of the terms and provisions of each Operative Document to be performed or observed by it, maintain each such Operative Document to which it is a party, promptly enforce in all material respects each such
Operative Document in accordance with its terms, take all such action to such end as may be from time to time reasonably requested by Holdings or Dynavax and make to each other party to each such Operative Document such demands and requests for
information and reports or for action as Symphony Dynamo is entitled to make under such Operative Document. 
 (vi) Symphony Dynamo shall permit the representatives of Holdings (including Holdings’ members and their respective representatives), each Symphony Fund and Dynavax, at each of their own expense and upon reasonable prior notice to
Symphony Dynamo, to visit the principal executive office of Symphony Dynamo, to discuss the affairs, finances and accounts of Symphony Dynamo with Symphony Dynamo’s officers and (with the consent of Symphony Dynamo, which consent will not be
unreasonably withheld) the Symphony Dynamo Auditors (as defined in Section 5(d)(iii) hereof), all at such reasonable times and as often as may be reasonably requested in writing. 
 (vii) Symphony Dynamo shall permit each Symphony Fund, at its own expense and upon reasonable prior notice to Symphony
Dynamo, to inspect and copy Symphony Dynamo’s books and records and inspect Symphony Dynamo’s properties at reasonable times. 
 (viii) Symphony Dynamo shall allow Dynavax or its designated representatives to have reasonable visitation and inspection rights with regard to the Programs and materials, documents and other information
relating thereto. 
 (ix) Symphony Dynamo shall permit each Symphony Fund to consult with and advise the
management of Symphony Dynamo on matters relating to the research and development of the Programs in order to develop the Product. 
 (x) On the Purchase Option Closing Date, or as soon thereafter as is practical, Symphony Dynamo shall deliver to Dynavax all materials, documents, files and other information relating to the Programs (or,
where necessary, copies thereof). 
  

					
		  	14	  	Amended and Restated Purchase Option Agreement

 (xi) During the Term, Dynavax shall have the right to consent to any
increase in the size of the Symphony Dynamo Board to more than five (5) directors. 
 (xii) During the Term,
Dynavax shall have the right to designate, remove and replace one (1) director of the Symphony Dynamo Board and consent to the selection of the two (2) independent directors (of the four (4) directors of Symphony Dynamo not chosen by
Holdings at the direction of Dynavax), in each case including any successors thereto and in accordance with the terms of Section 4(b)(iv). 
 (xiii) Symphony Dynamo shall indemnify the directors and officers of Symphony Dynamo against liability incurred by reason of the fact that such Person is or was a director or officer of Symphony Dynamo,
as permitted by Article VII of the Symphony Dynamo Charter and Section 9.01 of the Symphony Dynamo By-laws, as set forth in, and on the terms of, the Indemnification Agreement and the RRD Services Agreement, respectively. 
 (xiv) During the Term, Symphony Dynamo shall comply with, and cause any Persons acting for it to comply with, the terms of
the Investment Policy with respect to the investment of any funds held by it. 
 (xv) From and after
the Purchase Option Closing Date, Symphony Dynamo shall not make any further payments to RRD, and immediately prior to the Purchase Option Closing, Symphony Dynamo shall declare and pay as a dividend to Holdings an amount in
cash equal to $500,000, minus the sum of (A) any and all outstanding amounts pursuant to the RRD Services Agreement through the Purchase Option Closing Date, plus (B) all costs and expenses incurred by
Symphony Dynamo that are associated with the consummation of the Purchase Option (including tax preparation and filings but excluding a final audit), plus (C) all amounts paid by Symphony Dynamo for the purchase of a tail insurance policy
for Symphony Dynamo (the calculated total, the “Pre-Closing Holdings Dividend”). 
 (c) Symphony Dynamo covenants and
agrees that, until the expiration of the Term, it shall not, and shall cause its Subsidiaries (if any) not to, without Dynavax’s prior written consent (such consent, in the case of clause (x) below, not to be unreasonably withheld):

 (i) issue any Symphony Dynamo Equity Securities or any Equity Securities of any Subsidiary thereof (other than
any issuances of Equity Securities by Symphony Dynamo made in accordance with Section 1(b) hereof to Holdings so long as Symphony Dynamo is a wholly owned subsidiary of Holdings, or by a Subsidiary of Symphony Dynamo to Symphony Dynamo
or to another wholly owned Subsidiary of Symphony Dynamo); provided, however, that in any event any such Symphony Dynamo Equity Securities or Equity Securities of such Subsidiary shall be issued subject to the Purchase Option;

 (ii) redeem, repurchase or otherwise acquire, directly or indirectly, any Symphony Dynamo Equity Securities or
the Equity Securities of any Subsidiary of Symphony Dynamo; 
 (iii) create, incur, assume or permit to exist any
Debt other than any Debt incurred pursuant to the Operative Documents and the Development Budget (including payables incurred in the ordinary course of business) (“Excepted Debt”); provided, however, that
the aggregate outstanding principal amount of all such Excepted Debt for borrowed money shall not exceed $1,000,000 at any time; 
 (iv) declare or pay dividends or other distributions on any Symphony Dynamo Equity Securities other than any dividend declared from the proceeds of a sale or license of a discontinued Program to a third
party, in respect of which Symphony Dynamo shall be entitled to pay (subject to the existence of lawfully available funds) a dividend equal to the net amount (such net amount calculated as the gross proceeds received less amounts required to be paid
in respect of any and all corporate taxes owed by Symphony Dynamo as a result of the receipt of such gross amounts) of such amounts received from such third party; 
  

					
		  	15	  	Amended and Restated Purchase Option Agreement

 (v) enter into any transaction of merger or consolidation, or liquidate,
wind up or dissolve itself, or convey, transfer, license, lease or otherwise dispose of all, or a material portion of, its properties, assets or business; 
 (vi) other than in respect of the Programs, engage in the development of products for any other company or engage or participate in the development of products or engage in any other material line of
business; 
 (vii) other than entering into, and performing its obligations under, the Operative Documents and
participating in the Programs, engage in any action that negates or is inconsistent with any rights of Dynavax set forth herein; 
 (viii) other than as contemplated by the RRD Services Agreement and Section 6.2 of the Amended and Restated Research and Development Agreement, hire, retain or contract for the services of, any
employees until the termination of such agreements; 
 (ix) incur any financial commitments in respect of the
development of the Programs other than those set forth in the Development Plan and the Development Budget, or those approved by the Development Committee and, if so required by the terms of Paragraph 11 of the Development Committee Charter, the
Symphony Dynamo Board in accordance with the Operative Documents; 
 (x) other than any transaction contemplated
by the Operative Documents, enter into or engage in any Conflict Transactions without the prior approval of a majority of the Disinterested Directors of the Symphony Dynamo Board; or 
 (xi) waive, alter, modify, amend or supplement in any manner whatsoever any material terms and conditions of the RRD Services
Agreement, the Funding Agreement, the Subscription Agreement, or Articles 4 and 6 of the Amended and Restated Research and Development Agreement, except in compliance with the terms of the Operative Documents. 
 (d) Symphony Dynamo covenants and agrees to deliver, cause to be delivered, and provide access thereto, to each other Party, each Symphony
Fund, and such Auditors as Dynavax may designate, so long as such Auditors shall be subject to confidentiality requirements at least as stringent as the Confidentiality Agreement: 
 (i) upon request, copies of the then current Development Plan for each quarter, on or before March 31, June 30,
September 30, and December 31 of each year; 
 (ii) upon request, copies of the then current
Development Budget for each quarter, including a report setting forth in reasonable detail the projected expenditures by Symphony Dynamo pursuant to the Development Budget, on or before March 31, June 30, September 30, and
December 31 of each year; 
 (iii) prior to the close of each fiscal year, Symphony Dynamo shall cause the
Manager to seek to obtain from the Symphony Dynamo Auditors the Client Schedules to be provided to Dynavax’s Auditors in connection with the Symphony Dynamo Auditors’ audit of Symphony Dynamo. Within ten (10) Business Days after
the close of each fiscal year, Symphony Dynamo (or the Manager acting on its behalf) will provide Dynavax’s Auditors with the requested Client Schedules. If the Symphony Dynamo Auditors deliver the Client Schedules after the end of the
fiscal year, Symphony Dynamo (or the Manager acting on its behalf) will provide the completed Client Schedules to Dynavax’s Auditors within ten (10) Business Days of such receipt; 
  

					
		  	16	  	Amended and Restated Purchase Option Agreement

 (iv) prior to the close of each fiscal year, Dynavax’ Vice President of
Finance, the Symphony Dynamo Auditors, Dynavax’s Auditors and Symphony Dynamo (or the Manager acting on its behalf) shall agree to a completion schedule that will include (A) the provision by Symphony Dynamo to Dynavax of the financial
information reasonably necessary for Dynavax to consolidate and audit the financial results of Symphony Dynamo and (B) the following financial statements, including the related notes thereto, audited and certified by the Symphony Dynamo
Auditors: one (1) a balance sheet of Symphony Dynamo as of the close of such fiscal year, two (2) a statement of net income for such fiscal year, and three (3) a statement of cash flows for such fiscal year. Such audited annual
financial statements shall set forth in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and Symphony Dynamo (or the Manager acting on its behalf) shall, to the extent that
Symphony Dynamo (or the Manager acting on its behalf), using commercially reasonable means, can procure such an opinion, be accompanied by an opinion thereon of the Symphony Dynamo Auditors to the effect that such financial statements present
fairly, in all material respects, the financial position of Symphony Dynamo and its results of operations and cash flows and have been prepared in conformity with GAAP, and that the examination of such accountants in connection with such financial
statements has been made in accordance with generally accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the circumstances; 
 (v) within two (2) Business Days following each calendar month and upon receipt from Dynavax of its monthly invoice to
Symphony Dynamo, current accrued monthly vendor expenses and prepaid expenses: (A) the unaudited balance sheet of Symphony Dynamo for the previous calendar month; (B) the unaudited statement of net income for such previous calendar month;
(C) the unaudited statement of cash flows for such previous calendar month; (D) the trial balance schedule for such previous calendar month; and (E) related account reconciliations for such previous calendar month; 
 (vi) any other documents, materials or other information, including information and documentation of internal controls and
reporting as may be required by applicable law, rule or regulation (including information prepared in support of Symphony Dynamo’s efforts pursuant to Section 5(e)) pertaining to Holdings, the Programs or Symphony Dynamo as Dynavax
may reasonably request, including preliminary financial information; 
 (vii) within two (2) Business Days
following its receipt thereof from Symphony Dynamo’s tax return preparer, a copy of each income tax return to be filed by Symphony Dynamo with any foreign, federal, state or local taxing authority (including all supporting schedules thereto);

 (viii) promptly, and in any event within five (5) Business Days of receipt thereof, copies of any notice
to Symphony Dynamo from any federal or state Governmental Authority relating to any order, ruling, statute or other law or regulation that would reasonably be expected to have a Material Adverse Effect on Symphony Dynamo; 
 (ix) promptly upon receipt thereof, notice of all actions, suits, investigations, litigation and proceedings before any court
or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, affecting Symphony Dynamo; 
 (x) promptly upon receipt thereof, copies of any other notices, requests, reports, financial statements and other information and documents received by Symphony Dynamo under or pursuant to any other
Operative Document, including, without limitation, any notices of breach or termination of any subcontracts or licenses entered into or permitted pursuant to the Operative Documents; and 
 (xi) with reasonable promptness, such other data and information relating to the business, operations, affairs, financial
condition, assets or properties of Symphony Dynamo or relating to the ability of Symphony Dynamo to perform its obligations hereunder and under the Operative Documents as from time to time may be reasonably requested by Dynavax and/or Holdings;

  

					
		  	17	  	Amended and Restated Purchase Option Agreement

 provided, that neither Symphony Dynamo, nor the Manager acting on behalf of Symphony Dynamo, shall
have any liability to Dynavax for the failure to deliver financial documents or other materials hereunder, if such failure was caused by a failure of Dynavax to provide, in a timely manner, data required to prepare such financial documents or other
materials to Symphony Dynavax in a timely manner. 
 (e) Symphony Dynamo will use commercially reasonable efforts, at its own
expense (as set forth in the Management Budget), to cooperate with Dynavax in meeting Dynavax’s government compliance, disclosure, and financial reporting obligations, including without limitation under the Sarbanes-Oxley Act of 2002 and any
rules and regulations promulgated thereunder, and under FASB Interpretation No. 46. Without limiting the foregoing, Symphony Dynamo further covenants, until the expiration of the Term, that (w) the principal executive officer and the
principal financial officer of Symphony Dynamo, or persons performing similar functions, shall provide certifications to Dynavax corresponding to those required with respect to public companies for which a class of securities is registered under the
Exchange Act (“Public Companies”) under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002; (x) Symphony Dynamo shall maintain a system of disclosure controls and internal controls (as defined under the Exchange
Act) and conduct quarterly and annual evaluations of the effectiveness of such controls as required under the Exchange Act for Public Companies; (y) Symphony Dynamo shall provide to Dynavax an attestation report of the Symphony Dynamo Auditors
with respect to Symphony Dynamo management’s assessment of Symphony Dynamo’s internal controls as required under the Exchange Act for Public Companies; and (z) Symphony Dynamo will maintain, or cause to have maintained, such
sufficient evidentiary support for management’s assessment of the effectiveness of Symphony Dynamo’s internal controls as required for Public Companies. 
 (f) Dynavax agrees to provide reasonable assistance and support for the financial operations of Symphony Dynamo as may be reasonably requested by Symphony Dynamo from time to time during the Term;
provided that any such services shall be pursuant to a separate agreement specifying the nature and amount of assistance and support to be provided and the reimbursement to Dynavax of costs plus a reasonable profit in the provision of such
assistance and support. 
 Section 6. Notice of Material Event. Each Party agrees that, upon it receiving knowledge
of a material event or development with respect to any of the transactions contemplated hereby that, to the knowledge of its executive officers, is not known to the other Parties, such Party shall notify the other Parties in writing within three
(3) Business Days of the receipt of such knowledge by any executive officer of such Party; provided, that the failure to provide such notice shall not impair or otherwise be deemed a waiver of any rights any Party may have arising from such
material event or development and that notice under this Section 6 shall not in itself constitute notice of any breach of any of the Operative Documents. 
 Section 7. Assignment Transfers; Legend. 
 (a) Assignment by Dynavax
and Symphony Dynamo. Neither Dynavax nor Symphony Dynamo may assign, delegate, transfer, sell or otherwise dispose of (collectively, “Transfer”), in whole or in part, any or all of their rights or obligations hereunder to
any Person (a “Transferee”) without the prior written approval of each of the other Parties; provided, however, that Dynavax, without the prior approval of each of the other Parties, acting in accordance with
Article 14 of the Amended and Restated Research and Development Agreement, may make such Transfer to any Person which acquires all or substantially all of Dynavax’s assets or business (or assets or business related to the Programs) or
which is the surviving or resulting Person in a merger or consolidation with Dynavax; provided, further, that in the event of any Transfer, Dynavax or Symphony Dynamo, as applicable, shall provide written notice to the other Parties of
any such Transfer not later than thirty (30) days after such Transfer setting forth the identity and address of the Transferee and summarizing the terms of the Transfer. In no event shall such

  

					
		  	18	  	Amended and Restated Purchase Option Agreement

 
assignment alter the definition of “Dynavax Common Stock” except as a result of the surviving or resulting “parent” entity in a merger being other than Dynavax, in which case
any reference to Dynavax Common Stock shall be deemed to instead reference the common stock, if any, of the surviving or resulting entity. 
 (b) Assignment and Transfers by Holdings. Prior to the expiration of the Purchase Option, Holdings may not Transfer, in whole or in part, any or all of its Symphony Dynamo Equity Securities or any
or all of its rights or obligations hereunder to any Person (other than Dynavax) without the prior written consent of Dynavax. In addition, any Transfer of Symphony Dynamo Equity Securities by Holdings or any other Person to any Person other than
Dynavax shall be conditioned upon, and no effect shall be given to any such Transfer unless such transferee shall agree in writing in form and substance satisfactory to Dynavax to be bound by all of the terms and conditions hereunder, including the
Purchase Option, as if such transferee were originally designated as “Holdings” hereunder. 
 (c) Legend. Any
certificates evidencing Symphony Dynamo Equity Securities shall bear a legend in substantially the following form: 
 THE
SECURITIES OF SYMPHONY DYNAMO, INC., EVIDENCED HEREBY ARE SUBJECT TO AN OPTION, HELD BY DYNAVAX, AS DESCRIBED IN AN AMENDED AND RESTATED PURCHASE OPTION AGREEMENT (THE “PURCHASE OPTION AGREEMENT”) DATED AS OF NOVEMBER 9, 2009, BY
AND AMONG DYNAVAX TECHNOLOGIES CORPORATION, AND THE OTHER PARTIES THERETO, TO PURCHASE SUCH SECURITIES AT A PURCHASE PRICE DETERMINED PURSUANT TO SECTION 2 OF THE PURCHASE OPTION AGREEMENT, EXERCISABLE BY WRITTEN NOTICE AT ANY TIME DURING THE PERIOD
SET FORTH THEREIN. COPIES OF THE PURCHASE OPTION AGREEMENT ARE AVAILABLE AT THE PRINCIPAL PLACE OF BUSINESS OF SYMPHONY DYNAMO, INC. AT 7361 CALHOUN PLACE, SUITE 325, ROCKVILLE, MARYLAND 20855, AND WILL BE FURNISHED TO THE HOLDER HEREOF UPON WRITTEN
REQUEST WITHOUT COST. 
 Section 8. Costs and Expenses: Payments. Except as otherwise specified in
Section 2(i) hereof, each Party shall pay its own costs and expenses incurred in connection with the exercise of the Purchase Option; provided, however, that Dynavax shall pay any filing fees incurred in connection with any HSR
Filings made pursuant to this Agreement. 
 Section 9. Expiration: Termination of Agreement. 
 (a) Termination. 
 (i) This Agreement shall terminate upon the mutual written consent of all of the Parties. 
 (ii) Each of Holdings and Symphony Dynamo may terminate this Agreement in the event that Symphony Dynamo terminates the Amended and Restated Research and Development Agreement in accordance with its
terms. 
 (iii) Holdings may terminate this Agreement in the event that the Purchase Option Closing Date Shall
not have occurred by the six (6) month anniversary of the date hereof, in which case this agreement shall become null and void ab initio and the Original Agreement shall simultaneously be reinstated in its entirety and supersede this
Agreement in its entirety. 
  

					
		  	19	  	Amended and Restated Purchase Option Agreement

 Section 10. Survival: Indemnification. 
 (a) Survival of Representations and Warranties; Expiration of Certain Covenants. 
 (i) The representations and warranties of the Parties contained in this Agreement shall survive for a period of one year from
the making of such representations. The liability. of the Parties related to their respective representations and warranties hereunder shall not be reduced by any investigation made at any time by or on behalf of Holdings, Symphony Dynamo or
Dynavax, as applicable. 
 (ii) For the avoidance of doubt, the covenants and agreements set forth in Sections
Section 4(b), Section 5(b)(i), Section 5(b)(v)-Section 5(b)(ix), Section 5(b)(xi)-Section 5(b)(xiv), Section 5(c), Section 5(d)(i), 5(d)(ii), and
Section 5(d)(viii)-Section 5(d)(xi) shall, upon the expiration of the Term, expire and end without any further obligation by Symphony Dynamo or Holdings thereunder. 
 (iii) For the avoidance of doubt, the covenants and agreements set forth in
Section 5(b)(ii)-Section 4(b)(iii), Section 5(b)(x), Section 5(d)(iii)-Section 5(d)(v), Section 5(d)(vii), and Section 5(e) shall, upon the completion of all the
reporting, accounting and other obligations set forth therein with respect to the fiscal year in which this Agreement shall terminate, expire and end without any further obligation by Symphony Dynamo or Holdings thereunder. 
 (b) Indemnification. To the greatest extent permitted by applicable law, Dynavax shall indemnify and hold harmless Holdings and
Symphony Dynamo and Holdings shall indemnify and hold harmless Dynavax, and each of their respective Affiliates, officers, directors, employees, agents, partners, members, successors, assigns, representatives of, and each Person, if any (including
any officers, directors, employees, agents, partners, members of such Person) who controls Holdings, Symphony Dynamo and Dynavax, as applicable, within the meaning of the Securities Act or the Exchange Act, (each, an “Indemnified
Party”), from and against any and all actions, causes of action, suits, claims, losses, costs, interest, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnified Party
is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (hereinafter, a “Loss”), incurred by any Indemnified Party as a result of, or arising
out of, or relating to: (i) in the case of Dynavax being the Indemnifying Party, (A) any breach of any representation or warranty made by Dynavax herein or in any certificate, instrument or document delivered in connection and
contemporaneously herewith, or (B) any breach of any covenant, agreement or obligation of Dynavax contained herein or in any certificate, instrument or document delivered hereunder, including, without limitation, actions to enforce the Note,
and (ii) in the case of Holdings being the Indemnifying Party, (A) any breach of any representation or warranty made by Holdings or Symphony Dynamo herein or in any certificate, instrument or document delivered in connection and
contemporaneously herewith, or (B) any breach of any covenant, agreement or obligation of Holdings or Symphony Dynamo contained herein or in any certificate, instrument or document delivered hereunder. To the extent that the foregoing
undertaking by Dynavax or Holdings may be unenforceable for any reason, such Party shall make the maximum contribution to the payment and satisfaction of any Loss that is permissible under applicable law. 
 (c) Notice of Claims. Any Indemnified Party that proposes to assert a right to be indemnified under this Section 10 shall
notify Dynavax or Holdings, as applicable (the “Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit or proceeding against such Indemnified Party (an “Indemnified
Proceeding”) in respect of which a claim is to be made under this Section 10, or the incurrence or realization of any Loss in respect of which a claim is to be made under this Section 10, of the commencement of
such Indemnified Proceeding or of such incurrence or realization, enclosing a copy of all relevant documents, including all papers served and claims made, but the omission to so notify the applicable Indemnifying Party promptly of any such
Indemnified Proceeding or incurrence or realization shall not relieve (x) such Indemnifying Party from any liability that it may have to such

  

					
		  	20	  	Amended and Restated Purchase Option Agreement

 
Indemnified Party under this Section 10 or otherwise, except, as to such Indemnifying Party’s liability under this Section 10, to the extent, but only to the extent,
that such Indemnifying Party shall have been prejudiced by such omission, or (y) any other indemnitor from liability that it may have to any Indemnified Party under the Operative Documents. 
 (d) Defense of Proceedings. In case any Indemnified Proceeding shall be brought against any Indemnified Party, it shall notify the
applicable Indemnifying Party of the commencement thereof as provided in Section 10(c), and such Indemnifying Party shall be entitled to participate in, and provided such Indemnified Proceeding involves a claim solely for money damages
and does not seek an injunction or other equitable relief against the Indemnified Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified Proceeding with counsel reasonably satisfactory to such Indemnified Party.
After notice from such Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election so to assume the defense thereof and the failure by such Indemnified Party to object to such counsel within ten (10) Business Days
following its receipt of such notice, such Indemnifying Party shall not be liable to such Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred after such notice of election to assume such defense except as
provided below and except for the reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred by such Indemnified Party reasonably necessary in connection with the defense thereof. Such Indemnified Party shall
have the right to employ its counsel in any such Indemnified Proceeding, but the reasonable fees and expenses of such counsel shall be at the expense of such Indemnified Party unless: 
 (i) the employment of counsel by such Indemnified Party at the expense of the applicable Indemnifying Party has been
authorized in writing by such Indemnifying Party; 
 (ii) such Indemnified Party shall have reasonably concluded
in its good faith (which conclusion shall be determinative unless a court determines that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between the applicable Indemnifying Party and such
Indemnified Party in the conduct of the defense of such Indemnified Proceeding or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes of action available to such Indemnified Party (it being agreed
that in any case referred to in this clause (ii) such Indemnifying Party shall not have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party); 
 (iii) the applicable Indemnifying Party shall not have employed counsel reasonably acceptable to the Indemnified Party, to
assume the defense of such Indemnified Proceeding within a reasonable time after notice of the commencement thereof (provided, however, that this clause (iii) shall not be deemed to constitute a waiver of any conflict of interest that may arise
with respect to any such counsel); or 
 (iv) any counsel employed by the applicable Indemnifying Party shall
fail to timely commence or diligently conduct the defense of such Indemnified Proceeding and such failure has materially prejudiced (or, in the reasonable judgment of the Indemnified Party, is in danger of materially prejudicing) the outcome of such
Indemnified Proceeding; 
 in each of which cases the reasonable fees and expenses of counsel for such Indemnified Party shall be at the expense
of such Indemnifying Party. Only one counsel shall be retained by all Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any Indemnified Party reasonably concludes in good faith (which conclusion shall be
determinative unless a court determines that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties in the conduct of the
defense of such Indemnified Proceeding or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes or action available to such Indemnified Party. 
  

					
		  	21	  	Amended and Restated Purchase Option Agreement

 (e) Settlement. Without the prior written consent of such Indemnified Party, such
Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or related judgment (i) includes an unconditional
release of such Indemnified Party from all liability for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii) provides for the payment of money damages as the sole relief for the claimant (whether at law
or in equity), (iii) involves no finding or admission of any violation of law or the rights of any Person by the Indemnified Party, and (iv) is not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or
compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified Proceeding in respect of which any payment would result hereunder or under the Operative Documents without the prior written consent of the Indemnifying
Party, such consent not to be unreasonably conditioned, withheld or delayed. 
 Section 11. No Petition. Each of
Dynavax and Holdings covenants and agrees that, prior to the date which is one year and one day after the Purchase Option Closing Date, it will not institute or join in the institution of any bankruptcy, insolvency, reorganization or similar
proceeding against Symphony Dynamo. The provisions of this Section 11 shall survive the termination of this Agreement. 
 Section 12. Third-Party Beneficiary. Each of the Parties agrees that each Symphony Fund shall be a third-party beneficiary of this Agreement. 
 Section 13. Notices. Any notice, request, demand, waiver, consent, approval or other communication which is required or permitted to be given to any Party shall be in writing and shall be
deemed given only if delivered to the Party personally or sent to the Party by facsimile transmission (promptly followed by a hard-copy delivered in accordance with this Section 13), by next Business Day delivery by a nationally
recognized courier service, or by registered or certified mail (return receipt requested), with postage and registration or certification fees thereon prepaid, addressed to the Party at its address set forth below: 
 Dynavax: 
 Dynavax Technologies Corporation 
 2929 Seventh Street, Suite 100 
 Berkeley, CA 94710 
 Attn: Michael S. Ostrach, Esq., Vice President, 
 Chief Business Officer and General Counsel 
 Facsimile: (510) 848-1327 
 with copies to: 
 Cooley Godward Kronish LLP 
 Five Palo Alto Square, 4th Floor 
 3000 El Camino Real 
 Palo Alto, CA 94306-2155 
 Attn: Glen Y. Sato, Esq. 
 Facsimile: (650) 849-7400 
 Symphony Dynamo: 
 Symphony Dynamo, Inc. 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20855 
 Attn: Charles W. Finn, Ph.D. 
 Facsimile: (301) 762-6154 
  

					
		  	22	  	Amended and Restated Purchase Option Agreement

 Holdings: 
 Symphony Dynamo Holdings LLC 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20855 
 Attn: Robert L. Smith, Jr. 
 Facsimile: (301) 762-6154 
 with copies to: 
 Symphony Capital Partners, L.P. 
 875 Third Avenue 
 3rd Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile: (212) 632-5401 
 Symphony Strategic Partners, LLC 
 875 Third Avenue 
 3rd Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile: (212) 632-5401 
 or to such other address as such Party may from time to time specify by notice given in the manner provided herein to each other Party entitled to receive notice hereunder. 
 Section 14. Governing Law: Consent to Jurisdiction and Service of Process. 
 (a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York; except to the extent that
this Agreement pertains to the internal governance of Symphony Dynamo or Holdings, and to such extent this Agreement shall be governed and construed in accordance with the laws of the State of Delaware. 
 (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any
New York State court and Delaware State court or federal court of the United States of America sitting in The City of New York, Borough of Manhattan or Wilmington, Delaware, and any appellate court from any jurisdiction thereof, in any
action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in any such New York State court, any such Delaware State court or, to the fullest extent permitted by law, in such federal court. Each of the Parties agrees that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that any Party may otherwise have to bring any action or proceeding
relating to this Agreement. 
 (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any New York State or federal court, or any Delaware State
or federal court. Each of the Parties hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. Each of the parties hereby consents to
service of process by mail. 
  

					
		  	23	  	Amended and Restated Purchase Option Agreement

 Section 15. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES
ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 Section 16. Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or other attachments hereto) constitutes the entire agreement between the Parties with respect to
the matters covered hereby and supersedes all prior agreements and understanding with respect to such matters between the Parties. 
 Section 17. Amendment: Successors: Counterparts. 
 (a) The terms of this Agreement shall not be altered,
modified, amended, waived or supplemented in any manner whatsoever except by a written instrument signed by each of the Parties. 
 (b) Except as set forth in Section 12, nothing expressed or implied herein is intended or shall be construed to confer upon or to give to any Person, other than the Parties, any right, remedy or claim under or by reason of this
Agreement or of any term, covenant or condition hereof, and all the terms, covenants, conditions, promises and agreements contained herein shall be for the sole and exclusive benefit of the Parties and their successors and permitted assigns.

 (c) This Agreement may be executed in one or more counterparts, each of which, when executed, shall be deemed an original but
all of which, taken together, shall constitute one and the same Agreement. 
 Section 18. Specific Performance. The
Parties acknowledge that irreparable damage would result if this Agreement were not specifically enforced, and they therefore agree that the rights and obligations of the Parties under this Agreement may be enforced by a decree of specific
performance issued by a court of competent jurisdiction. Such a remedy shall, however, not be exclusive, and shall be in addition to any other remedies which any Party may have under this Agreement or otherwise. The Parties further acknowledge and
agree that a decree of specific performance may not be an available remedy in all circumstances. 
 Section 19.
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full
force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in a manner materially adverse to either party. Upon such determination that any term or other provision is invalid, illegal or
incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated
hereby are fulfilled to the extent possible. 
 Section 20. Tax Reporting. The Parties acknowledge and agree that,
for all federal and state income tax purposes: 
 (a)(i) Holdings shall be treated as the owner of all the Equity
Securities of Symphony Dynamo prior to the consummation of the Purchase Option; (ii) the Purchase Option shall be treated as an option to acquire all the Equity Securities of Symphony Dynamo; (iii) the Dynavax Closing Warrants shall be
treated as option premium payable in respect of the grant and exercise of the Purchase Option; and (iv) Symphony Dynamo shall be treated as the owner of all the Licensed Intellectual Property and shall be entitled to all deductions claimed
under Section 174 of the Code in respect of the Licensed Intellectual Property to the extent of the amounts funded by Symphony Dynamo; and 
  

					
		  	24	  	Amended and Restated Purchase Option Agreement

 (b) No Party shall take any tax position inconsistent with any position described in
Section 20(a) above, except (i) in the event of a “determination” (as defined in Section 1313 of the Code) to the contrary, or (ii) in the event either of the Parties receives an opinion of counsel to the effect
that there is no reasonable basis in law for such a position or that a tax return cannot be prepared based on such a position without being subject to substantial understatement penalties; provided, however, that in the case of Dynavax, such counsel
shall be reasonably satisfactory to Holdings. 
 Section 21. Original Agreement. 
 (a) The Original Agreement is hereby amended and superseded in its entirety and restated herein. Such amendment and restatement is effective
upon execution of this Agreement by the Parties. Upon such execution, all provisions of, rights granted and covenants made in the Original Agreement are hereby superseded in their entirety by the provisions hereof and shall have no further force or
effect. 
 (b) Defined terms in the Operative Documents (other than this Agreement) that refer to definitions in this Agreement
shall be deemed to refer to the definitions in the Original Agreement, except where the context requires otherwise. 
 Section 22. Amendment to Annex A. 
 (a) The definition of “Purchase Option
Agreement” in Annex A is hereby amended to read, “means the Purchase Option Agreement dated as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo, as the same may be amended, amended and restated, supplemented or
otherwise modified from time to time.” 
 (b) The definition of “Registration Rights Agreement” in
Annex A is hereby amended to read, “means the Registration Rights Agreement dated as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo, as the same may be amended, amended and restated, supplemented or otherwise modified
from time to time.” 
 [SIGNATURES FOLLOW ON NEXT PAGE] 
  

					
		  	25	  	Amended and Restated Purchase Option Agreement

 IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the day and year
first above written. 
  

			
	DYNAVAX TECHNOLOGIES CORPORATION
		
	By:	 	 /s/ Dino Dina, M.D.

	Name:	 	Dino Dina, M.D.
	Title:	 	President & Chief Executive Officer
	
	SYMPHONY DYNAMO HOLDINGS LLC
		
	By:	 	 Symphony Capital Partners, L.P.,
 its Manager

		
	By:	 	 Symphony Capital OF, L.P.,
 its general partner

		
	By:	 	 Symphony GP, LLC,
 its
general partner

		
	By:	 	 /s/ Mark Kessel

	Name:	 	Mark Kessel
	Title:	 	Managing Member
	
	SYMPHONY DYNAMO, INC.
		
	By:	 	 /s/ Harri V. Taranto

	Name:	 	Harri V. Taranto
	Title:	 	Chairman of the Board

 Signature Page
to the Amended and Restated Purchase Option Agreement 

 ANNEX A 
 CERTAIN DEFINITIONS 
 “$” means United States
dollars. 
 “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D promulgated
under the Securities Act of 1933, as amended. 
 “Act” means the Delaware Limited Liability Company Act,
6 Del. C. § 18-101 et seq. 
 “Ad Hoc Meeting” has the meaning set forth in
Paragraph 6 of Annex B of the Amended and Restated Research and Development Agreement. 
 “Additional
Funds” has the meaning set forth in Section 2(b) of the Funding Agreement. 
 “Additional Funding
Date” has the meaning set forth in Section 3 of the Funding Agreement. 
 “Additional
Party” has the meaning set forth in Section 13 of the Confidentiality Agreement. 
 “Additional
Regulatory Filings” means such Governmental Approvals as required to be made under any law applicable to the purchase of the Symphony Dynamo Equity Securities under the Purchase Option Agreement. 
 “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

 “Affected Member” has the meaning set forth in Section 27 of the Investors LLC Agreement.

 “Affiliate” means, with respect to any Person (i) any Person directly or indirectly controlling,
controlled by or under common control with such Person, (ii) any officer, director, general partner, member or trustee of such Person, or (iii) any Person who is an officer, director, general partner, member or trustee of any Person
described in clauses (i) or (ii) of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or “under common control with” shall mean the possession, direct or indirect, of the
power to direct or cause the direction of the management and policies of a Person or entity, whether through the ownership of voting securities, by contract or otherwise, or the power to elect at least 50% of the directors, managers, general
partners, or persons exercising similar authority with respect to such Person or entities. 
 “Amended and Restated
Research and Development Agreement” means the Amended and Restated Research and Development Agreement dated as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo. 
 “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  

					
		  		  	Amended and Restated Purchase Option Agreement

 “Auditors” means an independent certified public accounting firm of
recognized national standing. 
 “Avecia Agreement” has the meaning set forth in Schedule 12.1(f)
to the Amended and Restated Research and Development Agreement. 
 “Bankruptcy Code” means the United
States Bankruptcy Code. 
 “Berna” has the meaning set forth in Section 11.1(a) of the Amended and
Restated Research and Development Agreement. 
 “Business Day” means any day other than Saturday, Sunday
or any other day on which commercial banks in The City of New York or the City of San Francisco are authorized or required by law to remain closed. 
 “Cancer Products” mean any pharmaceutical product comprising a Selected ISS in the absence of any added tumor, cancer or viral antigen, for use in cancer treatment or therapy.

 “Cancer Program” means the identification, development, manufacture and/or use of any Cancer Products
in accordance with the Development Plan. 
 “Capital Contributions” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Capitalized Leases” means all leases that have been
or should be, in accordance with GAAP, recorded as capitalized leases. 
 “Cash Available for
Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and Restated Research and Development Agreement. 
 “Change of Control” means and includes the occurrence of any of the following events, but specifically excludes (i) acquisitions of capital stock directly from Dynavax for
cash, whether in a public or private offering, (ii) sales of capital stock by stockholders of Dynavax, and (iii) acquisitions of capital stock by or from any employee benefit plan or related trust: 
 (a) the merger, reorganization or consolidation of Dynavax into or with another corporation or legal entity in which
Dynavax’s stockholders holding the right to vote with respect to matters generally immediately preceding such merger, reorganization or consolidation, own less than fifty percent (50%) of the voting securities of the surviving entity; or

 (b) the sale of all or substantially all of Dynavax’s assets or business. 
 “Class A Member” means a holder of a Class A Membership Interest. 
 “Class A Membership Interest” means a Class A Membership Interest in Holdings. 
  

					
		  	2	  	Amended and Restated Purchase Option Agreement

 “Class B Member” means a holder of a Class B Membership interest.

 “Class B Membership Interest” means a Class B Membership Interest in Holdings. 
 “Class C Member” means a holder of a Class C Membership Interest. 
 “Class C Membership Interest” means a Class C Membership Interest in Holdings. 
 “Closing Certificate for Section 5.1(e)” means the written certificate, pertaining to the representations made
by Dynavax under Section 5.1(e) of the Novated and Restated Technology License Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing Date. 
 “Closing Certificate for Section 5.1(f)” means the written certificate, pertaining to the representations made
by Dynavax under Section 5.1(f) of the Novated and Restated Technology License Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing Date. 
 “Client Schedules” has the meaning set forth in Section 5(b)(i) of the RRD Services Agreement. 

“Clinical Budget Component” has the meaning set forth in Section 4.1 of the Amended and Restated Research
and Development Agreement. 
 “Closing Date” means April 18, 2006. 
 “CMC” means the chemistry, manufacturing and controls documentation as required for filings with Regulatory
Authority relating to the manufacturing, production and testing of drug products. 
 “Code” means the
Internal Revenue Code of 1986, as amended from time to time. 
 “Committed Capital” means
$50,000,000.00. 
 “Common Stock” means the common stock, par value $0.01 per share, of Symphony Dynamo.

 “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings LLC Agreement.

 “Company Property” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

 “Confidential Information” has the meaning set forth in Section 2 of the Confidentiality
Agreement. 
 “Confidentiality Agreement” means the Confidentiality Agreement, dated as of the Closing
Date, among Symphony Dynamo, Holdings, Dynavax, each Symphony Fund, SCP, SSP, Investors, Symphony Capital, RRD and Ann M. Arvin, M.D. 
  

					
		  	3	  	Amended and Restated Purchase Option Agreement

 “Conflict Transaction” has the meaning set forth in Article X
of the Symphony Dynamo Charter. 
 “Control” means, with respect to any material, information or
intellectual property right, that a Party owns or has a license to such item or right, and has the ability to grant the other Party access, a license or a sublicense (as applicable) in or to such item or right as provided in the Operative Documents
without violating the terms of any agreement or other arrangement with any third party. 
 “Debt” of any
Person means, without duplication: 
 (a) all indebtedness of such Person for borrowed money, 
 (b) all obligations of such Person for the deferred purchase price of property or services (other than any portion of any
trade payable obligation that shall not have remained unpaid for 91 days or more from the later of (A) the original due date of such portion and (B) the customary payment date in the industry and relevant market for such portion),

 (c) all obligations of such Person evidenced by bonds, notes, debentures or other similar instruments,

 (d) all obligations of such Person created or arising under any conditional sale or other title retention
agreement with respect to property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in an event of default are limited to repossession or sale of such property), 
 (e) all Capitalized Leases to which such Person is a party, 
 (f) all obligations, contingent or otherwise, of such Person under acceptance, letter of credit or similar facilities,

 (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any
Equity Securities of such Person, 
 (h) the net amount of all financial obligations of such Person in respect of
Hedge Agreements, 
 (i) the net amount of all other financial obligations of such Person under any contract or
other agreement to which such Person is a party, 
 (j) all Debt of other Persons of the type described in
clauses (a) through (i) above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed, directly or indirectly, by such Person through an agreement (A) to pay or purchase such Debt or to advance or
supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to make payment of such Debt or to assure
the holder of such Debt against loss, (C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is received or such services are rendered)
or (D) otherwise to assure a creditor against loss, and 
 (k) all Debt of the type described in clauses
(a) through (i) above secured by (or for which the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any Encumbrance on property (including accounts and contract rights) owned or held or used under lease
or license by such Person, even though such Person has not assumed or become liable for payment of such Debt. 
  

					
		  	4	  	Amended and Restated Purchase Option Agreement

 “Development Budget” means the budget (comprised of the Management
Budget Component and the Clinical Budget Component) for the implementation of the Development Plan (the initial form of which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the Amended and Restated Research and
Development Agreement as Annex D thereto), as may be further developed and revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 
 “Development Committee” has the meaning set forth in Article 3 of the Amended and Restated Research and
Development Agreement. 
 “Development Committee Charter” has the meaning set forth in Article 3 of
the Amended and Restated Research and Development Agreement. 
 “Development Committee Member” has the
meaning set forth in Paragraph I of Annex B to the Amended and Restated Research and Development Agreement. 
 “Development Plan” means the development plan covering all the Programs (the initial form of which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the Amended and Restated
Research and Development Agreement as Annex C thereto), as may be further developed and revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 

“Development Services” has the meaning set forth in Section 1(b) of the RRD Services Agreement. 

“Director(s)” has the meaning set forth in the Preliminary Statement of the Indemnification Agreement.

 “Disclosing Party” has the meaning set forth in Section 3 of the Confidentiality Agreement.

 “Discontinuation Closing Date” has the meaning set forth in Section 11.3 of the Amended and
Restated Research and Development Agreement. 
 “Discontinuation Date” means any date designated by
Symphony Dynamo which shall occur on or after the 90`h day following the receipt by Dynavax of notice from Symphony Dynamo of Symphony Dynamo’s intent to discontinue a Program in accordance with the terms of the Amended and Restated Research
and Development Agreement. 
 “Discontinuation Option” has the meaning set forth in Section 11.3 of
the Amended and Restated Research and Development Agreement. 
 “Discontinuation Price” has the meaning
set forth in Section 11.3 of the Amended and Restated Research and Development Agreement. 
 “Discontinuation
Price Dispute Notice” has the meaning set forth in Section 11.3(b) of the Amended and Restated Research and Development Agreement. 
  

					
		  	5	  	Amended and Restated Purchase Option Agreement

 “Discontinued Program” has the meaning set forth in
Section 2.11 of the Novated and Restated Technology License Agreement. 
 “Discontinuation Program
Funding” has the meaning set forth in Section 11.3(b) of the Amended and Restated Research and Development Agreement. 
 “Disinterested Directors” has the meaning set forth in Article X of the Symphony Dynamo Charter. 
 “Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Dynavax” means Dynavax Technologies Corporation, a Delaware corporation. 
 “Dynavax Common Stock” means the common stock, par value $0.001 per share, of Dynavax. 
 “Dynavax Common Stock valuation” has the meaning set forth in Section 2(e) of the Purchase Option Agreement. 
 “Dynavax Obligations” has the meaning set forth in Section 6.1 of the Amended and Restated Research and
Development Agreement. 
 “Dynavax Personnel” has the meaning set forth in Section 8.4 of the
Amended and Restated Research and Development Agreement. 
 “Dynavax Subcontractor” has the meaning set
forth in Section 6.2 of the Amended and Restated Research and Development Agreement. 
 “Early Purchase Option
Exercise” has the meaning set forth in Section 1(c)(iv) of the Purchase Option Agreement. 
 “Effective Registration Date” has the meaning set forth in Section 1(b) of the Registration Rights Agreement 
 “Encumbrance” means (i) any security interest, pledge, mortgage, lien (statutory or other), charge or option to purchase, lease or otherwise acquire any interest,
(ii) any adverse claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement, license or other encumbrance of any kind, preference or priority, or (iii) any other security agreement or preferential
arrangement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement). 
 “Enhancements” means findings, improvements, discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property and/or
Regulatory Files, in each case whether or not patentable. 
 “Equity Securities” means, with respect to
any Person, shares of capital stock of (or other ownership or profit interests in) such Person, warrants, options or other rights for the purchase or other

  

					
		  	6	  	Amended and Restated Purchase Option Agreement

 
acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, securities convertible into or exchangeable for shares of capital stock of (or
other ownership or profit interests in) such Person or warrants, rights or options for the purchase or other acquisition from such Person of such shares (or such other interests), and other ownership or profit interests in such Person (including,
without limitation, partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are authorized or otherwise existing on any date of determination.

 “ERISA” means the United States Employee Retirement Income Security Act of 1974, as amended.

 “Excepted Debt” has the meaning set forth in Section 5(c)(iii) of the Purchase Option
Agreement. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 “Excluded ISS” means (a) any ISS testing positive for
stimulation of TLR-9 by Dynavax prior to the Closing Date that is not a Selected ISS, or (b) any ISS made and tested for activity by Dynavax during the Term that (i) is not designed to have significant activity with a target other than
TLR-9 (whether or not it also acts through TLR-9) and (ii) is not a Selected ISS. 
 “Existing NDA”
has the meaning set forth in Section 2 of the Confidentiality Agreement. 
 “External Directors”
has the meaning set forth in the preamble of the Confidentiality Agreement. 
 “FDA” means the United
States Food and Drug Administration or its successor agency in the United States. 
 “FDA Sponsor” has
the meaning set forth in Section 5.1 of the Amended and Restated Research and Development Agreement. 
 “Final
Discontinuation Price” has the meaning set forth in Section 11.3(c) of the Amended and Restated Research and Development Agreement. 
 “Financial Audits” has the meaning set forth in Section 6.6 of the Amended and Restated Research and Development Agreement, 
 “Financing” has the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
 “Fiscal Year” has the meaning set forth in each Operative Document in which it appears. 
 “Form S-3” means the Registration Statement on Form S-3 as defined under the Securities Act. 
  

					
		  	7	  	Amended and Restated Purchase Option Agreement

 “FTE” has the meaning set forth in Section 4.1 of the Amended
and Restated Research and Development Agreement. 
 “Funding Agreement” means the Funding Agreement,
dated as of the Closing Date, among Dynavax, SCP and Investors. 
 “Funding Notice” has the meaning set
forth in Section 2(b) of the Funding Agreement. 
 “GAAP” means generally accepted accounting
principles in effect in the United States of America from time to time. 
 “Governmental Approvals”
means authorizations, consents, orders, declarations or approvals of, or filings with, or terminations or expirations of waiting periods imposed by any Governmental Authority. 
 “Governmental Authority” means any United States or non-United States federal, national, supranational, state,
provincial, local, or similar government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral body. 
 “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
 “Hedge Agreement” means any interest rate swap, cap or collar agreement, interest rate future or option contract,
currency swap agreement, currency future or option contract or other similar hedging agreement. 
 “Hepatitis B
Products” mean any pharmaceutical product comprising a Selected ISS, either alone or in combination with Hepatitis B Surface Antigen (HBsAg), whether conjugated or unconjugated to the applicable ISS, for use in Hepatitis B treatment or
therapy. 
 “Hepatitis B Program” means the identification, development, manufacture and/or use of any
Hepatitis B Products in Accordance with the Development Plan. 
 “Hepatitis C Products” mean any
pharmaceutical product comprising a Selected ISS, either alone or in combination with an added Hepatitis C antigen, whether conjugated or unconjugated to the applicable ISS, for use in Hepatitis C treatment or therapy. 
 “Hepatitis C Program” means the identification, development, manufacture and/or use of any Hepatitis C Products in
Accordance with the Development Plan. 
 “Holdings” means Symphony Dynamo Holdings LLC, a Delaware
limited liability company. 
 “Holdings Claims” has the meaning set forth in Section 5.01 of the
Warrant Purchase Agreement. 
 “Holdings LLC Agreement” means the Amended and Restated Limited Liability
Company Agreement of Holdings, dated as of the Closing Date. 
  

					
		  	8	  	Amended and Restated Purchase Option Agreement

 “HSR Act Filings” means the premerger notification and report forms
required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 “IND” means an
Investigational New Drug Application, as described in 21 U.S.C. § 355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 

“Indemnification Agreement” means the Indemnification Agreement among Symphony Dynamo and the Directors named
therein, dated as of the Closing Date. 
 “Indemnified Party” has the meaning set forth in each
Operative Document in which it appears. 
 “Indemnified Proceeding” has the meaning set forth in each
Operative Document in which it appears. 
 “Indemnifying Party” has the meaning set forth in each
Operative Document in which it appears. 
 “Independent Accountant” has the meaning set forth in
Section 11.3(c) of the Amended and Restated Research and Development Agreement. 
 “Initial Development
Budget” means the initial development budget prepared by representatives of Symphony Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated Research and Development Agreement as Annex D thereto.

 “Initial Development Plan” means the initial development plan prepared by representatives of Symphony
Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated Research and Development Agreement as Annex C thereto. 
 “Initial Funds” has the meaning set forth in Section 2(a) of the Funding Agreement. 
 “Initial Holdings LLC Agreement” means the Agreement of Limited Liability Company of Holdings, dated January 10, 2006. 
 “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of Investors, dated
January 10, 2006. 
 “Initial LLC Member” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement. 
 “Interest Certificate” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement. 
 “Investment Company Act” means the Investment Company Act of 1940, as
amended. 
 “Investment Overview” means the investment overview describing the transactions entered into
pursuant to the Operative Documents. 
  

					
		  	9	  	Amended and Restated Purchase Option Agreement

 “Investment Policy” has the meaning set forth in
Section 1(a)(vi) of the RRD Services Agreement. 
 “Investors” means Symphony Dynamo Investors
LLC. 
 “Investors LLC Agreement” means the Amended and Restated Agreement of Limited Liability Company
of Investors dated as of the Closing Date 
 “IRS” means the U.S. Internal Revenue Service. 

“ISS” means any synthetic oligonucleotide sequence or chimeric oligonucleotide sequence that modulates an immune
response, including, but not limited to, such sequences referred to by Dynavax as immunostimulatory sequences, chimeric immunomodulatory compounds and branched immunomodulatory compounds. 
 “Knowledge” means the actual (and not imputed) knowledge of the executive officers of Dynavax, without the duty of
inquiry or investigation. 
 “Law” means any law, statute, treaty, constitution, regulation, rule,
ordinance, order or Governmental Approval, or other governmental restriction, requirement or determination, of or by any Governmental Authority. 
 “License” has the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
 “Licensed Intellectual Property” means the Licensed Patent Rights, Symphony Dynamo Enhancements, Licensor Enhancements and the Licensed Know-How. 
 “Licensed Know-How” means any and all proprietary technology that is Controlled by Licensor as of the Closing Date
and that relates to the Licensed Patent Rights, Regulatory Files, ISSs or the Programs, including without limitation, manufacturing processes or protocols, know-how, writings, documentation, data, technical information, techniques, results of
experimentation and testing, diagnostic and prognostic assays, specifications, databases, any and all laboratory, research, pharmacological, toxicological, analytical, quality control pre-clinical and clinical data, and other information and
materials, whether or not patentable. 
 “Licensed Patent Rights” means: 
 (a) any and all patents, patent applications and invention disclosures Controlled by Licensor as of the Closing Date and
relating to ISSs or the Programs, including, but not limited to, the patents and patent applications listed on Annex B to the Novated and Restated Technology License Agreement; 
 (b) any and all reissues, continuations, divisionals, continuations-in-part (but only to the extent the subject matter in
such continuations-in-part has been disclosed in the patents or patent applications listed on Annex B), reexaminations, renewals, substitutes, extensions or foreign counterparts of the foregoing, whether filed prior to or after the expiration
or termination of the Purchase Option; and 
  

					
		  	10	  	Amended and Restated Purchase Option Agreement

 (c) any and all patents and patent applications that claim Licensor
Enhancements or Symphony Dynamo Enhancements. 
 “Licensor” means Dynavax. 
 “Licensor Enhancements” means all findings, improvements, discoveries, inventions, additions, modifications,
enhancements, derivative works, clinical development data, or changes to the Licensed Patent Rights, Licensed Know-How, Regulatory Files, ISSs, Products or the Programs, in each case, developed by Licensor during the Term in the course of performing
Dynavax’s rights and obligations under the Amended and Restated Research & Development Agreement (in each case whether or not patentable), to the extent such items do not otherwise qualify as Symphony Dynamo Enhancements hereunder,
regardless of whether such work is funded by Symphony Dynamo or Dynavax. 
 “Lien” has the meaning set
forth in Section 1.01 of the Holdings LLC Agreement. 
 “Liquidating Event” has the meaning set
forth in Section 8.01 of the Holdings LLC Agreement. 
 “LLC Agreements” means the Initial Holdings
LLC Agreement, the Holdings LLC Agreement, the Initial Investors LLC Agreement and the Investors LLC Agreement. 
 “Loss” has the meaning set forth in each Operative Document in which it appears. 
 “Management Budget Component” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement. 
 “Management Fee” has the meaning set forth in Section 6(a) of the RRD Services Agreement. 
 “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth in such LLC Agreement,
and (ii) for each other Operative Document in which it appears, RRD. 
 “Management Services” has
the meaning set forth in Section 1(a) of the RRD Services Agreement. 
 “Manager Event” has the
meaning set forth in Section 3.01(g) of the Holdings LLC Agreement. 
 “Material Adverse Effect”
means, with respect to any Person, a material adverse effect on (i) the business, assets, property or condition (financial or otherwise) of such Person or, (ii) its ability to comply with and satisfy its respective agreements and
obligations under the Operative Documents or, (iii) the enforceability of the obligations of such Person of any of the Operative Documents to which it is a party. 
 “Material Subsidiary” means, at any time, a Subsidiary of Dynavax having assets in an amount equal to at least 5% of the amount of total consolidated assets of Dynavax and its
Subsidiaries (determined as of the last day of the most recent reported fiscal quarter of Dynavax) or revenues or net income in an amount equal to at least 5% of the amount of total consolidated revenues or net income of Dynavax and its Subsidiaries
for the 12-month period ending on the last day of the most recent reported fiscal quarter of Dynavax. 
  

					
		  	11	  	Amended and Restated Purchase Option Agreement

 “Medical Discontinuation Event” means (a) as specified in each
Protocol, those data that, if collected in such Protocol, demonstrate that such Protocol should not be continued or (b) a series of adverse events, side effects or other undesirable outcomes that, when collected in a Protocol, would cause a
reasonable FDA Sponsor to discontinue such Protocol. 
 “Membership Interest” means (i) for each
LLC Agreement in which it appears, the meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it appears, the meaning set forth in the Holdings LLC Agreement. 
 “NASDAQ” means the National Association of Securities Dealers Automated Quotation System. 
 “NDA” means a New Drug Application, as defined in the regulations promulgated by the United States Food and Drug
Administration, or any foreign equivalent thereof. 
 “Non-Dynavax Capital Transaction” means any
(i) sale or other disposition of all or part of the Symphony Dynamo Shares or all or substantially all of the operating assets of symphony Dynamo, to a Person other than Dynavax or an Affiliate of Dynavax or (ii) distribution in kind of
the Symphony Dynamo Shares following the expiration of the Purchase Option. 
 “Non-Symphony Dynamo ISS”
means any ISS that is (i) first made and tested for activity by Dynavax during the Term and (ii) designed to have significant activity with a target other than TLR-9, whether or not it also acts through TLR-9. 
 “Novated and Restated Technology License Agreement” means the Novated and Restated Technology License Agreement,
dated as of the Closing Date, among Dynavax, Symphony Dynamo and Holdings. 
 “Operative Documents”
means, collectively, the Indemnification Agreement, the Holdings LLC Agreement, the Purchase Option Agreement, the Warrant Purchase Agreement, the Registration Rights Agreement, the Subscription Agreement, the Technology License Agreement, the
Novated and Restated Technology License Agreement, the RRD Services Agreement, the Research and Development Agreement, the Amended and Restated Research and Development Agreement, the Confidentiality Agreement, the Funding Agreement and each other
certificate and agreement executed in connection with any of the foregoing documents. 
 “Organizational
Documents” means any certificates or articles of incorporation or formation, partnership agreements, trust instruments, bylaws or other governing documents. 
 “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii) of the Purchase Option Agreement. 
 “Party(ies)” means, for each Operative Document or other agreement in which it appears, the parties to such
Operative Document or other agreement, as set forth therein. With respect to any

  

					
		  	12	  	Amended and Restated Purchase Option Agreement

 
agreement in which a provision is included therein by reference to a provision in another agreement, the term “Party” shall be read to refer to the parties to the document at hand, not
the agreement that is referenced. 
 “Payment Terms” has the meaning set forth in Section 8.2 of
the Amended and Restated Research and Development Agreement. 
 “Percentage” has the meaning set forth
in Section 1.01 of the Holdings LLC Agreement. 
 “Permitted Investments” has the meaning set forth
in Section 1.01 of the Holdings LLC Agreement. 
 “Permitted Lien” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Person” means any individual, partnership (whether
general or limited), limited liability company, corporation, trust, estate, association, nominee or other entity. 
 “Personnel” of a Party means such Party, its employees, subcontractors, consultants, representatives and agents. 
 “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or, if such bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar
rate for United States dollar loans, such other major money center commercial bank in New York City selected by the Manager. 
 “Products” means Cancer Products, Hepatitis B Products and Hepatitis C Products. 
 “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Program Option” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
 “Program Option Closing Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
 “Program Option Exercise Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated
Research and Development Agreement. 
 “Program Option Exercise Notice” has the meaning set forth in
Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
 “Program Option
Period” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
 “Programs” means Cancer Program, Hepatitis B Program and Hepatitis C Program. 
 “Protocol” means a written protocol that meets the substantive requirements of Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective May 9, 1997 and is included within
the Development Plan or later modified or added to the Development Plan pursuant to the Amended and Restated Research and Development Agreement. 
  

					
		  	13	  	Amended and Restated Purchase Option Agreement

 “Public Companies” has the meaning set forth in Section 5(e) of
the Purchase Option Agreement. 
 “Purchase Option” has the meaning set forth in Section 1(a) of
the Purchase Option Agreement. 
 “Purchase Option Agreement” means this Purchase Option Agreement dated
as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo. 
 “Purchase Option Closing” has
the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase Option Closing
Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase
Option Commencement Date” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement. 
 “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase Option Exercise Notice” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase Option Interim Date” has the meaning set forth in Section 2(b)(i) of the Purchase Option
Agreement. 
 “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement. 
 “Purchase Price” has the meaning set forth in Section 2(b) of the
Purchase Option Agreement. 
 “Put Option” has the meaning set forth in Section 2A of the Purchase
Option Agreement. 
 “Put Option Exercise Notice” has the meaning set forth in Section 2A of the
Purchase Option Agreement. 
 “QA Audits” has the meaning set forth in Section 6.5 of the Amended
and Restated Research and Development Agreement. 
 “Quarterly Price” has the meaning set forth in
Section 2(b)(i) of the Purchase Option Agreement. 
  

					
		  	14	  	Amended and Restated Purchase Option Agreement

 “Regents” has the meaning set forth in Section 3.1 of the
Novated and Restated Technology License Agreement. 
 “Regents Agreement” has the meaning set forth in
Section 3.1 of the Novated and Restated Technology License Agreement. 
 “Registration Rights
Agreement” means the Registration Rights Agreement dated as of the Closing Date, between Dynavax and Holdings. 
 “Registration Statement” has the meaning set forth in Section 1(b) of the Registration Rights Agreement. 
 “Regulatory Authority” means the United States Food and Drug Administration, or any successor agency in the United States, or any health regulatory authority(ies) in any other
country that is a counterpart to the FDA and has responsibility for granting registrations or other regulatory approval for the marketing, manufacture, storage, sale or use of drugs in such other country. 
 “Regulatory Allocation” has the meaning set forth in Section 3.06 of the Holdings LLC Agreement. 
 “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory Authority with respect to the
Programs. 
 “Related Oncology Products Agreement” has the meaning set forth in Section 1 1.4 of
the Amended and Restated Research and Development Agreement. 
 “Replacement Warrant(s)” has the meaning
set forth in Section 7.08 of the Warrant Purchase Agreement. 
 “Representative” of any Person
means such Person’s shareholders, principals, directors, officers, employees, members, managers and/or partners. 
 “Research and Development Agreement” means the Research and Development Agreement dated as of the Closing Date, between Dynavax and Holdings. 
 “Rhein” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development
Agreement. 
 “Rhein Sale Agreement” has the meaning set forth in Section 11.2(a) of the Amended
and Restated Research and Development Agreement. 
 “RRD” means RRD International, LLC, a Delaware
limited liability company. 
 “RRD Indemnified Party” has the meaning set forth in Section 10(a) of
the RRD Services Agreement. 
 “RRD Loss” has the meaning set forth in Section 10(a) of the RRD
Services Agreement. 
  

					
		  	15	  	Amended and Restated Purchase Option Agreement

 “RRD Parties” has the meaning set forth in Section 9(e) of the
RRD Services Agreement. 
 “RRD Personnel” has the meaning set forth in Section I(a)(ii) of
the RRD Services Agreement. 
 “RRD Services Agreement” means the RRD Services Agreement between
Symphony Dynamo and RRD, dated as the Closing Date, 2006. 
 “Schedule K-1” has the meaning set
forth in Section 9.02(a) of the Holdings LLC Agreement. 
 “Scheduled Meeting” has the meaning set
forth in Paragraph 6 of Annex B of the Amended and Restated Research and Development Agreement. 
 “Scientific
Discontinuation Event” has the meaning set forth in Section 4.2(c) of the Amended and Restated Research and Development Agreement. 
 “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership. 
 “SD Program Option” has the meaning set forth in Section 11.2(b) of the Amended and Restated Research and Development Agreement. 
 “SD Program Option Exercise Notice” has the meaning set forth in Section 11.2(b) of the Amended and Restated
Research and Development Agreement. 
 “SEC” means the United States Securities and Exchange Commission.

 “Securities Act” means the Securities Act of 1933, as amended. 
 “Selected ISS” means any ISS testing positive for stimulation of TLR-9 selected (i) for inclusion in the
Development Plan or (ii) as a backup ISS, in each case pursuant to Paragraph 12 of the Development Committee Charter. Selected ISS may include sequences that subsequent to the Closing Date are shown to act through one or more additional
mechanisms in addition to stimulation of TLR-9. 
 “Shareholder” means any Person who owns any Symphony
Dynamo Shares. 
 “Solvent” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement. 
 “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company.

 “Stock Payment Date” has the meaning set forth in Section 2 of the Subscription Agreement.

 “Stock Purchase Price” has the meaning set forth in Section 2 of the Subscription Agreement.

 “Subcontracting Agreement” has the meaning set forth in Section 6.2 of the Amended and Restated
Research and Development Agreement. 
  

					
		  	16	  	Amended and Restated Purchase Option Agreement

 “Subscription Agreement” means the Subscription Agreement between
Symphony Dynamo and Holdings, dated as the Closing Date. 
 “Subsidiary” of any Person means any
corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of the board of directors
of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency); (b) the interest in the capital or profits of
such partnership, joint venture or limited liability company; or (c) the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by such person and one or more of its other
Subsidiaries or by one or more of such Person’s other Subsidiaries. 
 “Surviving Entity” means the
surviving or resulting “parent” legal entity which is surviving entity to Dynavax after giving effect to a Change of Control. 
 “Symphony Capital” means Symphony Capital LLC, a Delaware limited liability company. 
 “Symphony Dynamo” means Symphony Dynamo, Inc., a Delaware corporation. 
 “Symphony Dynamo Auditors” has the meaning set forth in Section 5(b) of the RRD Services Agreement. 
 “Symphony Dynamo Board” means the board of directors of Symphony Dynamo. 
 “Symphony Dynamo By-laws” means the By-laws of Symphony Dynamo, as adopted by resolution of the Symphony Dynamo
Board on the Closing Date. 
 “Symphony Dynamo Charter” means the Amended and Restated Certificate of
Incorporation of Symphony Dynamo, dated as of the Closing Date. 
 “Symphony Dynamo Director Event” has
the meaning set forth in Section 3.01(h)(i) of the Holdings LLC Agreement. 
 “Symphony Dynamo
Enhancements” means findings, improvements, discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property, Regulatory Files, ISSs, Products
or the Programs, made by or on behalf of Symphony Dynamo during the Term, in each case whether or not patentable. 
 “Symphony Dynamo Equity Securities” means the Common Stock and any other stock or shares issued by Symphony Dynamo. 
 “Symphony Dynamo Loss” has the meaning set forth in Section 10(b) of the RRD Services Agreement. 
 “Symphony Dynamo Shares” has the meaning set forth in Section 2.02 of the Holdings LLC Agreement. 
  

					
		  	17	  	Amended and Restated Purchase Option Agreement

 “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware
limited partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company. 
 “Tangible
Materials” means any tangible documentation, whether written or electronic, existing as of the Closing Date or during the Term, that is Controlled by the Licensor, embodying the Licensed Intellectual Property, Regulatory Files, Products
or the Programs, including, but not limited to, documentation, patent applications and invention disclosures. 
 “Tax
Amount” has the meaning set forth in Section 4.02 of the Holdings LLC Agreement. 
 “Technology
License Agreement” means the Technology License Agreement, dated as of the Closing Date, between Dynavax and Holdings. 
 “Term” has the meaning set forth in Section 4(b)(iii) of the Purchase Option Agreement, unless otherwise stated in any Operative Document. 
 “Territory” means the world. 
 “Third Party IP” has the meaning set forth in Section 2.11 of the Novated and Restated Technology License Agreement. 
 “Third Party Licensor” means a third party from which Dynavax has received a license or sublicense to Licensed
Intellectual Property. 
 “Transfer” has for each Operative Document in which it appears the meaning set
forth in such Operative Document. 
 “Transferee” has, for each Operative Document in which it appears,
the meaning set forth in such Operative Document. 
 “Voluntary Bankruptcy” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Warrant(s)” means the “Warrant” as
defined in Section 2.01 of the Warrant Purchase Agreement, and/or any successor certificates exercisable for Warrant Shares issued by Dynavax. 
 “Warrant Closing” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
 “Warrant Date” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
 “Warrant Purchase Agreement” means the Warrant Purchase Agreement, dated as of the Closing Date, between Dynavax and Holdings. 
 “Warrant Shares” has the meaning set forth in Section 2.01 of the Warrant Purchase Agreement. 
 “Warrant Surrender Price” has the meaning set forth in Section 7.08 of the Warrant Purchase Agreement.

  

					
		  	18	  	Amended and Restated Purchase Option Agreement

 Exhibit 1 
 FORM OF PURCHASE OPTION EXERCISE NOTICE 
             , 20     
 Attention:
                             
 Ladies and Gentlemen: 
 Reference is hereby made to that certain Amended and
Restated Purchase Option Agreement dated as of November 9, 2009 (the “Purchase Option Agreement”) by and among Dynavax Technologies Corporation, a Delaware corporation (“Dynavax”), Symphony Dynamo
Holdings LLC, a Delaware limited liability company, and Symphony Dynamo, Inc., a Delaware corporation. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned thereto in the Purchase Option Agreement.

 Pursuant to Section 2(a) of the Purchase Option Agreement, Dynavax hereby irrevocably notifies you that it hereby
exercises the Purchase Option. 
 Subject to the terms set forth therein, Dynavax hereby affirms the representations and
warranties set forth in Section 3(a) of the Purchase Option Agreement, as of the date hereof. 
 Dynavax estimates that the
Purchase Option Closing Date will be                     . 
  

			
	Very truly yours,
	
	DYNAVAX TECHNOLOGIES CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	

 Exhibit 1 to the 
 Purchase Option Agreement 

 Exhibit 2 
 EXECUTION COPY 
 FORM OF DYNAVAX PROMISSORY NOTE 
 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR
OTHERWISE DISPOSED OF, UNLESS IN ACCORDANCE WITH THE FOREGOING SECURITIES LAWS AND WITH THE TERMS HEREOF. 
 PROMISSORY NOTE 
  

			
	$15,000,000.00	 	            ,     , 2009

 FOR VALUE RECEIVED, Dynavax Technologies Corporation, a Delaware corporation (“Obligor”), promises to pay to Symphony Dynamo Holdings LLC,
a Delaware limited liability company (“Payee”), in lawful money of the United States of America, the principal sum of Fifteen Million Dollars ($15,000,000.00). 
 This Promissory Note (this “Note”) has been executed and delivered pursuant to and in accordance with the terms and conditions of that certain Amended and Restated Purchase Option
Agreement, dated as of the date hereof, by and among Obligor, Payee and the other parties thereto (the “Agreement”) and is subject to the terms and conditions of the Agreement. Capitalized terms used in this Note without definition
shall have the respective meanings set forth in the Agreement. 
 1. PAYMENTS 
 1.1 MATURITY DATE 
 The principal amount of this Note shall be due and payable on December 31,
2012 (the “Maturity Date”). 
 1.2 INTEREST 
 The principal amount of this Note shall not bear interest. 
 1.3 MANNER OF PAYMENT 
 At the option of Obligor, the principal amount of this Note shall be paid in (i) cash, (ii) Dynavax Common Stock, or (iii) any combination
thereof. In the event Obligor elects to pay all or a portion of the outstanding principal amount of this Note using Dynavax Common Stock, in addition to any payment of cash by Obligor to Payee, Obligor shall issue to Payee on the date of such
payment the number of shares of Dynavax Common Stock (rounded up to the nearest whole number) equal to (a) (i) an amount equal to the portion of the outstanding principal amount of this Note to be repaid using Dynavax Common Stock,
divided by (ii) the average closing price of Dynavax Common Stock, as reported by the NASDAQ Global Market, or other national exchange that is the primary exchange on which Dynavax Common Stock is then listed, for the thirty
(30) trading days immediately preceding (but not including) the second trading day prior to the date of such payment multiplied by (b) 1.15. 
 All Dynavax Common Stock issued to Payee pursuant to the foregoing shall be registered pursuant to a registration statement filed concurrently with the issuance of such Dynavax Common Stock in accordance
with that certain Amended and Restated Registration Rights Agreement by and between the Obligor and Payee of even date herewith. In the event that such Dynavax Common Stock is not registered in accordance with the foregoing, Dynavax shall make all
payments of principal hereunder in cash. 

 All payments in cash on this Note shall be made by wire transfer of immediately available funds to an
account designated by Payee in writing or in such other manner as may be agreed to by the parties in writing. 
 1.4 PREPAYMENT 
 Obligor may, without premium or penalty, at any time and from time to time, prepay in cash all or any portion of the outstanding principal balance due under
this Note. 
 2. DEFAULTS 
 2.1 EVENTS
OF DEFAULT 
 The occurrence of any one or more of the following events with respect to Obligor shall constitute an event of default hereunder
(“Event of Default”): 
 (a) If Obligor shall fail to pay when due any payment of principal on this Note. 
 (b) If Obligor shall (i) apply for or consent to the appointment of a receiver, trustee or liquidator for itself or any of its assets or properties,
(ii) admit in writing its inability to pay its debts as they mature, (iii) make a general assignment for the benefit of creditors, (iv) be adjudicated as bankrupt or insolvent, (v) file a voluntary petition in bankruptcy, or a
petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute, or any answer admitting the material
allegations of a petition filed against it in any proceeding under any such law or if action shall be taken by Obligor for the purpose of effecting any of the foregoing, (vi) have commenced against it any case, proceeding or other action of a
nature described in (i) through (v) above which remains undismissed for a period of 60 days or (vii) take or be subject to any action similar to those specified in clauses (i) through (vi) in any jurisdiction; 
 (c) If an order, judgment or decree shall be entered with respect to Obligor or all or a substantial part of the assets of Obligor, appointing a receiver,
trustee or liquidator of Obligor, or any similar order, judgment or decree shall be entered or appointment made in any jurisdiction, and such order, judgment or decree or appointment shall continue unstayed and in effect for a period of 60 days.

 (d) If (i) Obligor shall consolidate or merge with, or sell, lease or otherwise transfer (in a single transaction or series of related
transactions) all or substantially all of its assets to, any other Person or (ii) any Subsidiary of Obligor that has assets representing all or substantially all of the assets of Obligor and its Subsidiaries, taken as a whole, shall consolidate
or merge with, or sell, lease or otherwise transfer (in a single transaction or series of related transactions) all or substantially all of its assets to, any other Person (other than Obligor or another Subsidiary thereof). 
 (e) If Obligor shall dissolve, be liquidated or wound up for any reason. 
 2.2 NOTICE BY MAKER 
 Obligor shall notify Payee in writing within five Business Days after the
occurrence of any Event of Default in accordance with Section 13 of the Agreement. 
 2.3 REMEDIES 
 Upon the occurrence of an Event of Default under clause (a) of Section 2.1, and at any time thereafter during the continuance of such Event of
Default, Payee may declare the unpaid principal balance of this Note to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the
principal of the Note so declared to be due and payable shall

 
become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by Obligor; and upon the occurrence of an Event of Default
under clauses (b), (c), (d) or (e) of Section 2.1, the unpaid principal balance of this Note shall automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived
by Obligor. Obligor shall pay all reasonable documented costs and expenses incurred by or on behalf of Payee in connection with Payee’s exercise of any or all of its rights and remedies under this Note, including, without limitation, reasonable
attorneys’ fees. 
 3. MISCELLANEOUS 
 3.1 WAIVER 
 The rights and remedies of Payee under this Note shall be cumulative and not alternative. No waiver by Payee of any right
or remedy under this Note shall be effective unless in a writing signed by Payee. Neither the failure nor any delay in exercising any right, power or privilege under this Note will operate as a waiver of such right, power or privilege, and no single
or partial exercise of any such right, power or privilege by Payee will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable
law, (a) no claim or right of Payee arising out of this Note can be discharged by Payee, in whole or in part, by a waiver or renunciation of the claim or right unless in a writing signed by Payee; (b) no waiver that may be given by Payee
will be applicable except in the specific instance for which it is given; and (c) no notice to or demand on Obligor will be deemed to be a waiver of any obligation of Obligor or of the right of Payee to take further action without notice or
demand as provided in this Note. Obligor hereby waives presentment, demand, protest and notice of dishonor and protest. 
 3.2 NOTICES

 Any notice required or permitted to be given hereunder shall be given in accordance with Section 13 of the Agreement. 
 3.3 SEVERABILITY 
 If any provision in this Note is
held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note will remain in full force and effect. Any provision of this Note held invalid or unenforceable only in part or degree will remain in full force
and effect to the extent not held invalid or unenforceable. 
 3.4 GOVERNING LAW 
 This Note shall be governed and construed in accordance with the laws of the State of New York. 
 3.5 CONSENT TO JURISDICTION 
 Any claim arising out of or relating to this Note or the transactions contemplated hereby may be
instituted in any New York State court, Delaware State court or federal court of the United States of America sitting in the The City of New York, borough of Manhattan or Wilmington Delaware, and any appellate court from any jurisdiction thereof,
and each party agrees not to assert, by way of motion, as a defense or otherwise, in any such claim, any claim that it is not subject personally to the jurisdiction of such court, that the claim is brought in an inconvenient forum, that the venue of
the claim is improper or that this Note or the subject matter hereof may not be enforced in or by such court. Each party further irrevocably submits to the jurisdiction of such court in any such claim. Any and all service of process and any other
notice in any such claim shall be effective against any party if given personally or by registered or certified mail, return receipt requested, or by any other means of mail that requires a signed receipt, postage prepaid, mailed to such party as
herein provided. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by law or to commence legal proceedings or otherwise proceed against any other party in any other jurisdiction.

 3.6 WAIVER OF JURY TRIAL 
 EACH PARTY HERETO IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS NOTE.

 3.7 PARTIES IN INTEREST 
 This Note
shall not be assigned or transferred by Payee without the express prior written consent of Obligor. Subject to the preceding sentence, this Note will be binding in all respects upon Obligor and inure to the benefit of Payee and its successors and
assigns. 
 3.8 SECTION HEADINGS; CONSTRUCTION 
 The headings of Sections in this Note are provided for convenience only and will not affect its construction or interpretation. All references to “Section” or “Sections” refer to the corresponding Section or Sections of
this Note unless otherwise specified. All words used in this Note will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the words “hereof’ and “hereunder” and similar
references refer to this Note in its entirety and not to any specific section or subsection hereof, the words “including” or “includes” do limit the preceding words or terms and the word “or” is used in the inclusive
sense. 
 [Remainder of page intentionally left blank.] 

 EXECUTION COPY 
 IN WITNESS WHEREOF, Obligor has executed and delivered this Note as of the date first stated above. 
 DYNAVAX TECHNOLOGIES CORPORATION 
  

			
	By:	 	  

	Name:	 	
	Title:	 	

 Exhibit 2 to the 
 Amended and Restated Purchase Option Agreement 

 Exhibit 3 
 EXECUTION COPY 
 FORM OF STANDSTILL AND CORPORATE GOVERNANCE LETTER AGREEMENT

 Symphony Dynamo Holdings LLC 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20855 
 [        ,     ], 2009 
 Dynavax Technologies Corporation 
 2929 Seventh
Street, Suite 100 
 Berkeley, CA 94710 
 Attn: Michael S. Ostrach, Esq., Vice President, 
 Chief Business Officer and General Counsel 
 Ladies and Gentlemen: 
 In connection with the
acquisition of shares of Common Stock, par value $0.001 per share (the “Common Stock”), of Dynavax Technologies Corporation, a Delaware corporation (the “Company”), by Symphony Dynamo Holdings LLC, a Delaware
limited liability company (together with its permitted successors, assigns and transferees, the “Purchaser”), pursuant to the terms of that certain Amended and Restated Purchase Option Agreement, dated as of November 9, 2009,
among the Company, the Purchaser and Symphony Dynamo, Inc. (the “Amended and Restated Purchase Option Agreement”), the Company and the Purchaser agree as follows: 
 Section 23. Definitions. For purposes of this letter agreement, the following terms have the respective meanings set forth
below: 
 “Affiliate” shall mean, with respect to any Person, (i) any Person directly or indirectly
controlling, controlled by or under common control with such Person, (ii) any officer, director, general partner, member or trustee of such Person, or (iii) any Person who is an officer, director, general partner, member or trustee of any
Person described in clauses (i) or (ii) of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or “under common control with” shall mean the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person or entity, whether through the ownership of voting securities, by contract or otherwise, or the power to elect at least 50% of the
directors, managers, general partners, or persons exercising similar authority with respect to such Person or entities. 
 “Beneficially Owns” (including the terms “Beneficial Ownership” or “Beneficially Owned”) shall mean beneficial ownership within the meaning of Rule 13d-3 under the Exchange Act. 

“Board” shall mean the Board of Directors of the Company. 
 “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended. 
 “Person” shall mean any individual, partnership (whether general or limited), limited liability company, corporation,
trust, estate, association, nominee or other entity. 

 Section 24. Standstill. Except for the exercise of the Dynavax Closing Warrants
(as defined in the Amended and Restated Purchase Option Agreement), the acquisition of Dynavax Closing Warrant Shares (as defined in the Amended and Restated Purchase Option Agreement), the acquisition of the Dynavax Promissory Note Shares (as
defined in the Amended and Restated Purchase Option Agreement) and the acquisition of Alternate Securities (as defined in the Amended and Restated Purchase Option Agreement), if any, for so long as the Purchaser and its Affiliates Beneficially Own
more than 10% of the Company’s outstanding Common Stock, neither the Purchaser nor any of its Affiliates shall, without the prior written consent of a majority of the independent members of the Board who are not Affiliated with the Purchaser,
in any manner, whether directly or indirectly: 
 Section 24A. make, effect, initiate, cause or participate in (i) any
acquisition of Beneficial Ownership of any securities of the Company or any securities of any subsidiary or other Affiliate of the Company, (ii) any acquisition of any assets of the Company or any assets of any subsidiary or other Affiliate of
the Company, (iii) any tender offer, exchange offer, merger, business combination, recapitalization, restructuring, liquidation, dissolution or extraordinary transaction involving the Company or any subsidiary or other Affiliate of the Company,
or involving any securities or assets of the Company or any securities or assets of any subsidiary or other Affiliate of the Company, or (iv) any “solicitation” of “proxies” (as those terms are used in the proxy rules of the
Securities and Exchange Commission (“SEC”)) or consents with respect to any securities of the Company; 
 Section 24B. form, join or participate in a “group” (as defined in the Securities Exchange Act and the rules promulgated thereunder) with respect to the Beneficial Ownership of any securities of the Company; 
 Section 24C. without limiting any rights of the Purchaser pursuant to Section 6 hereof, act, alone or in concert with others, to
seek to control or influence the management, board of directors or policies of the Company; 
 Section 24D. take any action
that might require the Company to make a public announcement regarding any of the types of matters set forth in clause “(a)” of this sentence; 
 Section 24E. agree or offer to take, or encourage or propose (publicly or otherwise) the taking of, any action prohibited by clause “(a)”, “(b)”, “(c)” or
“(d)” of this sentence; 
 Section 24F. assist, induce or encourage any other Person to take any action of the
type prohibited by clause “(a)”, “(b)”, “(c)”, “(d)” or “(e)” of this sentence; 
 Section 24G. enter into any discussions, negotiations, arrangement or agreement with any other Person relating to any of the foregoing; or 
 Section 24H. request or propose that the Company or any of the Company’s Affiliates amend, waive or consider the amendment or waiver of any provision set forth in this Section 2.

 Section 25. No Effect on Directors. Notwithstanding any of the foregoing, the provisions set forth in Section 2
shall in no way limit the ability of any individual who is serving as a director of the Company to take any actions (or to refrain from taking any actions) in his or her capacity as a director of the Company. 
 Section 26. Voting Agreement. In the event the Purchaser and its Affiliates Beneficially Own more than 33% of the Company’s
outstanding Common Stock, any shares of Common Stock entitled to vote for the election of directors Beneficially Owned by the Purchaser and its Affiliates in excess of 33% of the shares of Common Stock then outstanding, with respect to the election
or removal of directors only, shall be voted either, solely at the Purchaser’s election (a) as recommended by the Board or (b)(i) in an election, in the same proportion with the votes of shares of Common Stock voted in such election
(excluding shares with respect to which the votes were withheld, abstained or otherwise not cast) and not Beneficially Owned by the Purchaser (excluding withheld shares and abstentions) or (ii) in a removal vote, in the same proportions as all
outstanding shares of Common Stock not Beneficially Owned by the Purchaser (including shares with respect to which the votes were withheld,

  

 2 

 
abstained or otherwise not cast), whether at an annual or special meeting of stockholders of the Company, by written consent or otherwise. The Purchaser shall retain its right to vote (or to
withhold its vote) all of its shares on all other matters. 
 Section 27. Lock-Up. The Purchaser and its Affiliates
shall not, for a period of six (6) months after the date hereof, directly or indirectly, offer, sell, exchange, pledge, hypothecate, encumber, transfer, assign or otherwise dispose of, whether voluntarily, involuntarily or by operation of law,
other than to any Affiliate, any of its Dynavax Closing Shares, Dynavax Closing Warrants, Dynavax Closing Warrant Shares, Alternate Closing Securities (as defined in the Amended and Restated Purchase Option Agreement) or Alternate Securities, if
applicable, or Dynavax Promissory Note Shares, if applicable; provided, however, that nothing contained in this Section 5 shall in any way restrict (a) the ability of the Purchaser to transfer any Dynavax Closing Warrants, Dynavax Closing
Warrant Shares, Alternate Closing Securities or Alternate Securities, if applicable, or Dynavax Promissory Note Shares, if applicable, to Symphony Dynamo Investors LLC or Symphony Dynamo Holdings LLC and (b) the ability of Symphony Dynamo
Investors LLC and Symphony Dynamo Holdings LLC to transfer any Dynavax Closing Warrants, Dynavax Closing Warrant Shares, Alternate Closing Securities or Alternate Securities, if applicable, or Dynavax Promissory Note Shares, if applicable, to any of
their respective members. 
 Section 28. Board Composition. For so long as the Purchaser and its Affiliates Beneficially
Own more than 10% of the Company’s outstanding Common Stock, then, subject to applicable law and the rules and regulations of the SEC and the NASDAQ Stock Market, the Company will nominate and use its commercially reasonable efforts to cause to
be elected and cause to remain as directors on the Board (x) one (1) individual designated by the Purchaser (as determined in its sole discretion) and (y) one (1) individual who shall be an independent third party designated by
Purchaser and reasonably acceptable to the Company. 
 Section 29. Representations. Each party represents to the other
that: (a) this letter agreement has been duly authorized by all necessary corporate or partnership action, as the case may be; and (b) this letter agreement is a valid and binding agreement of such party, enforceable against it in
accordance with its terms. 
 Section 30. Specific Enforcement; Legal Effect. The parties hereto agree that any breach of
this letter agreement would result in irreparable injury to the other party and that money damages would not be an adequate remedy for such breach. Accordingly, without prejudice to the rights and remedies otherwise available under applicable law,
either party shall be entitled to specific performance and equitable relief by way of injunction or otherwise if the other party breaches or threatens to breach any of the provisions of this letter agreement. It is further understood and agreed that
no failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
right, power or privilege hereunder. If any term, provision, covenant or restriction in this letter agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this letter agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated, provided that the parties hereto shall negotiate in good faith to attempt to place the parties in the same position
as they would have been in had such provision not been held to be invalid, void or unenforceable. This letter agreement contains the entire agreement between the parties hereto concerning the matters addressed herein. No modification of this letter
agreement or waiver of the terms and conditions hereof shall be binding upon either party hereto, unless approved in writing by each such party; provided, however, that no waiver or amendment shall be effective as against the Company unless such
waiver or amendment is approved in writing by the vote of a majority of the independent members of the Board who are not Affiliated with the Purchaser. This Agreement shall be governed by and construed in accordance with the law of the State of New
York. 
 Section 31. Termination. This agreement shall continue in full force and effect from the date hereof until such
time as the Purchaser and its Affiliates Beneficially Own less than 10% of the Company’s outstanding Common Stock. 
  

 3 

 Section 32. Counterparts. This letter agreement may be executed in counterpart
(including by facsimile), each of which shall be deemed an original. 
 [Remainder of page left blank intentionally] 

 

 4 

 If you are in agreement with the terms set forth above, please sign this letter agreement in
the space provided below and return an executed copy to the undersigned. 
  

			
	 Very truly yours,

	
	SYMPHONY DYNAMO HOLDINGS LLC
		
	By:	 	 Symphony Capital Partners, L.P.,
 its Manager

		
	By:	 	 Symphony Capital GP, L.P.,
 its General Partner

		
	By:	 	 Symphony GP, LLC,
 its
General Partner

  

			
	By:	 	  

	Name:	 	
	Title:	 	

 Confirmed and Agreed: 
 DYNAVAX TECHNOLOGIES CORPORATION 
  

			
	By:	 	  

	Name:	 	
	Title:	 	

 Exhibit 3 to the 
 Amended and Restated Purchase Option Agreement 

 Exhibit 4 
 FORM OF WARRANT PURCHASE AGREEMENT 
 [See Attached] 
 Exhibit 4 to the 
 Amended and Restated Purchase Option AgreementWarrant Purchase Agreement

 Exhibit 10.48 
 EXECUTION COPY 
  
  
  
 WARRANT PURCHASE AGREEMENT 
 between 
 DYNAVAX TECHNOLOGIES CORPORATION 
 and 
 SYMPHONY
DYNAMO HOLDINGS, LLC 
  
  
 Dated as of November 9, 2009 
  
  
  
  
  

 Table of Contents 
  

					
	 	  	 	  	Page
	 ARTICLE I DEFINITIONS
	  	1
			
	 Section 1.01
	  	Definitions	  	1
		
	 ARTICLE II PURCHASE AND SALE OF WARRANTS
	  	1
			
	 Section 2.01
	  	Authorization to Issue Warrants	  	1
			
	 Section 2.02
	  	Purchase and Sale of Warrants	  	1
			
	 Section 2.03
	  	Warrant Date	  	2
			
	 Section 2.04
	  	Warrant Date Adjustment	  	2
			
	 Section 2.05
	  	Post-Warrant Date Adjustment	  	2
		
	 ARTICLE III CONDITIONS OF PURCHASE
	  	3
			
	 Section 3.01
	  	Conditions Precedent to Each Party’s Obligations	  	3
			
	 Section 3.02
	  	Conditions Precedent to Holdings’ Obligations	  	4
			
	 Section 3.03
	  	Conditions Precedent to Dynavax’s Obligations	  	5
		
	 ARTICLE IV REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	6
			
	 Section 4.01
	  	Representations, Warranties and Covenants of Holdings	  	6
			
	 Section 4.02
	  	Representations, Warranties and Covenants of Dynavax	  	8
		
	 ARTICLE V INDEMNITY
	  	10
			
	 Section 5.01
	  	Indemnification	  	10
			
	 Section 5.02
	  	Notice of Claims	  	10
			
	 Section 5.03
	  	Defense of Proceedings	  	11
			
	 Section 5.04
	  	Settlement	  	12
		
	 ARTICLE VI TRANSFER RESTRICTIONS
	  	12
			
	 Section 6.01
	  	Transfer Restrictions	  	12
			
	 Section 6.02
	  	Legends	  	13
			
	 Section 6.03
	  	Warrant Legend Removal	  	13
			
	 Section 6.04
	  	Improper Transfer	  	13
			
	 Section 6.05
	  	Limits on Daily Disposition	  	13
		
	 ARTICLE VII MISCELLANEOUS
	  	14
			
	 Section 7.01
	  	Notice of Material Event	  	14
			
	 Section 7.02
	  	Notices	  	14
			
	 Section 7.03
	  	Governing Law; Consent to Jurisdiction and Service of Process	  	15
			
	 Section 7.04
	  	Waiver of Jury Trial	  	15
			
	 Section 7.05
	  	Entire Agreement	  	16
			
	 Section 7.06
	  	Amendment and Waivers	  	16
			
	 Section 7.07
	  	Counterparts	  	16
			
	 Section 7.08
	  	Assignment and Successors	  	16

  

					
		  		  	Warrant Purchase Agreement

			
	Annex A	  	Certain Definitions
		
	Exhibit A	  	Form of Warrant
	Exhibit B	  	Warrant Conversion Example

  

					
		  		  	Warrant Purchase Agreement

 WARRANT PURCHASE AGREEMENT 
 This WARRANT PURCHASE AGREEMENT (this “Agreement”) is dated as of November 9, 2009, by and between DYNAVAX
TECHNOLOGIES CORPORATION, a Delaware corporation (“Dynavax”), and SYMPHONY DYNAMO HOLDINGS LLC, a Delaware limited liability company (together with its permitted successors, assigns and transferees, “Holdings”).

 WHEREAS, contemporaneously with the execution of this Agreement, Holdings, Dynavax, and Symphony Dynamo, Inc., a Delaware
corporation (“Symphony Dynamo”) are entering into an Amended and Restated Purchase Option Agreement (the “Purchase Option Agreement”) pursuant to which, among other things, Holdings is granting to Dynavax an option
to purchase all of the equity securities of Symphony Dynamo (the “Symphony Dynamo Equity Securities”) owned, or hereafter acquired, by Holdings on the terms set forth in the Purchase Option Agreement (the “Purchase
Option”); and 
 WHEREAS, in consideration for Holdings’ grant of the Purchase Option to Dynavax, Dynavax desires
to issue and sell to Holdings the Warrants described herein on the terms hereof. 
 NOW, THEREFORE, in consideration of the
foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (the “Parties”) agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.01 Definitions. Capitalized terms used but not defined herein are used as defined in Annex A hereto. 
 ARTICLE II 
 PURCHASE AND SALE OF WARRANTS 
 Section 2.01 Authorization to Issue Warrants. Dynavax has
authorized the issuance of a warrant (the “Warrant”, and together with any replacement warrants subsequently issued by Dynavax, the “Warrants”) representing the right to purchase 2,000,000 shares of Dynavax’s common
stock (subject to adjustment as set forth herein) (“Dynavax Common Stock”), par value $0.001 per share, at an exercise price per share of $1.94 (such shares, the “Warrant Shares”). The Warrants shall have a term of
five (5) years and shall be evidenced by certificates issued pursuant to this Agreement in the form set forth in Exhibit A hereto, with such appropriate insertions, omissions, substitutions, and other variations as are required or
permitted by this Agreement. 
 Section 2.02 Purchase and Sale of Warrants. Dynavax hereby agrees to issue to Holdings,
and Holdings hereby agrees to acquire from Dynavax, the Warrants on the Purchase Option Closing Date (hereinafter, the “Warrant Date”), subject to Sections 2.04 and 2.05, and subject to the fulfillment of the
conditions precedent described in Article III below. 
  

					
		  		  	Warrant Purchase Agreement

 Section 2.03 Warrant Date. Subject to the terms and conditions of this Agreement, the
issuance, sale and purchase of the Warrants contemplated by this Agreement shall take place at a closing on the Warrant Date (the “Warrant Closing”) to be held at the offices of Paul, Weiss, Rifkind, Wharton & Garrison LLP,
1285 Avenue of the Americas, New York, New York 10019, at 4:30 P.M., Eastern Time, following the satisfaction or waiver of all other conditions to the obligations of the Parties set forth in Article III hereof, or at such other place or at
such other time or such other date as Holdings and Dynavax shall mutually agree upon in writing. 
 Section 2.04 Warrant Date
Adjustment. If at any time or from time to time from and after the date hereof through the Warrant Date, (x) the number of outstanding shares of Dynavax Common Stock has been increased, decreased, changed into or exchanged for a different
number or kind of shares or securities as a result of a reorganization, recapitalization, stock dividend, stock split, reverse stock split or other similar change in capitalization, an appropriate and proportionate adjustment shall be made to the
number of Warrant Shares issuable upon the exercise of the Warrant or (y) Dynavax has issued Additional Dynavax Securities (any such issuance of Additional Dynavax Securities, a “Specified Dynavax Issuance”), Holdings may elect
(in accordance with the procedures set forth in Section 2.05) to receive the Alternate Securities specified in the Specified Issuance Notice (each as defined below) in lieu of the Warrants (such Alternate Securities paid to Holdings at the
Warrant Date, the “Alternate Closing Securities”). 
 Section 2.05 Post-Warrant Date Adjustment.

 (a) If at any time and from time to time from and after the Warrant Date through the date occurring six (6) months after
the Warrant Date (or if such date is not a Business Day, the first Business Day thereafter) (such date, the “Final Adjustment Date”), there is a Specified Dynavax Issuance, as soon as practicable, but in no event later than five
(5) Business Days after the delivery to Dynavax of a Holdings Election Notice (as defined below) (such date, the “Adjusted Securities Payment Date”), (i) Dynavax shall issue to Holdings such Alternate Securities in the
form specified in the Specified Issuance Notice, and (ii) Holdings shall deliver to Dynavax such Warrants or Alternate Closing Securities issued pursuant to this Agreement, as applicable, such that on the Adjusted Securities Payment Date
Holdings shall own Alternate Securities, together with all other securities of Dynavax issued, or other consideration transferred, to Holdings, to which Holdings is entitled in consideration of the transfer to Dynavax of the Symphony Dynamo Equity
Securities. The foregoing described transactions between Dynavax and Holdings shall be settled on a net basis. For the avoidance of doubt, the parties hereby acknowledge and agree that Holdings may exercise its rights under this Section 2.05(a)
following each Specified Dynavax Issuance that occurs after the date of this Agreement and on or prior to the Final Adjustment Date. 
 (b) Not later than five (5) Business Days prior to the consummation of a Specified Dynavax Issuance, Dynavax shall, in accordance with Section 7.02, deliver to Holdings a notice (a “Specified Issuance
Notice”) setting forth in reasonable detail: (i) a description of the form and terms of the Additional Dynavax Securities to be issued pursuant to the Specified Dynavax Issuance (such Additional Dynavax Securities, the
“Alternate Securities”); (ii) the price at which the Alternate Securities will be issued pursuant to the Specified Dynavax Issuance; (iii) the estimated date of issuance of such Alternate Securities; and (iv) the
amount and form of Alternate Securities that would be issued to an investor participating in the Specified Dynavax Issuance upon payment to Dynavax the Warrants. If Holdings elects to exercise its rights under Section 2.05(a) with respect to
a Specified Dynavax Issuance, Holdings, in accordance with Section 7.02, shall deliver to Dynavax a notice of such election not later than one (1) Business Day prior to the consummation of such Specified Dynavax Issuance (the
“Holdings Election Notice”). The failure of Holdings to notify Dynavax pursuant to this Section 2.05(b) shall be deemed to constitute the waiver by Holdings of its rights under Section 2.05 with respect to such
Specified Dynavax Issuance. 
  

					
		  	2	  	Warrant Purchase Agreement

 (c) “Additional Dynavax Securities” shall mean all shares of Dynavax
Common Stock, Options, Convertible Securities, notes, bonds, or any other securities issued by Dynavax, or cash or other consideration paid or delivered by or on behalf of Dynavax, other than the following (collectively, “Exempted
Securities”): 
 (i) rights, options or warrants to subscribe for, purchase or otherwise acquire Dynavax Common Stock
(“Options”), or shares of restricted stock or stock appreciation rights, issued to employees or directors of, or consultants or advisors to, Dynavax or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by
the board of directors of Dynavax; 
 (ii) (1) shares of Dynavax Common Stock actually issued upon the exercise of Options
or (2) shares of Dynavax Common Stock actually issued upon the conversion or exchange of any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Dynavax Common Stock, but excluding
Options (“Convertible Securities”), in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; 
 (iii) shares of Dynavax Common Stock, Options or Convertible Securities issued by reason of a dividend on the outstanding Dynavax Common Stock, stock split of the outstanding Dynavax Common Stock,
split-up of the outstanding Dynavax Common Stock or other distribution on shares of Dynavax Common Stock; or 
 (iv) shares of
Dynavax Common Stock sold and issued pursuant to that certain Equity Distribution Agreement dated August 17, 2009, by and between Dynavax and Wedbush Morgan Securities, Inc. (the “ATM Securities”). 
 ARTICLE III 
 CONDITIONS OF PURCHASE 
 Section 3.01 Conditions Precedent to Each Party’s Obligations. The
respective obligations of Dynavax and Holdings to effect the transactions contemplated hereby shall be subject to the satisfaction of the conditions precedent contained in this Section 3.01 or the waiver thereof in writing by Holdings
and Dynavax prior to or on the Warrant Date and each Adjusted Securities Payment Date. 
 (a) Approvals. All
Governmental Approvals imposed by any Governmental Authority in connection with the transactions contemplated by this Agreement and the other Operative Documents required to be in effect prior to or on the Warrant Date or such Adjusted Securities
Payment Date, as applicable, shall be in effect, the failure of which to be in effect would, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on either of the Parties. 
 (b) Litigation. No Governmental Authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any
law or Governmental Order (whether temporary, preliminary or permanent) that is in effect and restrains, enjoins or otherwise prohibits the consummation of the transactions contemplated hereby or in the other Operative Documents. 
 (c) Stockholder Approval. Dynavax shall have received approval by Dynavax’s stockholders of the issuance of the Warrant Shares
and any shares of Dynavax Common Stock or Alternate Closing Securities or Alternate Securities, as applicable, issuable in connection with the exercise of the Purchase Option by Dynavax under the Purchase Option Agreement, which such approval shall
satisfy the requirements of NASDAQ Marketplace Rule 5635. 
  

					
		  	3	  	Warrant Purchase Agreement

 Section 3.02 Conditions Precedent to Holdings’ Obligations. The obligation of
Holdings to effect the transactions contemplated hereby shall be subject to the satisfaction of the further conditions precedent contained in this Section 3.02, or the waiver thereof in writing by Holdings, prior to or on the Warrant
Date or such Adjusted Securities Payment Date, as applicable. 
 (a) Authorization, Execution and Delivery of Documents.
This Agreement and each of the other Operative Documents (including all schedules, annexes and exhibits thereto) required to be entered into shall have been duly authorized, executed and delivered by each of the parties thereto (other than Holdings)
and shall be in full force and effect. 
 (b) Issuance of Warrants or Alternate Securities. All actions required by any
applicable law, or necessary in the reasonable opinion of Holdings, to issue the Warrants or the Alternate Closing Securities or the Alternate Securities, as applicable, shall have been duly taken by Dynavax (or provisions therefore shall have been
made), including, without limitation, the making of all registrations and filings required to be made prior to or on the Warrant Date or such Adjusted Securities Payment Date, as applicable, and all necessary consents shall have been received.

 (c) Performance of Obligations by Dynavax; Representations and Warranties. Dynavax shall have performed in all
material respects and complied in all material respects with all agreements and conditions contained in this Agreement and the other Operative Documents that are required to be performed or complied with by it prior to or on the Warrant Date or such
Adjusted Securities Payment Date, as applicable. Each of Dynavax’s representations and warranties set forth in Section 4.02 of this Agreement shall be true and correct in all respects as of the Warrant Date or each Adjusted
Securities Payment Date, as applicable, with the same effect as though such representations and warranties were made on and as of the Warrant Date or each Adjusted Securities Payment Date, as applicable (or if stated to have been made as of an
earlier date, as of such date). 
 (d) Opinion of Counsel. Holdings shall have received an opinion letter from Cooley
Godward Kronish LLP, counsel for Dynavax, which opinion shall be, in form and substance, reasonably acceptable to Holdings. 
 (e) Warrant Date Certificate. Holdings shall have received a certificate from Dynavax executed by its Chief Financial Officer or other duly authorized executive officer, dated as of the Warrant Date or such Adjusted Securities
Payment Date, as applicable, in form and substance reasonably satisfactory to Holdings, certifying: 
 (i) (A) that the
Operative Documents to which Dynavax is a party have been duly authorized, executed and delivered by Dynavax, and are in full force and effect, and (B) that Dynavax has satisfied all conditions precedent contained in the Operative Documents to
which it is a party required to be satisfied by it on or prior to the Warrant Date or such Adjusted Securities Payment Date, as applicable; and 
  

					
		  	4	  	Warrant Purchase Agreement

 (ii) as to (A) the accuracy and completeness of the contents of Dynavax’s charter
documents, (B) the resolutions of Dynavax’s board of directors, duly authorizing Dynavax’s execution, delivery and performance of each Operative Document to which it is or is to be a party and each other document required to be
executed and delivered by it in accordance with the provisions hereof or thereof, and (C) the incumbency and signature of Dynavax’s representatives authorized to execute and deliver documents on its behalf in connection with the
obligations contemplated hereby and by the other Operative Documents. 
 (f) Further Documents, Certificates, Etc.
Holdings shall have received such other documents, certificates or opinions as Holdings may reasonably request in connection with the consummation of the transactions contemplated by this Agreement. 
 (g) No Events of Default. No breach, default, event of default or other similar event by Dynavax, and no event which with the giving
of notice, the passage of time, or both, would constitute any of the foregoing, under any Operative Document or any other material contract or agreement to which Dynavax is a party, shall have occurred and be continuing, and no condition shall exist
that constitutes, or with the giving of notice, the passage of time, or both, would constitute such default, event of default or other similar event. 
 (h) No Violation. The transactions contemplated hereby shall comply with all applicable law and no party (other than Holdings) to such transactions shall be in violation of any such applicable law.
Holdings shall not be subject to any penalty or liability pursuant to any violation of applicable law by virtue of the transactions contemplated hereby and by each of the other Operative Documents. 
 (i) Change in Law. There shall have been no change in any law, rule or regulation or the interpretation thereof (including any law,
rule or regulation relating to taxes) that prohibits or prevents the consummation of this Agreement or any of the transactions contemplated hereby (including the sale and purchase of the Warrants) or by the Operative Documents or that results in any
material increase in taxes payable by Holdings or Investors. 
 (j) Other Conditions Precedent. Dynavax shall have
satisfied and complied with all applicable conditions precedent set forth in each other Operative Document to which Dynavax is a party required to be satisfied and complied with prior to or on the Warrant Date. 
 Section 3.03 Conditions Precedent to Dynavax’s Obligations. The obligation of Dynavax to effect the transactions contemplated
hereby shall be subject to the satisfaction of the further conditions precedent contained in this Section 3.03, or the waiver thereof in writing by Dynavax, prior to or on the Warrant Date and each Adjusted Securities Payment Date.

 (a) Prior Warrant Delivery. Holdings shall deliver to Dynavax for cancellation all warrants issued by Dynavax to
Holdings or any Affiliate of Holdings under that certain Warrant Purchase Agreement, dated April 18, 2006, between Dynavax and Holdings, or upon the transfer of any warrants so issued. 
 (b) Authorization, Execution and Delivery of Documents. This Agreement and each of the other Operative Documents (including all
schedules and exhibits thereto) required to be entered into shall have been duly authorized, executed and delivered by each of the parties thereto (other than Dynavax) and shall be in full force and effect. 
  

					
		  	5	  	Warrant Purchase Agreement

 (c) Performance of Obligations by Holdings; Representations and Warranties.

 (i) As of the Warrant Date or such Adjusted Securities Payment Date, as applicable, Holdings shall have performed in all
material respects and complied in all material respects with all agreements and conditions contained in this Agreement and the other Operative Documents required to be performed or complied with by it prior to or at the Warrant Date or such Adjusted
Securities Payment Date, as applicable. Each of Holdings’ representations and warranties set forth in Section 4.01 of this Agreement shall be true and correct in all respects as of the Warrant Date or such Adjusted Securities
Payment Date, as applicable, as applicable with the same effect as though such representations and warranties were made on and as of the Warrant Date or such Adjusted Securities Payment Date, as applicable (or if stated to have been made as of an
earlier date, as of such date). 
 (ii) No breach, default, event of default or other similar event by Holdings, and no event
which with the giving of notice, the passage of time, or both, would constitute any of the foregoing, under any Operative Document or any other material contract or agreement to which Holdings is a party, shall have occurred and be continuing, and
no condition shall exist that constitutes, or with the giving of notice, the passage of time, or both, would constitute such default, event of default or other similar event. 
 (iii) The transactions contemplated hereby shall comply in all material respects with all applicable law, and no party (other than Dynavax)
to such transactions shall be in material violation of any such applicable law. Dynavax shall not be subject to any penalty or liability pursuant to any violation of applicable law by virtue of the transactions contemplated hereby and by each of the
other Operative Documents, the failure to comply with which would, either individually or in the aggregate, reasonably be expected to have a material adverse effect on the Programs. 
 (iv) Holdings shall have satisfied and complied with all applicable conditions precedent set forth in each other Operative Document to
which Holdings is a party required to be satisfied and complied with prior to or on the Warrant Date. 
 ARTICLE IV

 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 Section 4.01 Representations, Warranties and Covenants of Holdings. 
 (a) As of the date hereof, Holdings hereby represents and warrants, and, except to the extent that any of the following representations and
warranties is limited to the date of this Agreement or otherwise limited, on the Warrant Date and each Adjusted Securities Payment Date, shall be deemed to have represented and warranted, to Dynavax that: 
 (i) Organization. Holdings is a limited liability company, duly formed, validly existing and in good standing under the laws of the
State of Delaware. 
 (ii) Authority and Validity. Holdings has all requisite limited liability company power and
authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance by Holdings of this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary action required on the part of Holdings, and no other proceedings on the part of Holdings are necessary to authorize this Agreement or for Holdings to perform its obligations
under this Agreement. This Agreement constitutes the lawful, valid and legally binding obligation of 
  

					
		  	6	  	Warrant Purchase Agreement

 
Holdings, enforceable in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of
creditors’ rights generally and general equitable principles regardless of whether such enforceability is considered in a proceeding at law or in equity. 
 (iii) No Violation or Conflict. The execution, delivery and performance of this Agreement and the transactions contemplated hereby do not (A) violate, conflict with or result in the breach of
any provision of the Organizational Documents of Holdings, (B) conflict with or violate any law or Governmental Order applicable to Holdings or any of its assets, properties or businesses, or (C) conflict with, result in any breach of,
constitute a default (or event that with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or
cancellation of, or result in the creation of any Encumbrance on any of the assets or properties of Holdings, pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or other instrument or
arrangement to which Holdings is a party except, in the case of clauses (B) and (C), to the extent that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect on Holdings. 
 (iv) Governmental Consents and Approvals. Other than any HSR Filings
which, if such HSR Filings are required, will be obtained on or prior to the Warrant Date, the execution, delivery and performance of this Agreement by Holdings do not, and the consummation of the transactions contemplated hereby do not and will
not, require any Governmental Approval which has not already been obtained, effected or provided, except with respect to which the failure to so obtain, effect or provide would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect on Holdings. 
 (v) Litigation. There are no actions by or against Holdings pending before any
Governmental Authority or, to the knowledge of Holdings, threatened to be brought by or before any Governmental Authority, that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings. There are
no pending or, to the knowledge of Holdings, threatened actions to which Holdings is a party (or threatened to be named as a party) to set aside, restrain, enjoin or prevent the execution, delivery or performance of this Agreement or the Operative
Documents or the consummation of the transactions contemplated hereby or thereby by any party hereto or thereto. Holdings is not subject to any Governmental Order (nor, to the knowledge of Holdings, is there any such Governmental Order threatened to
be imposed by any Governmental Authority) that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings. 
 (vi) Accredited Investor. 
 (A) Holdings is and will remain at all relevant
times an “Accredited Investor”. 
 (B) Holdings has relied completely on the advice of, or has consulted with or has
had the opportunity to consult with, its own personal tax, investment, legal or other advisors and has not relied on Dynavax or any of its Affiliates for advice. Holdings has reviewed the Investment Overview and is aware of the risks disclosed
therein. Holdings acknowledges that it has had a reasonable opportunity to conduct its own due diligence with respect to the Products, the Programs, Symphony Dynamo, Dynavax and the transactions contemplated by the Operative Documents. 

 

					
		  	7	  	Warrant Purchase Agreement

 (C) Holdings has been advised and understands that the offer and sale of the Warrants and
the Warrant Shares and, if issued, the Alternate Securities, have not been registered under the Securities Act. Holdings is able to bear the economic risk of such investment for an indefinite period and to afford a complete loss thereof. 

(D) Holdings is acquiring the Warrants and the Warrant Shares solely for Holdings’ own account for investment purposes as a
principal and not with a view to the resale of all or any part thereof; provided, that Holdings may transfer all or part of the interest in the Warrants as set forth in Section 6.01 hereof. Holdings agrees that the Warrants and the
Warrant Shares and, if issued, the Alternate Securities, may not be resold (1) without registration thereof under the Securities Act (unless an exemption from such registration is available), or (2) in violation of any law. Holdings is not
and will not be an underwriter within the meaning of Section 2(11) of the Securities Act with respect to the Warrants and the Warrant Shares. 
 (E) No person or entity acting on behalf of, or under the authority of, Holdings is or will be entitled to any broker’s, finder’s, or similar fees or commission payable by Dynavax or any of its
Affiliates. 
 (F) Holdings acknowledges and agrees to treat the Warrants and, if issued, the Alternate Securities, for
federal, state and local income tax purposes as option premium paid in return for the grant, maintenance and exercise of the Purchase Option. 
 Section 4.02 Representations, Warranties and Covenants of Dynavax. 
 (a) As
of the date hereof, Dynavax hereby represents and warrants, and, except to the extent that any of the following representations and warranties is limited to the date of this Agreement or otherwise limited, on the Warrant Date and each Adjusted
Securities Payment Date, shall be deemed to have represented and warranted, to Holdings that: 
 (i) Organization.
Dynavax is a corporation, duly organized, validly existing and in good standing under the laws of the State of Delaware. 
 (ii) Authority and Validity. Dynavax has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery
and performance by Dynavax of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary action required on the part of Dynavax, and no other proceedings on the part of Dynavax,
other than the Stockholder Approval, are necessary to authorize this Agreement or for Dynavax to perform its obligations under this Agreement. This Agreement constitutes the lawful, valid and legally binding obligation of Dynavax, enforceable in
accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and general equitable principles regardless
of whether such enforceability is considered in a proceeding at law or in equity. 
 (iii) No Violation or Conflict. The
execution, delivery and performance of this Agreement and the transactions contemplated hereby do not (A) violate, conflict with or result in the breach of any provision of the Organizational Documents of Dynavax, (B) conflict with or
violate any law or Governmental Order applicable to Dynavax or any of its assets, properties or businesses, or (C) conflict with, result in any breach of, constitute a default (or event that with the giving of notice or lapse of time, or both,
would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the 
  

					
		  	8	  	Warrant Purchase Agreement

 
creation of any Encumbrance on any of the assets or properties of Dynavax, pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or
other instrument or arrangement to which Dynavax is a party except, in the case of clauses (B) and (C), to the extent that such conflicts, breaches, defaults or other matters would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on Dynavax. 
 (iv) Governmental Consents and Approvals. Other than any
HSR Filings which, if such HSR Filings are required, will be obtained on or prior to the Warrant Date, the execution, delivery and performance of this Agreement by Dynavax do not, and the consummation of the transactions contemplated hereby do not
and will not, require any Governmental Approval which has not already been obtained, effected or provided, except with respect to which the failure to so obtain, effect or provide would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect on Dynavax. 
 (v) Litigation. There are no actions by or against Dynavax pending
before any Governmental Authority or, to the knowledge of Dynavax, threatened to be brought by or before any Governmental Authority, that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Dynavax.
There are no pending or, to the knowledge of Dynavax, threatened actions, to which Dynavax is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or prevent the execution, delivery or performance of this Agreement or the
Operative Documents or the consummation of the transactions contemplated hereby or thereby by any party hereto or thereto. Dynavax is not subject to any Governmental Order (nor, to the knowledge of Dynavax, is there any such Governmental Order
threatened to be imposed by any Governmental Authority) that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Dynavax. 
 (vi) Private Placement. Assuming the accuracy of Holdings’ representations and warranties set forth in
Section 4.01, (i) the purchase and sale of the Warrants and, if issued, the Alternate Securities, is exempt from the registration requirements of the Securities Act, and (ii) no other offering of Common Stock by Dynavax (other
than the issuance of the Dynavax Closing Shares and, if issued, the Alternate Securities) will be integrated with the offering of the Warrants or the Warrant Shares or Alternate Securities, if applicable. Neither Dynavax nor any Person acting on its
behalf has or will offer the Warrants or the Warrant Shares by any form of general solicitation or general advertising and all filings required under Rule 503 of the Securities Act will be made in a timely manner. 
 (b) Dynavax covenants and agrees with Holdings that, so long as any of the Warrants are outstanding (including as such Warrants may be
reissued pursuant to transfer in accordance with Section 6.01 hereof), Dynavax shall take all action necessary to reserve and keep available out of its authorized and unissued Dynavax Common Stock, solely for the purpose of effecting the
exercise of the Warrants, 100% of the number of shares of Dynavax Common Stock issuable upon exercise of the Warrants. Upon exercise in accordance with the Warrants, the Dynavax Common Stock delivered thereby will be validly issued, fully paid and
nonassessable and free from all taxes, liens and charges with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of the Dynavax Common Stock. 
 (c) Dynavax acknowledges and agrees to treat the Warrants for federal, state and local income tax purposes as option premium paid in return
for the grant of the Purchase Option. 
  

					
		  	9	  	Warrant Purchase Agreement

 ARTICLE V 
 INDEMNITY 
 Section 5.01
Indemnification. To the greatest extent permitted by applicable law, Dynavax shall indemnify and hold harmless Holdings, and Holdings shall indemnify and hold harmless Dynavax, and each of their respective Affiliates, officers, directors,
employees, agents, partners, members, successors, assigns, representatives of, and each Person, if any (including any officers, directors, employees, agents, partners, members of such Person) who controls, Holdings and Dynavax, as applicable, within
the meaning of the Securities Act or the Exchange Act, (each, an “Indemnified Party”), from and against any and all actions, causes of action, suits, claims, losses, costs, interest, penalties, fees, liabilities and damages, and
expenses in connection therewith (irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (hereinafter, a
“Loss”), incurred by any Indemnified Party as a result of, or arising out of, or relating to: (i) in the case of Dynavax being the Indemnifying Party, (A) any breach of any representation or warranty made by Dynavax herein
or in any certificate, instrument or document delivered in connection and contemporaneously herewith, (B) any breach of any covenant, agreement or obligation of Dynavax contained herein or in any certificate, instrument or document delivered
hereunder, or (C) any untrue statement of a material fact about Dynavax contained in the reports filed by Dynavax with the SEC, or the omission therefrom of a material fact about Dynavax required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading, to the extent that such reports are attached to the Investment Overview; provided, that the information contained in a later filed report filed
prior to the date of this Agreement shall be deemed to update any related information contained in a previously filed report (the items set forth herein in clauses (A), (B) and (C) being hereinafter referred to as the
“Holdings Claims”), and (ii) in the case of Holdings being the Indemnifying Party, (x) any breach of any representation or warranty made by Holdings herein or in any certificate, instrument or document delivered in
connection and contemporaneously herewith, (y) any breach of any covenant, agreement or obligation of Holdings contained herein or in any certificate, instrument or document delivered hereunder, or (z) any untrue statement or alleged
untrue statement of a material fact about Holdings contained in the Investment Overview or the omission or alleged omission therefrom of a material fact about Holdings required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading, (the items set forth herein in clauses (x), (y) and (z) being hereinafter referred to as the “Dynavax Claims”). To the
extent that the foregoing undertaking by Dynavax or Holdings may be unenforceable for any reason, such Party shall make the maximum contribution to the payment and satisfaction of any Loss that is permissible under applicable law. 
 Section 5.02 Notice of Claims. Any Indemnified Party that proposes to assert a right to be indemnified under this Article V
shall notify Dynavax or Holdings, as applicable (the “Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit or proceeding against such Indemnified Party (an “Indemnified
Proceeding”) in respect of which a claim is to be made under this Article V, or the incurrence or realization of any Loss in respect of which a claim is to be made under this Article V, of the commencement of such Indemnified
Proceeding or of such incurrence or realization, enclosing a copy of all relevant documents, including all papers served and claims made, but the omission to so notify the applicable Indemnifying Party promptly of any such Indemnified Proceeding or
incurrence or realization shall not relieve (x) such Indemnifying Party from any liability that it may have to such 
  

					
		  	10	  	Warrant Purchase Agreement

 
Indemnified Party under this Article V or otherwise, except, as to such Indemnifying Party’s liability under this Article V, to the extent, but only to the extent, that such
Indemnifying Party shall have been prejudiced by such omission, or (y) any other indemnitor from liability that it may have to any Indemnified Party under the Operative Documents. 
 Section 5.03 Defense of Proceedings. In case any Indemnified Proceeding shall be brought against any Indemnified Party, it shall
notify the applicable Indemnifying Party of the commencement thereof as provided in Section 5.02, and such Indemnifying Party shall be entitled to participate in, and provided such Indemnified Proceeding involves a claim solely
for money damages and does not seek an injunction or other equitable relief against the Indemnified Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified Proceeding with counsel reasonably satisfactory to such
Indemnified Party. After notice from such Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election to so assume the defense thereof and the failure by such Indemnified Party to object to such counsel within ten
(10) Business Days following its receipt of such notice, such Indemnifying Party shall not be liable to such Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred after such notice of election to assume
such defense except as provided below and except for the reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred by such Indemnified Party reasonably necessary in connection with the defense thereof. Such
Indemnified Party shall have the right to employ its counsel in any such Indemnified Proceeding, but the reasonable fees and expenses of such counsel shall be at the expense of such Indemnified Party unless: 
 (i) the employment of counsel by such Indemnified Party at the expense of the applicable Indemnifying Party has been authorized in writing
by such Indemnifying Party; 
 (ii) such Indemnified Party shall have reasonably concluded in its good faith (which conclusion
shall be determinative unless a court determines that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between the applicable Indemnifying Party and such Indemnified Party in the conduct of
the defense of such Indemnified Proceeding or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes of action available to such Indemnified Party (it being agreed that in any case referred to in this
clause (ii) such Indemnifying Party shall not have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party); 
 (iii) the applicable Indemnifying Party shall not have employed counsel reasonably acceptable to the Indemnified Party, to assume the defense of such Indemnified Proceeding within a reasonable time after
notice of the commencement thereof (provided, however, that this clause (iii) shall not be deemed to constitute a waiver of any conflict of interest that may arise with respect to any such counsel); or 
 (iv) any counsel employed by the applicable Indemnifying Party shall fail to timely commence or diligently conduct the defense of such
Indemnified Proceeding and such failure has materially prejudiced (or, in the reasonable judgment of the Indemnified Party, is in danger of materially prejudicing) the outcome of such Indemnified Proceeding; 
 in each of which cases the reasonable fees and expenses of counsel for such Indemnified Party shall be at the expense of such Indemnifying Party. Only one
counsel shall be retained by all Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any Indemnified Party reasonably concludes in good faith (which conclusion shall be determinative unless a court determines that such
conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties in the conduct of the defense of such Indemnified Proceeding or that
there are or may be one or more different or additional defenses, claims, counterclaims, or causes or action available to such Indemnified Party. 
  

					
		  	11	  	Warrant Purchase Agreement

 Section 5.04 Settlement. Without the prior written consent of such Indemnified Party,
such Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or related judgment (i) includes an unconditional
release of such Indemnified Party from all liability for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii) provides for the payment of money damages as the sole relief for the claimant (whether at law
or in equity), (iii) involves no finding or admission of any violation of law or the rights of any Person by the Indemnified Party, and (iv) is not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or
compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified Proceeding in respect of which any payment would result hereunder or under the Operative Documents without the prior written consent of the Indemnifying
Party, such consent not to be unreasonably conditioned, withheld or delayed. 
 ARTICLE VI 
 TRANSFER RESTRICTIONS 
 Section 6.01 Transfer Restrictions. Holdings agrees (and agrees to cause all of its members and any subsequent transferees thereof to so agree) that (i) it will not, directly or indirectly,
offer, sell, assign, transfer, grant or sell a participation in, pledge or otherwise dispose of the Warrant or Warrant Shares (or solicit any offers to buy or otherwise acquire, or take a pledge of, any Warrant) unless such Warrant or Warrant Shares
are registered and/or qualified under the Securities Act and applicable state securities laws, or unless an exemption from the registration or qualification requirements is otherwise available; provided, that Holdings may transfer the Warrant
(or part of its interest therein) or Warrant Shares to Investors, RRD and each Symphony Fund, and Investors (but not any other member of Holdings) may further distribute Warrants or Warrant Shares to its respective members; (ii) (A) no
transfer of such Warrant, or (B) with respect to a private placement of the Warrant Shares, no transfer of such Warrant Shares shall be effective or recognized unless the transferor and the transferee make the representations and agreements
contained herein and furnish to Dynavax such certifications and other information as Dynavax may reasonably request to confirm that any proposed transfer complies with the restrictions set forth herein and any applicable laws; and
(iii) (x) Warrants may only be transferred in minimum denominations representing the right to purchase at least 50,000 Warrant Shares, and (y) prior to the registration of Warrant Shares as contemplated in the Registration Rights
Agreement, the Warrant Shares may only be transferred in minimum denominations of at least 50,000 Warrant Shares; provided, however, that in the event that any holder of a Warrant or Warrant Shares holds a Warrant representing the
right to purchase less than 50,000 Warrant Shares, or holds less than 50,000 Warrant Shares, as the case may be, such holder shall be entitled to exercise all, but not less than all, of the full amount of such Warrant and sell all, but not less than
all, such Warrant Shares delivered to it in connection therewith, notwithstanding the fact that the number of such Warrant Shares is less than 50,000; provided, further, that Holdings agrees (and agrees to cause its members and any
subsequent transferees thereof to so agree), that with respect to a Warrant, such holder of a Warrant will not sell or otherwise transfer any Warrant, except in private placements to Accredited Investors. 
  

					
		  	12	  	Warrant Purchase Agreement

 Section 6.02 Legends. 
 (a) Holdings acknowledges and agrees that Dynavax shall affix to each certificate evidencing outstanding Warrants (and any certificates
issued upon the transfer of the Warrants) a legend in substantially the following form (a “Warrant Legend”): 
 “NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN THE SUBJECT OF REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE, AND THE SAME HAVE BEEN (OR WILL BE,
WITH RESPECT TO THE SECURITIES ISSUABLE UPON EXERCISE HEREOF) ISSUED IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD,
TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 
 THE WARRANT EVIDENCED BY THIS CERTIFICATE IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE WARRANT PURCHASE AGREEMENT, DATED AS OF NOVEMBER 9, 2009, COPIES OF WHICH ARE ON FILE AT THE
PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER. NO REGISTRATION OF TRANSFER OF THIS WARRANT WILL BE MADE ON THE BOOKS OF THE ISSUER UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN COMPLIED WITH.” 
 Section 6.03 Warrant Legend Removal. If the certificates representing such Warrants, include a Warrant Legend (as set forth in
Section 6.02 hereof), Dynavax shall, upon a request from Holdings, or a member or subsequent transferee thereof, within two (2) Business Days after receiving such request, remove or cause to be removed (i) if the Warrants cease
to be restricted securities, the securities law portion of the Warrant Legend and/or (ii) in the event of a sale of the Warrants in compliance with the transfer restrictions, the transfer restriction portion of the Warrant Legend, from such
certificates representing the Warrants as Holdings, or such member or transferee, shall designate, in accordance with the terms hereof and, if applicable, in accordance with the terms of the applicable Warrant. 
 Section 6.04 Improper Transfer. Any attempt to sell, assign, transfer, grant or sell a participation in, pledge or otherwise dispose
of any Warrants or any Warrant Shares, not in compliance with this Agreement shall be null and void and Dynavax shall give no effect to such attempted sale, assignment, transfer, grant, sale of a participation, pledge or other disposition.

 Section 6.05 Limits on Daily Disposition. Holdings and its Affiliates each agree that, in the event that any holder of
a Warrant exercises the Warrant and determines to dispose of its Warrant Shares on the market, Holdings (and its Affiliates) or the transferee of Holdings of those Warrant Shares will not sell or otherwise dispose in any single day of Warrant Shares
totaling in excess of 35,000 shares in the aggregate (as reported on the NASDAQ national market or such other national exchange representing the primary exchange on which Dynavax Common Stock is listed); provided, however, that
Holdings (and its Affiliates) and any transferees may sell or otherwise dispose of their Warrant Shares without regard to the share limitations hereunder in a private placement to accredited investors; and provided further, that any holder of
Warrant Shares holding less than 35,000 shares shall not be subject to the restrictions set forth in this Section 6.05. Holdings and its Affiliates shall notify any transferee of a Warrant or Warrant Shares of the terms of this
Section 6.05. but shall in no event be responsible for monitoring the disposition of the Warrant Shares by any transferee. 
  

					
		  	13	  	Warrant Purchase Agreement

 ARTICLE VII 
 MISCELLANEOUS 
 Section 7.01 Notice of
Material Event. Each Party agrees that, upon it receiving knowledge of a material event or development with respect to any of the transactions contemplated hereby that, to the knowledge of its executive officers, is not known to the other
Parties, such Party shall notify the other Parties in writing within three (3) Business Days of the receipt of such knowledge by any executive officer of such Party; provided, that the failure to provide such notice shall not impair or
otherwise be deemed a waiver of any rights any Party may have arising from such material event or development, and that notice under this Section 7.01 shall not in itself constitute notice of any breach of any of the Operative Documents.

 Section 7.02 Notices. Any notice, request, demand, waiver, consent, approval, or other communication which is required
or permitted to be given to any Party hereto shall be in writing and shall be deemed given only if delivered to the Party personally or sent to the Party by facsimile transmission (promptly followed by a hard-copy delivered in accordance with this
Section 7.02), by next Business Day delivery by a nationally recognized courier service, or by registered or certified mail (return receipt requested), with postage and registration or certification fees thereon prepaid, addressed to the
Party at its address set forth below: 
 Dynavax: 
 Dynavax Technologies Corporation 
 2929 Seventh Street, Suite 100 
 Berkeley, CA 94710 
 Attn: Michael S. Ostrach, Esq., Vice President, 
 Chief Business Officer and General Counsel 
 Facsimile: (510) 848-1327

 with copies to: 
 Cooley Godward Kronish LLP 
 Five Palo Alto Square, 4th Floor 
 3000 El Camino Real 
 Palo Alto, CA 94306-2155 
 Attn: Glen Y. Sato, Esq. 
 Facsimile: (650) 849-7400 
 Holdings: 
 Symphony Dynamo Holdings LLC 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20855 
 Attn: Robert L. Smith, Jr. 
 Facsimile:    (301) 762-6154 
  

					
		  	14	  	Warrant Purchase Agreement

 with a copy to: 
 Symphony Capital Partners, L.P. 
 875 Third Avenue, 3rd Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile:    (212) 632-5401 

and 
 Symphony
Strategic Partners, LLC 
 875 Third Avenue, 3rd Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile:    (212) 632-5401 
 or to such other address as such Party may from time to time specify by notice given in the manner provided herein to each other Party entitled to receive notice hereunder. 
 Section 7.03 Governing Law; Consent to Jurisdiction and Service of Process. 
 (a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York; except to the extent
that this Agreement pertains to the internal governance of Dynavax, and to such extent this Agreement shall be governed and construed in accordance with the laws of the State of Delaware. 
 (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of
any New York State court and any Delaware State court or federal court of the United States of America sitting in The City of New York, Borough of Manhattan or Wilmington, Delaware, and any appellate court from any jurisdiction thereof, in any
action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in any such New York State court, any such Delaware State court or, to the fullest extent permitted by law, in such federal court. Each of the Parties agrees that a final judgment in any such action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that any Party may otherwise have to bring any action or proceeding relating to
this Agreement. 
 (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may legally and
effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any New York State or federal court, or any Delaware State or federal court.
Each of the Parties hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. Each of the parties hereby consents to service of process
by mail. 
 Section 7.04 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY
IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
  

					
		  	15	  	Warrant Purchase Agreement

 Section 7.05 Entire Agreement. This Agreement (including any Annexes, Schedules,
Exhibits or other attachments here) constitutes the entire agreement between the Parties with respect to the matters covered hereby and supersedes all prior agreements and understandings with respect to such matters between the Parties. 

Section 7.06 Amendment and Waivers. The terms of this Agreement shall not be waived, altered, modified, amended or supplemented in
any manner whatsoever except by a written instrument signed by each of the Parties. Any Party may waive, solely with respect to itself, any one or more of its rights hereunder without the consent of any other Party hereto; provided, that no such
waiver shall be effective unless set forth in a written instrument executed by the Party hereto against whom such waiver is to be effective. 
 Section 7.07 Counterparts. This Agreement may be executed in one or more counterparts, each of which, when executed, shall be deemed an original but all of which taken together shall constitute one
and the same Agreement. 
 Section 7.08 Assignment and Successors. Neither Dynavax nor Holdings may assign, delegate,
transfer, sell or otherwise dispose of (collectively, “Transfer”), in whole or in part, any or all of its rights or obligations hereunder to any Person (a “Transferee”) without the prior written approval of
the other Party; provided, however, that Dynavax, without the prior approval of the other Party, acting in accordance with Article 14 of the Amended and Restated Research and Development Agreement, may make such Transfer to any Person
which acquires all or substantially all of Dynavax’s assets or business (or assets or business related to the Programs) or which is the surviving or resulting Person in a merger or consolidation with Dynavax; provided further, that in
the event of any such Transfer, Dynavax or Holdings, as applicable, shall provide written notice to the other Parties of any such Transfer not later than thirty (30) days after such Transfer setting forth the identity and address of the
Transferee and summarizing the terms of the Transfer. In the event that the surviving or resulting “parent” entity (the “Surviving Entity”) in a merger or acquisition involving Dynavax is an entity other than Dynavax, then
Holdings or any subsequent holder of a Warrant shall either exercise such Warrant or surrender such Warrant in exchange for a new Warrant exercisable for shares of the common stock of the Surviving Entity (the “Replacement
Warrant”); provided, that: 
 (i) If the terms of such merger or acquisition shall provide for consideration
that consists of a combination of cash and stock of the Surviving Entity, then any Replacement Warrant issued to the holders of the Warrants shall be solely for stock of the Surviving Entity, at an exchange ratio reflecting the total consideration
paid by the Surviving Entity at the time of such change in control as if the total consideration (including cash) for each share of Dynavax Common Stock was instead paid only in stock of the Surviving Entity at the time of such change of control (as
illustrated on Exhibit B hereto), and the holders of the Replacement Warrants shall have the registration rights for stock issuable upon exercise of the Replacement Warrants as provided under the Registration Rights Agreement; and 

(ii) If prior to the end of the Term, such a merger or acquisition shall occur and the consideration for such merger or acquisition
shall be paid entirely in cash, then any holder of any outstanding Warrant shall then have the option to elect within fifteen (15) Business Days of receiving notice of the public announcement of the merger or acquisition by written notice of
election to Dynavax, either (1) to retain such Warrant and the right to exercise such Warrant for shares of Dynavax Common Stock in accordance with the terms of such Warrant and this Agreement, which exercise shall occur no later than
immediately prior to the closing of such merger or acquisition; or (2) to surrender such

  

					
		  	16	  	Warrant Purchase Agreement

 
outstanding Warrant to Dynavax in consideration of a cash payment for each share of Dynavax Common Stock subject to purchase under such Warrant in an amount equal to forty percent (40%) of
the per share cash consideration to be received by a holder of one share of Dynavax Common Stock to be tendered in the merger or acquisition; provided that the aggregate total cash payments to all holders of the Warrants shall not exceed five
million dollars ($5,000,000) (the “Warrant Surrender Price”). The Warrant Surrender Price shall be paid upon the surrender of the Warrants promptly following the closing of the all cash merger or acquisition. Any failure by the
Holder to deliver a written notice of election to Dynavax pursuant to this Section 7.08(ii) shall be deemed an election of clause (1) of this Section 7.08(ii). 
 Following a merger or acquisition involving the payment of non-cash consideration in which Dynavax is not the Surviving Entity, any reference to
“Dynavax Common Stock” shall be deemed instead to refer to the common stock of the Surviving Entity. For purposes of this Section 7.08 “common stock of the Surviving Entity” shall include stock of such
corporation of any class which is not preferred as to dividends or assets over any other class of stock of such corporation, and which is not subject to redemption and shall also include any evidences of indebtedness, shares of stock or other
securities which are convertible into or exchangeable for any such stock, either immediately or upon the arrival of a specified date or the occurrence of a specified event and any warrants or other rights to subscribe for or purchase any such stock.
The foregoing provisions of this Section 7.08 shall similarly apply to successive mergers, acquisitions, consolidations or disposition of assets. 
 [SIGNATURES FOLLOW ON NEXT PAGE] 
  

					
		  	17	  	Warrant Purchase Agreement

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
respective officers or other representatives thereunto duly authorized, as of the date first above written. 
  

			
	DYNAVAX TECHNOLOGIES CORPORATION
		
	By:	 	 /s/ Michael S. Ostrach

	Name:	 	Michael S. Ostrach
	Title:	 	Vice President
	
	SYMPHONY DYNAMO HOLDINGS LLC
		
	By:	 	 Symphony Capital Partners, L.P.,
 its Manager

		
	By:	 	Symphony Capital GP, L.P.,
		 	its General Partner
		
	By:	 	Symphony GP, LLC,
		 	its General Partner
		
	By:	 	 /s/ Mark Kessel

	Name:	 	Mark Kessel
	Title:	 	Managing Member

 Signature Page to
the Warrant Purchase Agreement 

 ANNEX A 
 CERTAIN DEFINITIONS 
 “$” means United States
dollars. 
 “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D promulgated
under the Securities Act of 1933, as amended. 
 “Act” means the Delaware Limited Liability Company Act,
6 Del. C. § 18-101 et seq. 
 “Ad Hoc Meeting” has the meaning set forth in
Paragraph 6 of Annex B of the Amended and Restated Research and Development Agreement. 
 “Additional
Funds” has the meaning set forth in Section 2(b) of the Funding Agreement. 
 “Additional Funding
Date” has the meaning set forth in Section 3 of the Funding Agreement. 
 “Additional
Party” has the meaning set forth in Section 13 of the Confidentiality Agreement. 
 “Additional
Regulatory Filings” means such Governmental Approvals as required to be made under any law applicable to the purchase of the Symphony Dynamo Equity Securities under the Purchase Option Agreement. 
 “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

 “Affected Member” has the meaning set forth in Section 27 of the Investors LLC Agreement.

 “Affiliate” means, with respect to any Person (i) any Person directly or indirectly controlling,
controlled by or under common control with such Person, (ii) any officer, director, general partner, member or trustee of such Person, or (iii) any Person who is an officer, director, general partner, member or trustee of any Person
described in clauses (i) or (ii) of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or “under common control with” shall mean the possession, direct or indirect, of the
power to direct or cause the direction of the management and policies of a Person or entity, whether through the ownership of voting securities, by contract or otherwise, or the power to elect at least 50% of the directors, managers, general
partners, or persons exercising similar authority with respect to such Person or entities. 
 “Amended and Restated
Research and Development Agreement” means the Amended and Restated Research and Development Agreement dated as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo. 
 “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  

 1 

 “Auditors” means an independent certified public accounting firm of
recognized national standing. 
 “Avecia Agreement” has the meaning set forth in Schedule 12.1(f) to the
Amended and Restated Research and Development Agreement. 
 “Bankruptcy Code” means the United States
Bankruptcy Code. 
 “Berna” has the meaning set forth in Section 11.1(a) of the Amended and
Restated Research and Development Agreement. 
 “Business Day” means any day other than Saturday, Sunday
or any other day on which commercial banks in The City of New York or the City of San Francisco are authorized or required by law to remain closed. 
 “Cancer Products” mean any pharmaceutical product comprising a Selected ISS in the absence of any added tumor, cancer or viral antigen, for use in cancer treatment or therapy.

 “Cancer Program” means the identification, development, manufacture and/or use of any Cancer Products
in accordance with the Development Plan. 
 “Capital Contributions” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Capitalized Leases” means all leases that have been
or should be, in accordance with GAAP, recorded as capitalized leases. 
 “Cash Available for
Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and Restated Research and Development Agreement. 
 “Change of Control” means and includes the occurrence of any of the following events, but specifically excludes (i) acquisitions of capital stock directly from Dynavax for
cash, whether in a public or private offering, (ii) sales of capital stock by stockholders of Dynavax, and (iii) acquisitions of capital stock by or from any employee benefit plan or related trust: 
 (a) the merger, reorganization or consolidation of Dynavax into or with another corporation or legal entity in which
Dynavax’s stockholders holding the right to vote with respect to matters generally immediately preceding such merger, reorganization or consolidation, own less than fifty percent (50%) of the voting securities of the surviving entity; or

 (b) the sale of all or substantially all of Dynavax’s assets or business. 
 “Class A Member” means a holder of a Class A Membership Interest. 
 “Class A Membership Interest” means a Class A Membership Interest in Holdings. 
  

 2 

 “Class B Member” means a holder of a Class B Membership interest.

 “Class B Membership Interest” means a Class B Membership Interest in Holdings. 
 “Class C Member” means a holder of a Class C Membership Interest. 
 “Class C Membership Interest” means a Class C Membership Interest in Holdings. 
 “Closing Certificate for Section 5.1(e)” means the written certificate, pertaining to the representations made
by Dynavax under Section 5.1(e) of the Novated and Restated Technology License Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing Date. 
 “Closing Certificate for Section 5.1(f)” means the written certificate, pertaining to the representations made
by Dynavax under Section 5.1(f) of the Novated and Restated Technology License Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing Date. 
 “Client Schedules” has the meaning set forth in Section 5(b)(i) of the RRD Services Agreement. 
 “Clinical Budget Component” has the meaning set forth in Section 4.1 of the Amended and Restated Research and
Development Agreement. 
 “Closing Date” means April 18, 2006. 
 “CMC” means the chemistry, manufacturing and controls documentation as required for filings with Regulatory
Authority relating to the manufacturing, production and testing of drug products. 
 “Code” means the
Internal Revenue Code of 1986, as amended from time to time. 
 “Committed Capital” means
$50,000,000.00. 
 “Common Stock” means the common stock, par value $0.01 per share, of Symphony Dynamo.

 “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings LLC Agreement.

 “Company Property” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

 “Confidential Information” has the meaning set forth in Section 2 of the Confidentiality
Agreement. 
 “Confidentiality Agreement” means the Confidentiality Agreement, dated as of the Closing
Date, among Symphony Dynamo, Holdings, Dynavax, each Symphony Fund, SCP, SSP, Investors, Symphony Capital, RRD and Ann M. Arvin, M.D. 
  

 3 

 “Conflict Transaction” has the meaning set forth in Article X of the
Symphony Dynamo Charter. 
 “Control” means, with respect to any material, information or intellectual
property right, that a Party owns or has a license to such item or right, and has the ability to grant the other Party access, a license or a sublicense (as applicable) in or to such item or right as provided in the Operative Documents without
violating the terms of any agreement or other arrangement with any third party. 
 “Debt” of any Person
means, without duplication: 
 1. all indebtedness of such Person for borrowed money, 
 2. all obligations of such Person for the deferred purchase price of property or services (other than any portion of any
trade payable obligation that shall not have remained unpaid for 91 days or more from the later of (A) the original due date of such portion and (B) the customary payment date in the industry and relevant market for such portion),

 3. all obligations of such Person evidenced by bonds, notes, debentures or other similar instruments,

 4. all obligations of such Person created or arising under any conditional sale or other title retention
agreement with respect to property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in an event of default are limited to repossession or sale of such property), 
 5. all Capitalized Leases to which such Person is a party, 
 6. all obligations, contingent or otherwise, of such Person under acceptance, letter of credit or similar facilities,

 7. all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any
Equity Securities of such Person, 
 8. the net amount of all financial obligations of such Person in respect of
Hedge Agreements, 
 9. the net amount of all other financial obligations of such Person under any contract or
other agreement to which such Person is a party, 
 10. all Debt of other Persons of the type described in
clauses (a) through (i) above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed, directly or indirectly, by such Person through an agreement (A) to pay or purchase such Debt or to advance or
supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to make payment of such Debt or to assure
the holder of such Debt against loss, (C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is received or such services are rendered)
or (D) otherwise to assure a creditor against loss, and 
 11. all Debt of the type described in clauses
(a) through (i) above secured by (or for which the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any Encumbrance on property (including accounts and contract rights) owned or held or used under lease
or license by such Person, even though such Person has not assumed or become liable for payment of such Debt. 
  

 4 

 “Development Budget” means the budget (comprised of the Management
Budget Component and the Clinical Budget Component) for the implementation of the Development Plan (the initial form of which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the Amended and Restated Research and
Development Agreement as Annex D thereto), as may be further developed and revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 
 “Development Committee” has the meaning set forth in Article 3 of the Amended and Restated Research and Development
Agreement. 
 “Development Committee Charter” has the meaning set forth in Article 3 of the Amended and
Restated Research and Development Agreement. 
 “Development Committee Member” has the meaning set forth
in Paragraph I of Annex B to the Amended and Restated Research and Development Agreement. 
 “Development
Plan” means the development plan covering all the Programs (the initial form of which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the Amended and Restated Research and Development Agreement as
Annex C thereto), as may be further developed and revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 
 “Development Services” has the meaning set forth in Section 1(b) of the RRD Services Agreement. 
 “Director(s)” has the meaning set forth in the Preliminary Statement of the Indemnification Agreement. 

“Disclosing Party” has the meaning set forth in Section 3 of the Confidentiality Agreement. 
 “Discontinuation Closing Date” has the meaning set forth in Section 11.3 of the Amended and Restated Research
and Development Agreement. 
 “Discontinuation Date” means any date designated by
Symphony Dynamo which shall occur on or after the 90th day
following the receipt by Dynavax of notice from Symphony Dynamo of Symphony Dynamo’s intent to discontinue a Program in accordance with the terms of the Amended and Restated Research and Development Agreement. 
 “Discontinuation Option” has the meaning set forth in Section 11.3 of the Amended and Restated Research and
Development Agreement. 
 “Discontinuation Price” has the meaning set forth in Section 11.3 of the
Amended and Restated Research and Development Agreement. 
 “Discontinuation Price Dispute Notice” has
the meaning set forth in Section 11.3(b) of the Amended and Restated Research and Development Agreement. 
  

 5 

 “Discontinued Program” has the meaning set forth in
Section 2.11 of the Novated and Restated Technology License Agreement. 
 “Discontinuation Program
Funding” has the meaning set forth in Section 11.3(b) of the Amended and Restated Research and Development Agreement. 
 “Disinterested Directors” has the meaning set forth in Article X of the Symphony Dynamo Charter. 
 “Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Dynavax” means Dynavax Technologies Corporation, a Delaware corporation. 
 “Dynavax Common Stock” means the common stock, par value $0.001 per share, of Dynavax. 
 “Dynavax Common Stock valuation” has the meaning set forth in Section 2(e) of the Purchase Option Agreement. 
 “Dynavax Obligations” has the meaning set forth in Section 6.1 of the Amended and Restated Research and
Development Agreement. 
 “Dynavax Personnel” has the meaning set forth in Section 8.4 of the
Amended and Restated Research and Development Agreement. 
 “Dynavax Subcontractor” has the meaning set
forth in Section 6.2 of the Amended and Restated Research and Development Agreement. 
 “Early Purchase Option
Exercise” has the meaning set forth in Section 1(c)(iv) of the Purchase Option Agreement. 
 “Effective Registration Date” has the meaning set forth in Section 1(b) of the Registration Rights Agreement. 
 “Encumbrance” means (i) any security interest, pledge, mortgage, lien (statutory or other), charge or option to purchase, lease or otherwise acquire any interest,
(ii) any adverse claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement, license or other encumbrance of any kind, preference or priority, or (iii) any other security agreement or preferential
arrangement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement). 
 “Enhancements” means findings, improvements, discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property and/or
Regulatory Files, in each case whether or not patentable. 
  

 6 

 “Equity Securities” means, with respect to any Person, shares of
capital stock of (or other ownership or profit interests in) such Person, warrants, options or other rights for the purchase or other acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person,
securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or other acquisition from such Person of such shares (or such other
interests), and other ownership or profit interests in such Person (including, without limitation, partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other
interests are authorized or otherwise existing on any date of determination. 
 “ERISA” means the United
States Employee Retirement Income Security Act of 1974, as amended. 
 “Excepted Debt” has the meaning
set forth in Section 5(c)(iii) of the Purchase Option Agreement. 
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “Excluded
ISS” means (a) any ISS testing positive for stimulation of TLR-9 by Dynavax prior to the Closing Date that is not a Selected ISS, or (b) any ISS made and tested for activity by Dynavax during the Term that (i) is not
designed to have significant activity with a target other than TLR-9 (whether or not it also acts through TLR-9) and (ii) is not a Selected ISS. 
 “Existing NDA” has the meaning set forth in Section 2 of the Confidentiality Agreement. 
 “External Directors” has the meaning set forth in the preamble of the Confidentiality Agreement. 
 “FDA” means the United States Food and Drug Administration or its successor agency in the United States. 
 “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and Restated Research and Development
Agreement. 
 “Final Discontinuation Price” has the meaning set forth in Section 11.3(c) of the
Amended and Restated Research and Development Agreement. 
 “Financial Audits” has the meaning set forth
in Section 6.6 of the Amended and Restated Research and Development Agreement. 
 “Financing” has
the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
 “Fiscal Year”
has the meaning set forth in each Operative Document in which it appears. 
 “Form S-3” means the
Registration Statement on Form S-3 as defined under the Securities Act. 
  

 7 

 “FTE” has the meaning set forth in Section 4.1 of the Amended
and Restated Research and Development Agreement. 
 “Funding Agreement” means the Funding Agreement,
dated as of the Closing Date, among Dynavax, SCP and Investors. 
 “Funding Notice” has the meaning set
forth in Section 2(b) of the Funding Agreement. 
 “GAAP” means generally accepted accounting
principles in effect in the United States of America from time to time. 
 “Governmental Approvals”
means authorizations, consents, orders, declarations or approvals of, or filings with, or terminations or expirations of waiting periods imposed by any Governmental Authority. 
 “Governmental Authority” means any United States or non-United States federal, national, supranational, state,
provincial, local, or similar government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral body. 
 “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
 “Hedge Agreement” means any interest rate swap, cap or collar agreement, interest rate future or option contract,
currency swap agreement, currency future or option contract or other similar hedging agreement. 
 “Hepatitis B
Products” mean any pharmaceutical product comprising a Selected ISS, either alone or in combination with Hepatitis B Surface Antigen (HBsAg), whether conjugated or unconjugated to the applicable ISS, for use in Hepatitis B treatment or
therapy. 
 “Hepatitis B Program” means the identification, development, manufacture and/or use of any
Hepatitis B Products in Accordance with the Development Plan. 
 “Hepatitis C Products” mean any
pharmaceutical product comprising a Selected ISS, either alone or in combination with an added Hepatitis C antigen, whether conjugated or unconjugated to the applicable ISS, for use in Hepatitis C treatment or therapy. 
 “Hepatitis C Program” means the identification, development, manufacture and/or use of any Hepatitis C Products in
Accordance with the Development Plan. 
 “Holdings” means Symphony Dynamo Holdings LLC, a Delaware
limited liability company. 
 “Holdings Claims” has the meaning set forth in Section 5.01 of the
Warrant Purchase Agreement. 
 “Holdings LLC Agreement” means the Amended and Restated Limited Liability
Company Agreement of Holdings, dated as of the Closing Date. 
  

 8 

 “HSR Act Filings” means the premerger notification and report forms
required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 “IND” means an
Investigational New Drug Application, as described in 21 U.S.C. § 355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 
 “Indemnification Agreement” means the Indemnification Agreement among Symphony Dynamo and the Directors named
therein, dated as of the Closing Date. 
 “Indemnified Party” has the meaning set forth in each
Operative Document in which it appears. 
 “Indemnified Proceeding” has the meaning set forth in each
Operative Document in which it appears. 
 “Indemnifying Party” has the meaning set forth in each
Operative Document in which it appears. 
 “Independent Accountant” has the meaning set forth in
Section 11.3(c) of the Amended and Restated Research and Development Agreement. 
 “Initial Development
Budget” means the initial development budget prepared by representatives of Symphony Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated Research and Development Agreement as Annex D thereto.

 “Initial Development Plan” means the initial development plan prepared by representatives of Symphony
Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated Research and Development Agreement as Annex C thereto. 
 “Initial Funds” has the meaning set forth in Section 2(a) of the Funding Agreement. 
 “Initial Holdings LLC Agreement” means the Agreement of Limited Liability Company of Holdings, dated January 10, 2006. 
 “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of Investors, dated
January 10, 2006. 
 “Initial LLC Member” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement. 
 “Interest Certificate” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement. 
 “Investment Company Act” means the Investment Company Act of 1940, as
amended. 
 “Investment Overview” means the investment overview describing the transactions entered into
pursuant to the Operative Documents. 
  

 9 

 “Investment Policy” has the meaning set forth in
Section 1(a)(vi) of the RRD Services Agreement. 
 “Investors” means Symphony Dynamo Investors LLC.

 “Investors LLC Agreement” means the Amended and Restated Agreement of Limited Liability Company of
Investors dated as of the Closing Date 
 “IRS” means the U.S. Internal Revenue Service. 
 “ISS” means any synthetic oligonucleotide sequence or chimeric oligonucleotide sequence that modulates an immune
response, including, but not limited to, such sequences referred to by Dynavax as immunostimulatory sequences, chimeric immunomodulatory compounds and branched immunomodulatory compounds. 
 “Knowledge” means the actual (and not imputed) knowledge of the executive officers of Dynavax, without the duty of
inquiry or investigation. 
 “Law” means any law, statute, treaty, constitution, regulation, rule,
ordinance, order or Governmental Approval, or other governmental restriction, requirement or determination, of or by any Governmental Authority. 
 “License” has the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
 “Licensed Intellectual Property” means the Licensed Patent Rights, Symphony Dynamo Enhancements, Licensor Enhancements and the Licensed Know-How. 
 “Licensed Know-How” means any and all proprietary technology that is Controlled by Licensor as of the Closing Date
and that relates to the Licensed Patent Rights, Regulatory Files, ISSs or the Programs, including without limitation, manufacturing processes or protocols, know-how, writings, documentation, data, technical information, techniques, results of
experimentation and testing, diagnostic and prognostic assays, specifications, databases, any and all laboratory, research, pharmacological, toxicological, analytical, quality control pre-clinical and clinical data, and other information and
materials, whether or not patentable. 
 “Licensed Patent Rights” means: 
 1. any and all patents, patent applications and invention disclosures Controlled by Licensor as of the Closing Date and
relating to ISSs or the Programs, including, but not limited to, the patents and patent applications listed on Annex B to the Novated and Restated Technology License Agreement; 
 2. any and all reissues, continuations, divisionals, continuations-in-part (but only to the extent the subject matter in such
continuations-in-part has been disclosed in the patents or patent applications listed on Annex B), reexaminations, renewals, substitutes, extensions or foreign counterparts of the foregoing, whether filed prior to or after the expiration or
termination of the Purchase Option; and 
  

 10 

 3. any and all patents and patent applications that claim Licensor
Enhancements or Symphony Dynamo Enhancements. 
 “Licensor” means Dynavax. 
 “Licensor Enhancements” means all findings, improvements, discoveries, inventions, additions, modifications,
enhancements, derivative works, clinical development data, or changes to the Licensed Patent Rights, Licensed Know-How, Regulatory Files, ISSs, Products or the Programs, in each case, developed by Licensor during the Term in the course of performing
Dynavax’s rights and obligations under the Amended and Restated Research & Development Agreement (in each case whether or not patentable), to the extent such items do not otherwise qualify as Symphony Dynamo Enhancements hereunder,
regardless of whether such work is funded by Symphony Dynamo or Dynavax. 
 “Lien” has the meaning set
forth in Section 1.01 of the Holdings LLC Agreement. 
 “Liquidating Event” has the meaning set
forth in Section 8.01 of the Holdings LLC Agreement. 
 “LLC Agreements” means the Initial Holdings
LLC Agreement, the Holdings LLC Agreement, the Initial Investors LLC Agreement and the Investors LLC Agreement. 
 “Loss” has the meaning set forth in each Operative Document in which it appears. 
 “Management Budget Component” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement. 
 “Management Fee” has the meaning set forth in Section 6(a) of the RRD Services Agreement. 
 “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth in such LLC Agreement,
and (ii) for each other Operative Document in which it appears, RRD. 
 “Management Services” has
the meaning set forth in Section 1(a) of the RRD Services Agreement. 
 “Manager Event” has the
meaning set forth in Section 3.01(g) of the Holdings LLC Agreement. 
 “Material Adverse Effect”
means, with respect to any Person, a material adverse effect on (i) the business, assets, property or condition (financial or otherwise) of such Person or, (ii) its ability to comply with and satisfy its respective agreements and
obligations under the Operative Documents or, (iii) the enforceability of the obligations of such Person of any of the Operative Documents to which it is a party. 
 “Material Subsidiary” means, at any time, a Subsidiary of Dynavax having assets in an amount equal to at least 5% of the amount of total consolidated assets of Dynavax and its
Subsidiaries (determined as of the last day of the most recent reported fiscal quarter of Dynavax) or revenues or net income in an amount equal to at least 5% of the amount of total consolidated revenues or net income of Dynavax and its Subsidiaries
for the 12-month period ending on the last day of the most recent reported fiscal quarter of Dynavax. 
  

 11 

 “Medical Discontinuation Event” means (a) as specified in each
Protocol, those data that, if collected in such Protocol, demonstrate that such Protocol should not be continued or (b) a series of adverse events, side effects or other undesirable outcomes that, when collected in a Protocol, would cause a
reasonable FDA Sponsor to discontinue such Protocol. 
 “Membership Interest” means (i) for each
LLC Agreement in which it appears, the meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it appears, the meaning set forth in the Holdings LLC Agreement. 
 “NASDAQ” means the National Association of Securities Dealers Automated Quotation System. 
 “NDA” means a New Drug Application, as defined in the regulations promulgated by the United States Food and Drug
Administration, or any foreign equivalent thereof. 
 “Non-Dynavax Capital Transaction” means any
(i) sale or other disposition of all or part of the Symphony Dynamo Shares or all or substantially all of the operating assets of symphony Dynamo, to a Person other than Dynavax or an Affiliate of Dynavax or (ii) distribution in kind of
the Symphony Dynamo Shares following the expiration of the Purchase Option. 
 “Non-Symphony Dynamo ISS”
means any ISS that is (i) first made and tested for activity by Dynavax during the Term and (ii) designed to have significant activity with a target other than TLR-9, whether or not it also acts through TLR-9. 
 “Novated and Restated Technology License Agreement” means the Novated and Restated Technology License Agreement,
dated as of the Closing Date, among Dynavax, Symphony Dynamo and Holdings. 
 “Operative Documents”
means, collectively, the Indemnification Agreement, the Holdings LLC Agreement, the Purchase Option Agreement, the Warrant Purchase Agreement, the Registration Rights Agreement, the Subscription Agreement, the Technology License Agreement, the
Novated and Restated Technology License Agreement, the RRD Services Agreement, the Research and Development Agreement, the Amended and Restated Research and Development Agreement, the Confidentiality Agreement, the Funding Agreement and each other
certificate and agreement executed in connection with any of the foregoing documents. 
 “Organizational
Documents” means any certificates or articles of incorporation or formation, partnership agreements, trust instruments, bylaws or other governing documents. 
 “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii) of the Purchase Option Agreement. 
 “Party(ies)” means, for each Operative Document or other agreement in which it appears, the parties to such
Operative Document or other agreement, as set forth therein. With respect to any agreement in which a provision is included therein by reference to a provision in another agreement, the term “Party” shall be read to refer to the parties to
the document at hand, not the agreement that is referenced. 
  

 12 

 “Payment Terms” has the meaning set forth in Section 8.2 of the
Amended and Restated Research and Development Agreement. 
 “Percentage” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Permitted Investments” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Permitted Lien” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
 “Person” means any individual, partnership (whether
general or limited), limited liability company, corporation, trust, estate, association, nominee or other entity. 
 “Personnel” of a Party means such Party, its employees, subcontractors, consultants, representatives and agents. 
 “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or, if such bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar
rate for United States dollar loans, such other major money center commercial bank in New York City selected by the Manager. 
 “Products” means Cancer Products, Hepatitis B Products and Hepatitis C Products. 
 “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Program Option” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
 “Program Option Closing Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
 “Program Option Exercise Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated
Research and Development Agreement. 
 “Program Option Exercise Notice” has the meaning set forth in
Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
 “Program Option
Period” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
 “Programs” means Cancer Program, Hepatitis B Program and Hepatitis C Program. 
 “Protocol” means a written protocol that meets the substantive requirements of Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective May 9, 1997 and is included within
the Development Plan or later modified or added to the Development Plan pursuant to the Amended and Restated Research and Development Agreement. 
  

 13 

 “Public Companies” has the meaning set forth in Section 5(e) of
the Purchase Option Agreement. 
 “Purchase Option” has the meaning set forth in Section 1(a) of
the Purchase Option Agreement. 
 “Purchase Option Agreement” means the Amended and Restated Purchase
Option Agreement dated as of the date hereof, among Dynavax, Holdings and Symphony Dynamo. 
 “Purchase Option
Closing” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase
Option Closing Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase Option Commencement Date” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement. 
 “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
 “Purchase Option Exercise Notice” has the meaning set forth in Section 2(a) of the Purchase Option Agreement.

 “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the Purchase Option
Agreement. 
 “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase Option
Agreement. 
 “QA Audits” has the meaning set forth in Section 6.5 of the Amended and Restated
Research and Development Agreement. 
 “Regents” has the meaning set forth in Section 3.1 of the
Novated and Restated Technology License Agreement. 
 “Regents Agreement” has the meaning set forth in
Section 3.1 of the Novated and Restated Technology License Agreement. 
 “Registration Rights
Agreement” means the Amended and Restated Registration Rights Agreement dated as of the date hereof, between Dynavax and Holdings. 
 “Registration Statement” has the meaning set forth in Section 1(b) of the Registration Rights Agreement. 
  

 14 

 “Regulatory Authority” means the United States Food and Drug
Administration, or any successor agency in the United States, or any health regulatory authority(ies) in any other country that is a counterpart to the FDA and has responsibility for granting registrations or other regulatory approval for the
marketing, manufacture, storage, sale or use of drugs in such other country. 
 “Regulatory Allocation”
has the meaning set forth in Section 3.06 of the Holdings LLC Agreement. 
 “Regulatory Files”
means any IND, NDA or any other filings filed with any Regulatory Authority with respect to the Programs. 
 “Related
Oncology Products Agreement” has the meaning set forth in Section 1 1.4 of the Amended and Restated Research and Development Agreement. 
 “Replacement Warrant(s)” has the meaning set forth in Section 7.08 of the Warrant Purchase Agreement. 
 “Representative” of any Person means such Person’s shareholders, principals, directors, officers, employees,
members, managers and/or partners. 
 “Research and Development Agreement” means the Research and
Development Agreement dated as of the Closing Date, between Dynavax and Holdings. 
 “Rhein” has the
meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
 “Rhein
Sale Agreement” has the meaning set forth in Section 11.2(a) of the Amended and Restated Research and Development Agreement. 
 “RRD” means RRD International, LLC, a Delaware limited liability company. 
 “RRD Indemnified Party” has the meaning set forth in Section 10(a) of the RRD Services Agreement. 
 “RRD Loss” has the meaning set forth in Section 10(a) of the RRD Services Agreement. 
 “RRD Parties” has the meaning set forth in Section 9(e) of the RRD Services Agreement. 
 “RRD Personnel” has the meaning set forth in Section I(a)(ii) of the RRD Services Agreement. 
 “RRD Services Agreement” means the RRD Services Agreement between Symphony Dynamo and RRD, dated as the Closing
Date, 2006. 
 “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings LLC
Agreement. 
  

 15 

 “Scheduled Meeting” has the meaning set forth in Paragraph 6 of
Annex B of the Amended and Restated Research and Development Agreement. 
 “Scientific Discontinuation
Event” has the meaning set forth in Section 4.2(c) of the Amended and Restated Research and Development Agreement. 
 “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership. 
 “SD
Program Option” has the meaning set forth in Section 11.2(b) of the Amended and Restated Research and Development Agreement. 
 “SD Program Option Exercise Notice” has the meaning set forth in Section 11.2(b) of the Amended and Restated Research and Development Agreement. 
 “SEC” means the United States Securities and Exchange Commission. 
 “Securities Act” means the Securities Act of 1933, as amended. 
 “Selected ISS” means any ISS testing positive for stimulation of TLR-9 selected (i) for inclusion in the
Development Plan or (ii) as a backup ISS, in each case pursuant to Paragraph 12 of the Development Committee Charter. Selected ISS may include sequences that subsequent to the Closing Date are shown to act through one or more additional
mechanisms in addition to stimulation of TLR-9. 
 “Shareholder” means any Person who owns any Symphony_
Dynamo Shares. 
 “Solvent” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement. 
 “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company.

 “Stock Payment Date” has the meaning set forth in Section 2 of the Subscription Agreement.

 “Stock Purchase Price” has the meaning set forth in Section 2 of the Subscription Agreement.

 “Subcontracting Agreement” has the meaning set forth in Section 6.2 of the Amended and Restated
Research and Development Agreement. 
 “Subscription Agreement” means the Subscription Agreement between
Symphony Dynamo and Holdings, dated as the Closing Date. 
 “Subsidiary” of any Person means any
corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of the board of directors
of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency); (b) the interest in the capital or profits of
such partnership, joint venture or limited liability company; or (c) the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by such person and one or more of its other
Subsidiaries or by one or more of such Person’s other Subsidiaries. 
  

 16 

 “Surviving Entity” means the surviving or resulting
“parent” legal entity which is surviving entity to Dynavax after giving effect to a Change of Control. 
 “Symphony Capital” means Symphony Capital LLC, a Delaware limited liability company. 
 “Symphony Dynamo” means Symphony Dynamo, Inc., a Delaware corporation. 
 “Symphony
Dynamo Auditors” has the meaning set forth in Section 5(b) of the RRD Services Agreement. 
 “Symphony Dynamo Board” means the board of directors of Symphony Dynamo. 
 “Symphony Dynamo By-laws” means the By-laws of Symphony Dynamo, as adopted by resolution of the Symphony Dynamo Board on the Closing Date. 
 “Symphony Dynamo Charter” means the Amended and Restated Certificate of Incorporation of Symphony Dynamo, dated as
of the Closing Date. 
 “Symphony Dynamo Director Event” has the meaning set forth in
Section 3.01(h)(i) of the Holdings LLC Agreement. 
 “Symphony Dynamo Enhancements” means findings,
improvements, discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property, Regulatory Files, ISSs, Products or the Programs, made by or on behalf of
Symphony Dynamo during the Term, in each case whether or not patentable. 
 “Symphony Dynamo Equity
Securities” means the Common Stock and any other stock or shares issued by Symphony Dynamo. 
 “Symphony
Dynamo Loss” has the meaning set forth in Section 10(b) of the RRD Services Agreement. 
 “Symphony
Dynamo Shares” has the meaning set forth in Section 2.02 of the Holdings LLC Agreement. 
 “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware limited partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company. 
 “Tangible Materials” means any tangible documentation, whether written or electronic, existing as of the Closing
Date or during the Term, that is Controlled by the Licensor, embodying the Licensed Intellectual Property, Regulatory Files, Products or the Programs, including, but not limited to, documentation, patent applications and invention disclosures.

  

 17 

 “Tax Amount” has the meaning set forth in Section 4.02 of the
Holdings LLC Agreement. 
 “Technology License Agreement” means the Technology License Agreement, dated
as of the Closing Date, between Dynavax and Holdings. 
 “Term” has the meaning set forth in
Section 4(b)(iii) of the Purchase Option Agreement, unless otherwise stated in any Operative Document. 
 “Territory” means the world. 
 “Third Party IP” has the meaning set
forth in Section 2.11 of the Novated and Restated Technology License Agreement. 
 “Third Party
Licensor” means a third party from which Dynavax has received a license or sublicense to Licensed Intellectual Property. 
 “Transfer” has for each Operative Document in which it appears the meaning set forth in such Operative Document. 
 “Transferee” has, for each Operative Document in which it appears, the meaning set forth in such Operative Document. 
 “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
 “Warrant(s)” means the “Warrant” as defined in Section 2.01 of the Warrant Purchase Agreement, and/or
any successor certificates exercisable for Warrant Shares issued by Dynavax. 
 “Warrant Closing” has
the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
 “Warrant Date” has the
meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
 “Warrant Purchase
Agreement” means the Warrant Purchase Agreement, dated as of the date hereof, between Dynavax and Holdings. 
 “Warrant Shares” has the meaning set forth in Section 2.01 of the Warrant Purchase Agreement. 
 “Warrant Surrender Price” has the meaning set forth in Section 7.08 of the Warrant Purchase Agreement. 
  

 18 

 Exhibit A 
 FORM OF WARRANT 
 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE
HEREOF HAVE BEEN THE SUBJECT OF REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE, AND THE SAME HAVE BEEN (OR WILL BE, WITH RESPECT TO THE SECURITIES ISSUABLE UPON EXERCISE HEREOF) ISSUED IN
RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED
UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 
 THE WARRANT EVIDENCED BY THIS CERTIFICATE IS SUBJECT TO
CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE WARRANT PURCHASE AGREEMENT, DATED AS OF NOVEMBER 9, 2009, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER. NO REGISTRATION OF TRANSFER OF THIS WARRANT WILL BE MADE ON
THE BOOKS OF THE ISSUER UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN COMPLIED WITH. 
 DYNAVAX TECHNOLOGIES
CORPORATION 
 WARRANT TO PURCHASE COMMON STOCK 
  

			
	 No. CW-  
	  	[        ,    ], 2009

 Void After [        ,    ], 2014 
 THIS CERTIFIES THAT, for value received, SYMPHONY
DYNAMO HOLDINGS LLC, a Delaware limited liability company, with its principal office at 7361 Calhoun Place, Suite 325, Rockville, MD 20855, or its assigns (the “Holder”), is entitled to subscribe
for and purchase at the Exercise Price (defined below) from DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation, with its principal office at 2929 Seventh Street, Suite 100,
Berkeley, CA 94710-2753 (the “Company”) Two Million (2,000,000) shares of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”), subject to adjustment as provided herein. 
 This Warrant is being issued pursuant to the terms of the Warrant Purchase Agreement, dated November 9, 2009, between the Company and
the Holder (the “Warrant Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Warrant Purchase Agreement. 
 1. DEFINITIONS. Capitalized terms used but not defined herein are used as defined in the Warrant Purchase Agreement.
As used herein, the following terms shall have the following respective meanings: 
 (a) “Common Stock” shall mean
shares of Dynavax Technologies Corporation Common Stock, par value $0.001. 
 (b) “Exercise Period” shall mean the
period commencing on [        ], 20[    ] and ending on [        ], 20[    ], except as otherwise
provided below. 
  

 B-1 

 (c) “Exercise Price” shall mean $1.94 per share, subject to adjustment pursuant to
Section 4 below. 
 (d) “Exercise Shares” shall mean the outstanding and unexercised shares of Common Stock
issuable upon exercise of this Warrant from time to time, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Sections 4, 6 and 7 below. 
 (e) “Purchase Option” shall have the meaning set forth in the Warrant Purchase Agreement. 
 2. EXERCISE OF WARRANT. 
 2.1 Generally. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by
delivery of the following to the Company at its address set forth above (or at such other address as it may designate pursuant to Section 12 hereof): 
 (a) an executed Notice of Exercise in the form attached hereto; 
 (b) payment of
the Exercise Price of the shares thereby subscribed for by means of any of the following: (i) wire transfer; (ii) cashier’s check drawn on a U.S. bank made out to the Company; or (iii) a cashless exercise pursuant to
Section 2.2; and 
 (c) this Warrant. 
 Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder,
if the Holder so designates, shall be issued and delivered to the Holder as soon as practicable, but in no event later than thirty (30) days, after the date of exercise pursuant to this Section 2.1. The Company shall, upon request of the
Holder, if available and if allowed under applicable securities laws, use commercially reasonable efforts to deliver Exercise Shares electronically through the Depository Trust Corporation or another established clearing corporation performing
similar functions, or if requested by Holder, certificates evidencing the Exercise Shares. If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of the Exercise Shares, deliver to Holder a new Warrant
evidencing the rights of Holder to purchase the unexercised Exercise Shares remaining under this Warrant, which new Warrant shall in all other respects be identical to this Warrant. 
 The person in whose name any Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of
record of such shares on the date on which the Notice of Exercise, this Warrant and payment of the Exercise Price and all taxes required to be paid by the Holder, if any, were made, irrespective of the date of delivery of any certificate or
certificates evidencing the Exercise Shares, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of the Exercise Shares at
the close of business on the next business day on which the stock transfer books are open. 
 2.2 Cashless Exercise. The
Holder may exercise the Warrant pursuant to Section 2.1(b)(iii) and receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by delivery and notice of cashless exercise in accordance with
Section 2.1, in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula: 
 X = Y (A-B)  
              A 
 Where X =
    the number of shares of Common Stock to be issued to the Holder 
  

 B-2 

 Y =     the number of shares of Common Stock purchasable under the
Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised (at the date of such calculation) 
 A =     the fair market value of one share of Common Stock (at the date of such calculation) 
 B =     Exercise Price (as adjusted to the date of such calculation) 
 For purposes of the above calculation, the fair market value of one share of Common Stock shall equal the average closing price of the Common Stock, as reported by the NASDAQ National Market, or other national exchange that is then the
primary exchange on which the Common Stock is listed, for the thirty (30) trading days immediately preceding the second trading day prior to the date on which the Holder delivers to the Company the Warrant and an executed Notice of Exercise in
the form attached hereto. If the Common Stock is not quoted on the NASDAQ National Market, or listed on another national exchange, the fair market value of one share of Common Stock shall be determined by the Company’s Board of Directors in
good faith. 
 2.3 Legend. 
 (a) All certificates evidencing the shares to be issued to the Holder may bear the following legends: 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE, AND THE SAME HAVE BEEN ISSUED IN RELIANCE
ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. SUCH SHARES MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION OR
EXEMPTION THEREFROM.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER
AS SET FORTH IN THE WARRANT PURCHASE AGREEMENT, DATED AS OF NOVEMBER 9, 2009 COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER. NO REGISTRATION OF TRANSFER OF THESE SHARES WILL BE MADE ON THE BOOKS OF THE ISSUER UNLESS AND
UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN COMPLIED WITH.” 
 (b) If the certificates representing shares include either or
both of the legends set forth in Section 2.3(a) hereof, the Company shall, upon a request from a Holder, or subsequent transferee of a Holder, as soon as practicable but in no event more than thirty (30) days after receiving such
request, remove or cause to be removed (i) if the shares cease to be restricted securities, the securities law portion of the legend and/or (ii) in the event of a sale of the shares subject to issuance following the transfer of the shares
in compliance with the transfer restrictions, the transfer restriction portion of the legend, from certificates representing the shares delivered by a Holder (or a subsequent transferee). 
 2.4 Charges, Taxes and Expenses. Issuance of the Exercise Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of any electronic or paper certificate, all of which taxes and expenses shall be paid by the Company, and such

  

 B-3 

 
certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event Exercise Shares are to be issued in a
name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto. 
 3. COVENANTS OF
THE COMPANY. 
 3.1 No Impairment. Except and to the extent as waived or consented to by
the Holder, the Company shall at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect the exercise rights of the Holder
against impairment. 
 3.2 Notices of Record Date. If at any time: 
 (a) the Company shall take a record of the holders of Common Stock for the purpose of entitling them to receive a dividend or other
distribution, or any right to subscribe for or purchase any evidences of its indebtedness, any shares of stock of any class or any other securities or property, or to receive any other right (other than with respect to any equity or equity
equivalent security issued pursuant to a rights plan adopted by the Company’s Board of Directors); 
 (b) there shall be
any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any consolidation or merger of the Company, or any sale, transfer or other disposition of all or substantially all the
property, assets or business of the Company; or 
 (c) there shall be a voluntary or involuntary dissolution, liquidation or
winding up of the Company; 
 then, in any one or more of such cases, the Company shall give to Holder at least ten (10) days’ prior
written notice of the record date for such dividend, distribution or right or for determining rights to vote in respect of any such reorganization, reclassification, recapitalization, consolidation, merger, sale, transfer, disposition, dissolution,
liquidation or winding up of the Company. Any notice provided hereunder shall specify the date on which the holders of Common Stock shall be entitled to any such dividend, distribution or right, and the amount and character thereof, and the then
current estimated date for the closing of the transaction contemplated by any proposed reorganization, reclassification, recapitalization, consolidation, merger, sale, transfer, disposition, dissolution, liquidation or winding up of the Company.

 4. ADJUSTMENT OF EXERCISE PRICE. 
 4.1 Changes in Common Stock. In the event of changes in the outstanding Common Stock by reason of stock dividends, split-ups,
recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations or the like, the number and class of shares available under this Warrant in the aggregate and the Exercise Price shall be
correspondingly adjusted to give the Holder of this Warrant, on exercise for the same aggregate Exercise Price, the total number, class and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the
Holder continued to hold such shares until after the event requiring adjustment. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant pursuant to this Section 4.1.

 5. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this
Warrant, including as a consequence of any adjustment pursuant hereto. If the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such
fraction a sum in cash equal to the product resulting from multiplying the fair market value of an Exercise Share (determined as provided in Section 2.2 hereof) by such fraction. 
  

 B-4 

 6. CORPORATE TRANSACTIONS. In the event that the
Company enters into a merger or acquisition in which the surviving or “resulting” parent entity (“Surviving Entity”) is other than the Company, then the Holder shall surrender the Warrant for a new warrant exercisable in return
for shares or common stock of the Surviving Entity (as defined in the Warrant Purchase Agreement) (the “Replacement Warrant”); provided that: 
 6.1 Mixed Consideration. In accordance with Section 7.08 of the Warrant Purchase Agreement, if the consideration for a merger or acquisition consists of a combination of cash and stock
of the Surviving Entity, then the Replacement Warrant issued to Holder shall be solely for common stock of the Surviving Entity at an exchange ratio reflecting the total consideration paid by the Surviving Entity at the time of such change in
control as if the total consideration (including cash) for each share of the Common Stock was instead paid only in common stock of the Surviving Entity at the time of such change of control (as illustrated on Exhibit B to the Warrant Purchase
Agreement), and the holders of the Replacement Warrants shall have the registration rights for stock issuable upon exercise of the Replacement Warrants as provided under the Registration Rights Agreement; or 
 6.2 Cash Consideration. In accordance with Section 7.08 of the Warrant Purchase Agreement, if prior to the end of the
Term (as defined in the Warrant Purchase Agreement), a merger or acquisition shall occur and the consideration for such merger or acquisition shall be paid entirely in cash, then the Holder of this Warrant shall then have the option to irrevocably
elect within fifteen (15) Business Days of the public announcement of the merger or acquisition by written notice of election to the Company, either (a) to retain the Warrant and the right to exercise the Warrant then outstanding for
Exercise Shares in accordance with the terms of this Warrant, which exercise shall occur no later than immediately prior to the closing of such merger or acquisition; or (b) to surrender the Warrant to the Company in consideration of a cash
payment for each share of the Common Stock subject to purchase under this Warrant in an amount equal to forty percent (40%) of the per share cash consideration to be received by a holder of one share of the Company’s Common Stock to be
tendered in the merger or acquisition, provided that the aggregate total cash payments to all holders of outstanding Warrants shall not exceed five million dollars ($5,000,000) (the “Warrant Surrender Price”). The Warrant Surrender Price
shall be paid upon the surrender of the Warrants promptly following the closing of the all cash merger or acquisition. Any failure by the Holder to deliver a written notice of election to the Company pursuant to this Section 6.2 shall be deemed
an election of Section 6.2(a) hereunder. 
 Following a merger or acquisition involving consideration of cash and stock in which the
Surviving Entity is other than the Company, reference to Common Stock shall instead be deemed a reference to the common stock of the Surviving Entity. For purposes of Section 6.1, “common stock of the Surviving Entity” shall include
stock of such corporation of any class which is not preferred as to dividends or assets over any other class of stock of such corporation and which is not subject to redemption and shall also include any evidences of indebtedness, shares of stock or
other securities which are convertible into or exchangeable for any such stock, either immediately or upon the arrival of a specified date or the occurrence of a specified event and any warrants or other rights to subscribe for or purchase any such
stock. The foregoing provisions of this Section 6 shall similarly apply to successive reorganizations, reclassifications, mergers, consolidations or disposition of assets. 
 7. NOTICE OF ADJUSTMENT. Whenever the number of Exercise Shares or number or kind
of securities or other property purchasable upon the exercise of this Warrant or the Exercise Price is adjusted, as herein provided, the Company shall give notice thereof to the Holder at the address of such Holder appearing on the books of the
Company, which notice shall state the number of Exercise Shares (and other securities or property) purchasable upon the exercise of this Warrant and the Exercise Price of such Exercise Shares (and other securities or property) after such adjustment,
setting forth a brief statement of the facts requiring such adjustment and setting forth the computation by which such adjustment was made. 
  

 B-5 

 8. ADDITIONAL ADJUSTMENTS. This Warrant is
subject to the provisions of Section 2.05 of the Warrant Purchase Agreement. 
 9. ORDERLY
SALE. This Warrant and the Exercise Shares are subject to the provisions of Sections 6.04 and 6.05 of the Warrant Purchase Agreement. 
 10. NO STOCKHOLDER RIGHTS. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to
the exercise hereof. Upon the exercise of this Warrant in accordance with Section 2, the Exercise Shares so purchased shall be and be deemed to be issued to such Holder as the record owner of such shares as of the close of business on the date
of such exercise. 
 11. TRANSFER OF WARRANT. Subject to applicable
laws, the restriction on transfer set forth on the first page of this Warrant and the provisions of Article VI of the Warrant Purchase Agreement, this Warrant and all rights hereunder are transferable by the Holder, in person or by duly authorized
attorney, upon delivery of this Warrant, the Assignment Form attached hereto and funds sufficient to pay any transfer taxes payable upon the making of such transfer, to any transferee designated by Holder. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Exercise Shares without having a new Warrant issued. The
Company may require, as a condition of allowing a transfer (i) that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary
for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute
and deliver to the Company an investment letter in form and substance acceptable to the Company, (iii) that the transferee be an “accredited investor” as defined in Rule 501(a) promulgated under the Securities Act and (iv) the
transferee agree in writing to be bound by the terms of this Warrant and the Warrant Purchase Agreement as if an original signatory thereto. 
 12. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or
destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so
lost, stolen, mutilated or destroyed. 
 13. NOTICES, ETC. Any notice, request,
demand, waiver, consent, approval or other communication that is required or permitted to be given hereto shall be in writing and shall be deemed given only if delivered to the applicable party personally or sent to the party by facsimile
transmission (promptly followed by a hard-copy delivered in accordance with this Section 12), by next business day delivery by a nationally recognized courier service, or by registered or certified mail (return receipt requested), with postage
and registration or certification fees thereon prepaid, addressed to the party at its address set forth in the Warrant Purchase Agreement, or at such other address as the Company or Holder may designate by ten (10) days advance written notice
to the other party hereto. 
 14. ACCEPTANCE. Receipt of this Warrant by the Holder shall
constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 15.
GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by the laws of the State of New York. 
  

 B-6 

 16. SATURDAYS, SUNDAYS, HOLIDAYS,
ETC. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or a legal holiday, then such action may be taken or such right may be exercised
on the next succeeding day not a Saturday, Sunday or legal holiday. 
 17. AMENDMENT. This Warrant
may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. 
 18.
SUCCESSORS AND ASSIGNS. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the
Company and the successors and permitted assigns of Holder. 
 19. REGISTRATION RIGHTS.
The holder of this Warrant and of the Exercise Shares shall be entitled to the registration rights and other applicable rights with respect to the Exercise Shares as and to the extent set forth in the Warrant Purchase Agreement and the
Registration Rights Agreement. 
 20. HEADINGS. The headings used in this Warrant are for the
convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. 
  

 B-7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly
authorized officer as of [DATE OF ISSUE]. 
  

			
	DYNAVAX TECHNOLOGIES CORPORATION
		
	 By:
	 	  

	 Title:
	 	  

  

 B-8 

 NOTICE OF EXERCISE 
  

			
	TO:	  	DYNAVAX TECHNOLOGIES CORPORATION
		
	ATTN:	  	CHIEF FINANCIAL OFFICER

 (1) The undersigned hereby elects to purchase      shares of Common Stock of DYNAVAX TECHNOLOGIES CORPORATION (the
“Company”) pursuant to the terms of the attached Warrant dated [DATE OF ISSUE], as follows: 
      shares pursuant to the terms of the cashless exercise provisions set forth in 
 Section 2.2, and shall tender payment of all applicable transfer taxes, if any. 
 (2) Please issue said shares of
Common Stock in the name of the undersigned or in such other name as is specified below: 
  
  
 (Name) 

 
  
  
  
 (Address) 
 (iii)(3) The undersigned represents that:

 (A) It is an “accredited investor” within the meaning of Rule 501(a) of Regulation D promulgated
under the Securities Act of 1933, as amended (the “Securities Act”). 
 (B) It has relied completely on
the advice of, or has consulted with or has had the opportunity to consult with, its own personal tax, investment, legal or other advisors and has not relied on the Company or any of its affiliates for advice. 
 (C) It has been advised and understands that the offer and sale of the attached Warrant and the shares of Common Stock issued
upon exercise of the Warrant (the “Warrant Shares”) have not been registered under the Securities Act. It is able to bear the economic risk of such investment for an indefinite period and to afford a complete loss thereof. 
 (D) It is acquiring the Warrant Shares solely for its own account for investment purposes as a principal and not with a view
to the resale of all or any part thereof. It agrees that the Warrant Shares may not be resold (1) without registration thereof under the Securities Act (unless an exemption from such registration is available), or (2) in violation of any
law. It acknowledges that the Company is not required to register the Warrant Shares under the Securities Act. It is not and will not be an underwriter within the meaning of Section 2(11) of the Securities Act with respect to the Warrant
Shares. 
 (E) No person or entity acting on behalf of, or under the authority of, the undersigned is or will be
entitled to any broker’s, finder’s or similar fees or commission payable by the Company or any of its affiliates. 
  

 B-9 

					
	  
	 		  	  

	(Date)	 		  	(Signature)
		 		  	  

		 		  	(Print Name)

  

 B-10 

 ASSIGNMENT FORM 
 (To assign the foregoing Warrant, execute this form and 
 supply required information. Do not use this form 
 to purchase shares.)

 FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
 Name:                                      
                                         
                                         
                                         
                                         
                                         
  
 (Please Print) 
 Address:                                      
                                         
                                         
                                         
                                         
                                       
 (Please Print) 
 Dated:
            , 20     
  

			
	Holder’s
Signature:	 	  

		
	Holder’s
Address:	 	  

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. 
  

 B-11 

 Exhibit B 
 WARRANT CONVERSION EXAMPLE 
 In the event that Dynavax is the target of a
merger or acquisition in which the share purchase price paid by the acquiror is paid in cash or a mixture of cash and stock, the outstanding Warrants are to be exchanged for Replacement Warrants of the Surviving Entity such that the holders of
Warrants shall receive additional Replacement Warrants in lieu of the cash portion of the share purchase price, as set out in the following example: 
  

	 	•	 	 A holder hereunder holds a Warrant exercisable for 100,000 shares of Dynavax Common Stock at an exercise price of $8.00, and the share purchase price
paid by the acquiror is $10.00 per share of Dynavax Common Stock, with $3.00 to be paid in cash and $7.00 to be paid in shares of the common stock of the Surviving Entity (“New Stock”), based on a price of $70.00 per share of New
Stock. 

  

	 	•	 	 The Warrants of the holder, exercisable for 100,000 shares of Dynavax Common Stock, shall be converted as follows: 

  

	 	(1)	The New Stock portion of the purchase price ($7.00 / share, or a ratio of New Stock to Dynavax Common Stock of 10 to 1) shall yield a Replacement Warrant exercisable
for 10,000 shares of New Stock; and 

  

	 	(2)	The cash portion of the purchase price ($3.00 / share, or $300,000 total) shall, at the New Stock price of $70 /share, yield a Replacement Warrant exercisable for 4,286
shares of New Stock ($300,000 / $70). 

  

	 	•	 	 Therefore, in such a scenario, a holder of a Warrant exercisable for 100,000 shares of Dynavax Common Stock would receive Replacement Warrants
exercisable for an aggregate total of 14,286 shares of New Stock at an exercise price of $56.00 per share.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]